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Summary
Breast cancer causes 20% of all cancer deaths in women in the
U.K. The inadequacy of existing methods used to stage tumours at
presentation is reflected by the high proportion of women with apparently
localised disease who later die from metastases. Better ways of assessing
the biological aggressiveness of the disease are therefore required.
Evidence suggests that cancers exert an inhibitory or 'blocking'
effect, proportional to tumour load, on immune function. This may be
mediated through the action of the combined products of tumour cell
materials and host antibody, circulating immune complexes (CICs), on
immune competent cells. CICs have been reported to depress % T lymphocyte
counts and also under certain conditions to stimulate lymphocyte activity.
A new method of assessing lymphocyte function by measuring the
consumption of separated lymphocytes has been developed which utilises
this possible stimulatory effect.
In the present study % T lymphocyte counts were depressed and
lymphocyte C>2 consumption increased in patients with breast cancer
compared with benign breast disease (p<0.001) and this was stage related
(p<0.05). Neither test was affected by previously defined prognostic
factors or local treatment and was not predictive of disease recurrence.
Both tests returned towards control values in patients benefiting from
endocrine manipulation (p<0.02) and this effect was seen prior to
objective clinical evidence of benefit.
The factor(s) responsible for increased lymphocyte 0^ consumption
was present in the sera from patients with cancer and IC related diseases and
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affected the T-rich lymphocyte population only. It had many features in
cannon with 'blocking' factor(s) and with ICs, and indeed, lymphocyte 0^
consumption correlated significantly with % T counts (r= -0.409; p<0.001)
and CIC levels (r= 0.399; p<0.005) in controls and patients with benign
and malignant breast disease.
This suggests that CICs may be responsible for the depression of
% T counts and stimulation of T lymphocyte consumption in breast
cancer patients, and can be used as a gauge of tumour activity permitting





One fifth of deaths in women dying of cancer in the United Kingdom
are from carcinoma of the breast, the incidence of this disease increasing
steeply with age from 35 years onwards (Forrest 1986).
Once a diagnosis of breast cancer has been made the subsequent
step is to assess the extent of the disease, this being the main criterion
in selection of an appropriate treatment modality. At the present time
this usually entails haematological and biochemical testing of marrow and
liver function, radiography of chest and breasts and where indicated, isotope
bone scanning and liver scanning by isotopes, ultrasound or both. The
prognosis of the patient may be better gauged by using information on, for
example, oestrogen receptor content (Knight et al. 1977), progesterone
receptor content (Horwitz & McGuire 1977), size, attachments and histological
grade (Fisher et al. 1976), DNA content (Atkin & Kay 1979) and cell labelling
index (Meyer et al. 1983; Silvestrimi et al. 1985) of the primary tumour, but
the most important prognostic indicator in early breast cancer is involvement
of axillary nodes (Cutler et al. 1969; Bonadonna et al. 1978). Others have
attempted, by combining several such prognostic factors into a prognostic
index (Blarney 1983), to obtain more sensitive mechanisms by which to
predict outcome. Further information relating to prognosis in patients with
recurrence of disease or metastases can be obtained from the disease free
interval, the predominant site of the lesions, and the menopausal status
(Kardinal & Donegan 1979).
However, at this time, there is no adequate way of demonstrating
the presence of occult metastases in those with apparent locoregional
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disease only, on tumour staging; many patients with involved axillary
nodes and a substantial proportion of those without node invasion having
widely disseminated disease at presentation (Lancet 1977). More over,
it may be extremely difficult to assess the efficacy of treatment in
patients given systemic therapy for sane time, a trial period of at least
12 weeks normally being necessary before this can be ascertained.
Occasionally it may indeed be impossible to tell by objective means whether
or not the patient is responding to treatment, a substantial number having
no objectively measurable disease by UICC criteria (Hayward et al. 1977).
Present methods of predicting the prognosis and responsiveness of breast
cancer are therefore clearly of insufficient calibre, necessitating
a search for other ways of assessing the biological aggressiveness of the
disease if we are to obtain information on which to base therapeutic
regimes and attain speedier evaluation of any given treatment, permitting
earlier selection of alternative treatment modalities.
Human chorionic gonadotrophin (HCG) produced by trophoblastic
tumours (Bagshawe 1969), and alphafeto protein (AFP) often found in patients
with primary liver tumours and testicular teratomas (Sell & Becker 1978)
are markers which allow measurement of tumour burden and response to
treatment in a systemic fashion. These reflect tumour activity more
than tumour volume, for instance, patients with testicular teratomas
which have responded to chemotherapy will have normal tumour marker levels,
despite computerised tomographic evidence of enlarged retroperitoneal
lymph nodes. These are usually found to contain differentiated tissue
on surgical excision (Jones et al. 1982). Adenocarcinomas, because
of their low cell turnover rates and surrounding non-malignant stroma
are not capable of showing a rapid decrease in total tumour volume when
measured by more routine radiological or physical methods (Parker &
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Bagshawe 1985). The use of markers to measure tumour activity, rather
than change in size, should therefore give a more accurate and informative
assessment of what is actually happening to a tumour on treatment.
Such tumour products have been looked for in breast cancer and
sporadic reports have been published of 'ectopic' hormone production,
for example, parathyroid hormone (Maglivit et al. 1971), HCG (Braunstein
et al. 1973) and calcitonin (Hillyard et al. 1976), unique milk products
such as alpha lactalbumin (Woods et al. 1979) and casein (Hendrick &
Franchiment 1974), enzymes such as placental alkaline phosphatase (Stolbach
et al. 1969), and various other products such as ferritin (Marcus & Zinberg
1975), pregnancy associated alpha macroglobulin (Stimson 1975), other acute
phase proteins (Cooper and Stone 1979), and carcinoma embryonic antigen
(Tormey & Waalkes 1978). However, the presence of these substances is too
infrequent to be of clinical value (Hilf 1985) and their specificity
for breast cancer similarly disappointing.
The best tumour marker would be one specific only to the tumour
and produced and released into the serum at a rate proportional to
tumour turnover. A tumour specific antigen would meet this requirement
but there is little evidence that such an entity exists in any of the
spontaneous human tumours (Baldwin 1984). On the other hand, if it
could be shown that tumour products affect the immune system in a
certain manner and that the degree to which this happens is related
to the volume or, better still, the activity of tumour present, we
should then be able to indirectly assess tumour burden and behaviour
by measuring certain parameters of immune function.
Bearing this in mind, this thesis examines firstly, the evidence
linking cancer and immunity and secondly, the data indicating that
immune impairment is a consequence of tumour development and progressive
4
growth and that such dysfunction is related to inhibitory or 'blocking'
factors, these possibly being immune complexes, present in the serum of
tumour bearers. Finally, the main purpose of this study is to shew
that these 'blocking' factors alter some particular aspects of lymphocyte





2. Imnunoloqy and Cancer
2.1. Introduction
The idea that tumours frequently occur but are prevented from
developing by the host irrmunological rejection mechanism, so that they seldom
become apparent, was propounded by Thomas (1959) and later elaborated by
Burnet (1964; 1970a) as the 'Theory of Immune Surveillance'. Long before
then, a similar theory was proposed by Ehrlich (1909) when he wrote
"I am convinced that aberrant germs appear very often during the foetal and
neonatal development periods, which are extremely complicated. Fortunately,
these germs remain inactive in the majority of people because of the immune
system. If this self protection did not exist we could expect that carcinomas
would appear with overwhelming frequency." (from Beverley 1983).
The idea that the host can immunologically recognise a tumour as
foreign and thereafter respond in an aggressive fashion to it, led to the
hope that by stimulating the immune system, tumour rejection would occur.
Furthermore, by developing hetero-antisera to tumour antigens it should
be possible to use these antisera for diagnostic and therapeutic purposes.
The hypothesis of immune surveillance, however, poses several
problematical questions. Firstly, is there any evidence relating immunity
to cancer; secondly, do tumours carry new antigens recognisable as different
from the antigens on a normal cell; thirdly, can the host recognise and
respond specifically to such neoantigens and if so, what is the effector
system involved; and fourthly, if such immunological responses do occur,
why do tumours continue to grow in the face of these? Perhaps cancer
patients have depressed immunity allowing this to happen, or indeed, is it
possible that tumours themselves cause host immune depression?
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2.2. Evidence Relating Immunity and Cancer in Humans
2.2.1. Clinical
2.2.1.1. Tumour histology: MacCarthy (1922) reported that one of the
factors which influenced longevity in cancer was lymphocytic infiltration of
the tumour. Microscopic evidence of an 'inflammatory' infiltrate in and around
the tumour and sinus histiocytosis in the regional nodes have been implicated
many times since then as manifestations of host resistance to tumour and have
been shown to be associated with improved prognosis in cancer of the stomach
(Black et al. 1954), of the breast (Black & Spear 1958; Anastassiades &
Pryce 1966), and in Hodgkin's disease (Lukes et al. 1966). Berg (1956) was
initially rather sceptical of the significance of sinus histiocytosis
in terms of a host reaction but did find (Berg 1959) a 'peripheral plasma
cellular reaction' in the primary breast cancers and the nodal metastases,
correlating with degenerative change in the cancer cells, in a group of
unexpected long-term survivors with anaplastic breast cancers. Tsakraklides
et al. (1973) showed that regional lymph nodes could be classified into four
histological patterns designated lymphocyte predominance, germinal centre
predominance, unstimulated and lymphocyte depleted. Survival data from those
with carcinoma of the uterine cervix (Tsakraklides et al. 1973) and
carcinoma of the breast (Tsakraklides et al. 1974) correlated with these
histologic patterns, lymphocyte predominance being common in those with good
prognosis, lymphocyte depletion common in those with bad prognosis and the
other two histological patterns common in those with intermediate prognosis.
Black and Leis (1971) using the 'skin window' technique demonstrated that
a hypersensitivity type of cellular response to autologous breast tissue
correlated with the degree of sinus histiocytosis in the regional nodes
and with stage of disease. The suggestion that a host reaction may occur
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which modifies invasion can also be seen in the study by Fenoglio and
Pascal (1982) on neoplastic change in colorectal adenomas. They found that
tumours with a prominent lympho-plasmacytic infiltrate in which there were
well formed germinal centres surrounding the invasive focus tended to be
less invasive, the majority of the lesions being categorised as
Dukes' A. Nind et al. (1973) found a correlation between peripheral blood
lymphocyte reactivity and the type of lymphocytic infiltrate of tumours.
Eighty percent of patients with anergic peripheral blood lymphocytes had
diffuse stromal leucocyte infiltration of their tumours including large
lymphocytes and plasma cells; whereas 50% of patients with reactive peripheral
blood lymphocytes showed a tendency to discrete perivascular aggregation of
small hyperchromatic lymphocytes, a finding which never occurred in the
tumours of anergic patients. Surprisingly, however, there was no correlation
between these findings and prognosis.
Other investigators have attempted to elucidate the relationship
between cancer and such histological phenomena by looking at the cell subsets
involved, their effectiveness against tumour antigens and their competence
on being assayed immunologically. These in vitro studies have not
shown any strong antitumour effect (Cochran 1982) although this could
admittedly be a problem of appropriate cell selection.
It is possible that the importance of tumour mononuclear cell
infiltration has been exaggerated and may have little to do with host
resistance, but rather, defective tumour growth. Berg (1971) noted that in
his experience of 20 spontaneously regressing malignant melanomas:
"In no instance was there a prominent round cell reaction. The tumour cells
just seemed to fade away.". He and Robbins (1964) also found that women
demonstrating the morphological patterns of host resistance in one breast
went on to develop a second primary in the other breast at the same rate
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as those without such patterns; hardly what one would expect in a resistant
host. Richardson (1965) similarly found that medullary breast cancers did
just as well whether or not they contained lymphocytic infiltrates.
Such conflicting data are difficult to interpret. On balance it would
seem that where there is lymphocyte infiltration it appears to be relatively
inefficient, certainly by the time tumours have developed sufficiently
to present clinically (Stewart 1969a). One cannot be sure whether these
histological appearances are just epiphenomena of no immunological importance,
or, that the changes are part of an immunological response which, in the
majority of cases, is made ineffective by the local action of the tumour.
The latter possibility is discussed later.
2.2.1.2. Tumour behaviour
Tumour regression: Spontaneous regression of human tumours, though
rare, has been well documented (Everson & Cole 1966; Smithers 1962). Tumours
most noted for this phenomenon are neuroblastoma, malignant melanoma,
hypernephroma, choriocarcinoma, Burkitt's lymphoma and breast carcinoma.
Minor viral and bacterial infections, fever of unknown aetiology and
changes in hormonal balance sometimes appear to play a role in these
inexplicable regressions (Morton et al. 1983). Examples of excision of the
primary tumour followed by spontaneous regression of lung secondaries have
been reported and this has been observed most commonly with hypernephromas.
Choriocarcinoma (Li et al. 1958) and Burkitt's lymphoma (Burkitt 1967)
occasionally regress following very low doses of chemotherapy raising the
possibility of initial cell destruction being followed by a stimulated
immune host response; indeed one of Burkitt's cases regressed following a
diagnostic biopsy only.
Smithers (1962) felt that most regressions of breast cancer, chorio¬
carcinoma, ovarian cancer and perhaps hypernephroma, could be explained
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by changes in the host hormonal milieu. He suggested that regressing neuro¬
blastomas and teratomas were examples of embryomal tissue undergoing
maturation and that some soft tissue sarcomas in regression are embryomal
in character and unstable in nature. This spontaneous differentiation,
therefore, may have little or no immunological foundation. However,
Everson and Cole (1966) pointed out that there was evidence for
differentiation in only five of 29 spontaneously regressing neuroblastomas.
Variation in tumour growth rate; occurs between individuals with
similar histological tumours, some progressing more rapidly than others.
This may be the result of an individual's immunogenic!ty but could be due
to the host's hormonal, metabolic, psychological or biological make-up,
or perhaps the effect of an external factor such as infection. However,
within individuals there may also be variations in growth rate in the
form of waxing or waning of tumour deposits. Malignant melanomas, for
example, may be seen to regress as others develop and breast cancers
occasionally appear to undergo fluxes in growth rate without any obvious
change in the host's hormonal status.
Subclinical incidence: The incidence of certain tumours such as neuro¬
blastoma and carcinomas of the thyroid and prostate has been found to be
higher at postmortem examination than would be expected on the basis of
clinical incidence (Gordon-Taylor 1959; Currie 1980) raising the possibility
that in otherwise normal healthy people tumours are developing and regressing
all the time.
Dormancy: Histologically identical metastases to the original primary
tumour develop in some patients 10 to 30 or more years following resection
of the original lesion. It appears unlikely that these secondaries are just
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extremely slow growing ones as, when they do develop, they often grow very
rapidly. Hadfield (1954) found it difficult to believe that cellular
proliferation in the residual tumour over such a prolonged period of time
could be continuous and suggested that it was hard to escape the conclusion
that the cells of the dormant growth must be in a state of temporary mitotic
arrest. "Dormant cells are prone to lurk in or near the site of the original
operation, in regional lymph nodes, or in deeply placed organs." (Gordon-
Taylor 1959) and in at least 50% of cases the reactivated metastases are
found in the haemopoietic bone marrow. Carcinoma of the breast and prostate
are the most usual tumours to exhibit dormancy and it is possible that the
phenomenon is hormonally based; tumour and host co-existing until an
hormonal environment develops which is suitable for tumour growth. Many
other cancers of organs not obviously under hormonal control have been
shown capable of latent recurrence and because of this it is difficult to
explain dormancy only in terms of hormonal milieu. Gordon-Taylor (1959)
related instances of apparently cured women who developed late recurrences
of their breast cancers following stress events such as infection or
relatively trivial surgical procedures. Others have also related stress to
the development of previously dormant tumours and more recently there have
been reports in the literature on the effect of stress on cell-mediated
immunity (CMI) (Schleifer et al. 1983; Stein et al. 1985; Denman 1986).
However, what changes there are in CMI are probably brought about by
changing Cortisol levels and it may be that this is more pertinent to the
appearance of latent cancer than any immunological upset.
Circulating tumour cells: Griffiths et al. (1973) and other authors
have found tumour cells present in the peripheral blood of patients
undergoing surgery, many of whom never developed metastases. This suggests
the existence of a highly efficient mechanism for the destruction of
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circulating tumour cells. The nature of this mechanism is speculative
but a host immune defence may be one of them. Griffiths discovered that
patients, in whose blood free tumour cells were seen at operation,
surprisingly appeared to have a better prognosis than those whose blood
contained none. This finding was verified by investigators from the same
centre (White et al. 1976) in a follow-up study in which they also
demonstrated that tumour cells could be maintained in the circulation for
much longer periods of time by giving perioperative anticoagulants. They
suggested that improved prognosis was secondary to prevention of attachment
of tumour cells to the vascular endothelium, possibly as a result of increased
levels of fibrinolysins. A specifically directed immunological defence
mechanism acting against cancer cells in the blood should be equally effective
against cancer cells within the tissues and as this is clearly not the case,
it therefore seems unlikely that this is the cause of tumour cell destruction
in the circulation. It is more probable that such destruction is due to
tumour cell trauma and non-specific defence mechanisms in the circulation
itself but to date, no one has been able to explain the mechanism
satisfactorily.
Family history; There is increased risk in blood relatives of
developing the same malignancies (Ponder 1984), even when inherited disorders
leading to malignancy such as retinoblastoma, familial polyposis coli,
xeroderma pigmentosum, immune deficiency syndromes, etc., are excluded. This
may be in the order of a two to four-fold increased risk for relatives of
patients when compared to the control population (Ponder 1984) for the more
common adult cancers, and it is tempting to implicate weakened familial
immunological host defence through perhaps inadequacy of IR gene expression.
Furthermore tumour directed immunity has been shown with high frequency in the
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relatives of cancer patients with sane tumours when compared with controls
(Cochran 1982). Examples of such tumours are osteogenic sarcoma, neuro¬
blastoma, leukaemia, Burkitt's lymphoma and breast cancer. The vast majority
of these relatives do not develop the cancer and it is again tempting to
conclude that exposure to the immunogenic stimulus results in immunisation
only, a satisfactory outcome for the host immune defence mechanism.
Whether this tumour-directed immunity is transmitted vertically or
horizontally, the latter being reminiscent of the spread of feline-leukaemia
virus, is open to debate. However, it should be borne in mind that although
tumour directed inmunity reactions can be demonstrated in a high proportion
of cancer patients, it can also be shown in 15 to 20% of ostensibly
normal controls (Cochran 1982). The question of the specificity of these
reactions and therefore their relevance to cancer must be in doubt.
*
Other perhaps more rational explanations for familial clustering
can be given, the exposure of members of a family to the same environment
(carcinogens) being the most obvious. Genetically, members of a family may
be more susceptible to certain carcinogens in that the genetically determined
differences in the metabolism of drugs between individuals may also apply
to the handling of carcinogens. Additionally, factors such as dietary fat
and hormonal status must be taken into account when considering carcinomas
of the breast, ovary, endometrium and large bowel (Lemon 1984).
Multiple primary tumours: Although it is rare to have two synchronous
tumours this does happen; but more commonly sequential tumours develop
(Cochran 1982). Indeed, one primary increases the risk of a second.
Barber (1984) noted that carcinoma of the breast predisposes the patient
to develop colonic, rectal or ovarian cancer. Similarly, there is
increased risk for patients who have carcinana of the ovary or endometrium
to present later with a breast primary. Harwood (1984) noted "The clinician
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treating cancer of the head and neck is facing an epidemic of second
respiratory tract malignancies of such a magnitude that it is progressively
replacing the initial primary cancer as the major cause of death in these
patients.". The misfortune of these patients might be attributed to
defective host immune surveillance and indeed seme second tumours especially
of the lymphatic and reticulo-endothelial system appear to follow the rather
immunosuppressive treatments of chemotherapy and radiotherapy applied to
the first tumour (Whang-Peng & Sieber 1984). Such treatment, or indeed,
the immunosuppressive effects of the first tumour itself (as we shall see
later), might allow oncogenic viruses to exert their effect at a cellular
level at that time, or perhaps after further depression of CMI following
opportunistic invasion of the host by immunosuppressive viruses. These
tumours may possibly be related in seme way or another to defective immune
surveillance.
Immunologically unrelated explanations for multiple primary tumours
are just as, if not more, likely. The mutagenic effects of radiotherapy or
chemotherapy may be the result of chromosomal damage. Successful treatment
of the first tumour may result in patients surviving long enough to
manifest a second tumour in a less carcinogen-sensitive tissue, or a
second tumour to a different carcinogen altogether. These may be exogenous
carcinogens such as chemical, viral or physical agents, or endogenous
carcinogens such as hormones. Certainly hormones appear to be implicated in
the development of certain tumours such as breast, endometrium and ovary.
Dietary fat is closely correlated to the incidence of large bowel, breast and
ovarian tumours perhaps as a result of its effect on bile acid metabolism and
oestrogen metabolism (Hill & Thompson 1984). It seems probable that multiple
cancers are the net result of exposure to carcinogens, and the effect on the
host of mutagenic therapy for the first tumour. The possible role of
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oncogenic viruses and their relationship to the host immune system cannot
however be excluded.
2.2.1.3. Immune deficiency
According to the theory of immune surveillance, immune deficiency,
whether congenital or acquired, should result in an increase in the
incidence of tumours of all types of tissue, often occurring metochronously
and this effect would be most marked in those with defective CMI. What
actually happens can be seen when tumour development is examined in relation
to age, allergic individuals, immune deficiency states, and immunologically
privileged sites.
Age: and immune function are indisputably related. Indeed seme,
including Burnet (1970b) have suggested that the ageing process may to some
degree follow impairment of the immune system. There appears to be diminished
immune function in the foetus, the early infant, and the elderly; these
extremes of age being times of greater risk from infectious disease.
Nagel (1983), in a review of the literature on ageing and immunity, noted
that humoral immunity showed little obvious change with age, but CMI
appeared increasingly depressed with advancing years. The fact that most kinds
of cancer, excluding those in organs directly influenced by female hormonal
status around the menopause, have curves of specific age incidence which rise
logarithmically with age, led to the suggestion that cancers were more common
at this time in life because they were allowed to grow in the face of defect¬
ive irrmunological surveillance (Burnet 1970b). Good (1972) further argued that
because with age, CMI involved in the host defence to tumour becomes
impaired whilst humoral immunity with its potential negative 'blocking' effect
on this host reaction is retained, there is imbalance in the elderly
favouring the development of malignancy.
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The possibility exists, however, that the increasing incidence of
cancers with age is merely related to the length of exposure to background and
spontaneous carcinogenic stimuli. It has been shown (Peto et al. 1975) that
tumour induction in mice is a feature of duration of exposure to the
carcinogen rather than the age of the animal when exposed to this carcinogen.
If this holds true for humans, no intrinsic effects of ageing such as failing
immunological surveillance need be postulated to explain the vast increases,
in old age, of the incidence rates of human cancers.
Allergy: is a cell-mediated immune phenomenon. It is conceivable that
those displaying such hyperreactive cell-mediated responses to antigens
might invoke the same powerful responses to tumours. Fisherman (1960) using
the triad of flexural eczema in early childhood, development of hay fever at
puberty and atopic asthma in middle life, was able to categorise those in his
study into atopic and non-atopic types. He found that in his control
population four times as many people gave a history indicating atopy as those
from a group of approximately 1,300 cancer patients. Similarly, MacKay (1966)
found that controls had greater than twice the number of individuals giving
a history of allergy as patients with cancer but this phenomenon was seen
only in women.
Congenital immune deficiency: Melief and Schwartz (1975) reported that
cancer develops in approximately 10% of patients with spontaneous immune
deficiency diseases. Forty-seven of the 58 patients in their series, however,
had either lymphoma or acute leukaemia. Good (1972) found a similar proportion
of malignancies. Those with mainly CMI deficiencies such as ataxia
telangiectasia and Wiskott-Aldrich syndrome were prone to develop tumours of
the lymphoreticular system, as were common variable immunodeficiency syndrome
patients who have mixed humoral and cellular immune deficiency. These patients
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also had a slightly higher preponderance of epithelial and rare tumours than
the control population. Patients with Bruton's agammaglobulinaemia have
intact GMI but deficient B lymphocyte activity and they too have an
increased susceptibility to development of cancers, 10% presenting with
leukaemia (Good 1972).
Acquired immune deficiency: other than secondary to nuclear accidents
or to transmitable viruses is usually the result of medical manipulation
in the area of autoimmune diseases or transplantation procedures. In renal
allograft patients, Hoover and Fraumeni (1973) found a 350-fold risk to
patients of developing reticulum cell sarcoma and a 35-fold risk of lymphomas.
The overall risk of developing malignancies in other organs was hardly
affected, a notable exception being tumours of the liver which possibly can
be attributed to horizontal transmission of hepatitis virus, the hepatitis B
virus being implicated in hepatocellular carcinoma (Lancet 1981a; Weiss 1984).
Five percent of renal transplant patients reported by Melief and Schwartz
(1975) developed cancers, mainly malignant lymphomas, but also epithelial
cancers of the skin, lip or cervix. These investigators pointed out that the
incidence of reticulum cell sarcoma in women in this study was 700 times
greater than expected, yet the incidence of the most common female cancer,
carcinoma of the breast, was not increased at all. They attributed the
increased incidence of epithelial cancers to an increased frequency of
physical examination in these patients when compared with the control
population. Kinlen et al. (1979) examined, in a multicentre study, almost
4,000 renal transplant patients who had been given immunosuppressive drugs
for at least three months and over 1,300 patients with other medical
conditions necessitating immunosuppressive therapy. They noted in the trans¬
plant group a 60-fold increase in non-Hodgkins' lymphoma and an excess of
squamous cell skin cancers and mesenchymal tumours although the total number
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of these was very small. They also found the tumour induction period for
lymphomas to be very short and suggested, as a consequence of this finding,
that the cause of these tumours might be an oncogenic virus. Patients in
Kinlen's study who had immunosuppressive therapy for medical conditions;
rheumatoid arthritis, glomerulonephritis, ankylosing spondylitis etc.,
although having increased development of tumours, were not affected to
nearly the same extent as patients who had undergone transplantation. The
implication from this is that the transplant patients developed more tumours
because they were more deeply immunosuppressed as a result of prolonged
renal failure and prolonged period of administration of immunosuppressive
drugs. Interestingly, conditions with chronically but not severe defective
cell-mediated, and especially T cell, immunity as occurs in leprosy and
chronic renal failure, do not appear to have an increased incidence of cancer.
Immunologically privileged sites: Areas of the body having no, or little,
connection with the lymphatic system are relatively independent of the immune
system. The anterior chamber of the eye in humans and the hamster cheek-pouch
are characterised by absence of lymphatic drainage. Intracerebral, prostatic
and testicular tissues, and to a lesser extent the liver, are areas having
poor lymphatic connections. Such sites are immunologically privileged but
do not have the increased incidence of cancers which one would expect
if immunity were important in the prevention of tumour development.
In sunmary, immune deficiency does result in an increase in cancers.
These, however, tend to be lymphoreticular tumours with no obvious increased
evidence in the common solid cancers affecting man. It can be argued that
patients with congenital immune deficiency may develop tumours as a result
of associated genetic factors, or that those with acquired immune deficiency
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have been subjected to immunosuppressive medication which itself is directly
oncogenic. Another possible suggestion (Currie 1980) is that immunologically
suppressed individuals are more prone to infections by viruses some of which
are oncogenic (Weiss 1984). For instance nude mice which are athymic and
cannot mount allograft or xenograft rejection reactions nor respond to viral
infections also have a high incidence of lymphoreticular tumours but no
increased incidence of other tumours (Rygaard & Povlsen 1974), behaving just
as immunosuppressed humans do. Proponents of the theory of immune surveillance
might suggest that because these mice have to be kept in a germ free environ¬
ment they do not came into contact with other tumour producing carcinogens,
or that these lymphoreticular cancers develop not because of defective
surveillance, but secondary to a defect in cellular interactions and
regulations in a defective immune system. Certainly there is no increased
incidence of tumours of all kinds occurring spontaneously and synchronously
in immunodepressed individuals and neither is there an increased incidence of
tumours occurring in immunologically privileged sites. The tumours which do
develop belong to a specialised group and may be the result of oncogenic
viruses (Kinlen 1982), these being permitted to exert their effect in the
face of a defective host immune response. The evidence to date suggests,
however, that there is no strong link betwen impaired immunity and the
development of the more common tumours in man in Western society.
2.2.2. Experimental
Tumour transplantation experiments and cutaneous testing to tumour
extracts were performed on the basis that tumours had associated antigens
recognisable as foreign by the host. The experiments were an attempt firstly
to detect antitumour immunity in vivo in humans, to elucidate the
mechanism of tumour rejection, to correlate immune reactivity with other
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parameters of prognostic significance, and finally to define and purify,
if possible, specific tumour antigens.
2.2.2.1. Tumour transplantation Allografts: Southam et al. (1957)
intradermally inoculated tissue cultured tumours into patients with advanced
incurable cancers and short life expectancy. Many had infections, metabolic
complications and cachexia but surprisingly were still able to produce
antibody against viruses inoculated at the same time. Most of these patients
rejected the tumours, but slowly when compared to control patients who
uniformly exhibited rapid rejection of the tumour inoculum. In same cancer
patients the inoculated tumour continued to grow locally and occasionally
these tumours recurred locally following excision of the site of inoculation.
Two of these particular patients continued to exhibit this local growth up
until death from their own original tumours, six and nine weeks later, one of
these patients having metastases of inoculated tumour to her axillary nodes.
These investigators later showed that tumours from individuals with more
aggressive disease were more likely to 'take' than more localised growths
(Southam et al. 1966), and that successful growth was also related to the
immune status of the recipient (Southam et al. 1965). Scanlon et al. (1965)
reported the death from metastatic melanoma of an 80 year old woman who had
been the recipient of an inoculum of her daughter's tumour, in an attempt
to raise antimelanoma serum. Whether or not this was the result of depressed
CMI related to her age must remain hypothetical.
Reports of inadvertent transplantation of tumours have cane from the
field of renal transplant surgery (Mcintosh et al. 1965; Martin et al. 1965;
Kinlen 1982) but these tumours usually regress on cessation of therapeutic
immune suppression (Kinlen 1982) as indeed do most of the lympho
proliferative lesions which develop secondary to immunosuppressive therapy
in transplant recipients (Starzl et al. 1984).
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Autografts: have a low incidence of successful growth in humans, most
being rejected even in those with advanced cancer. Southam et al. (1965)
showed this to be dependent on the immune status of the recipients measured
by skin reactivity to tuberculin and DNFB, and macrophage mobilisation.
4
Successful growth was also dependent on inoculum size, 10 cells never
g
being successful, 10 cells always inducing growth, and intermediate
numbers of cells successfully growing, depending on the recipient's immune
status. Mixing autologous leukocytes (?lymphocytes) with the tumour cells
prior to inoculation resulted in cessation or slewing of growth in half the
recipients. Under these conditions to achieve successful 'take' the number of
tumour cells in the inoculum had to be increased ten-fold. Similar tumour
dose-related effects have been seen in animals (Old et al. 1962;
Stjernsward 1968). Southam and his colleagues believed that the mechanism
of tumour rejection was probably cell-mediated, most likely through the
lymphocyte population, as autologous plasma had little tumour inhibitory
activity in this system (Southam et al. 1966).
To summarise tumour transplantation phenomena, it would appear that
although the rejection of homograft tumours is to some extent dependent
on the patient's irrmune status, it is almost certainly related to HLA
associated antigens rather than a response to tumour associated antigens.
Autochthonous tumour rejection on the other hand does seem to depend on a
cell-mediated reaction specific for the tumour cells. In attempting to
elucidate this and to find out more about the antigens involved, investigators
turned to the effects of cutaneous testing to tumour extracts, as well as to
other less direct techniques consisting largely of examination of the
interactions of tumour cells with various effector limbs of the immune
response.
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2.2.2.2 Cutaneous testing to tumour extracts: One of the earliest methods
used to detect cell-mediated antitumour immunity was the induction of
delayed-type skin hypersensitivity using crude extracts of autologous
tumour. Previously, a humoral immediate-type skin response had been noted
to autologous crude extract of tumour (Curtis et al. 1961).
Hughes and Lytton (1964) showed that autologous cytoplasmic particles
from various cancers, injected intradermally, produced a positive reaction
of the immediate type. This was followed in 11 out of 50 patients by a
delayed-type response. Two of these patients also reacted in this fashion
to extracts of benign tissue from the same organ from which the cancer was
extracted. Three of 11 patients with breast cancer displayed delayed-type
hypersensitivity and none of these reacted to control breast tissue extract.
There was no correlation with tumour histology or nodal status.
Stewart (1969b) demonstrated that the delayed hypersensitivity reaction
was to the tumour cells and not to nuclear material or bacterial antigen,
and later (Stewart 1969a) that skin reactivity was proportional to lympho¬
cytic invasion of the tumour. The same author, with Orizaga (1971), reported
delayed hypersensitivity reactions in 12 of 56 patients with breast cancer
on testing up to four days following surgery. Positive reactions occurred
more commonly in those with anaplastic tumours and node involvement and in
those tumours showing a high degree of infiltration with lymphocytes and
plasma cells. Peculiarly, this reactivity appeared to be inversely related to
survival in that only 42% of patients who were skin test positive were alive
at two and a half years compared with 78% of those who were non-reactive.
They postulated that this was because these particular tumours were so
aggressive that they overcame the lymphoid reaction or even that this
reaction was stimulatory. Another finding was that 50% of these patients
displayed cross-reactivity on testing with allogeneic tumour extracts,
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indicating perhaps a viral aetiology for these breast cancers.
Others have used membrane preparations in an effort to develop a well
characterised standardised skin test for breast cancer. Alford et al. (1973)
showed that approximately half of breast cancer patients were reactive to
membrane preparations of their own or allogeneic tumour membrane preparations
but were non-reactive to extracts of normal breast tissue. Patients with
benign breast disease or other types of tumour were non-reactive. Further
purification of the membrane preparation by sonication and elution on
Sephadex G-200 resulted in a fraction which caused reactivity in 9 of
10 patients with breast cancer; but 2 of 4 patients with other types
of cancer also responded, as did 12 of 22 with normal or benign breast
disease.
Another approach to the in vivo detection of CMI to breast cancer
was the use of the 'skin window' technique where a section of autologous
tumour or benign disease tissue mounted on a coverslip is placed over an
abraided area of skin. The nature and amount of cellular infiltration is
evaluated approximately 24 hours later (Black & Leis 1971; Black & Leis 1973).
Cellular infiltrates indicative of hypersensitivity reactions were induced in
40% of cancer patients as compared with 10% of patients with benign breast
disease. Positive infiltrates were induced more often in those with
premalignant mastopathy and in-situ cacinoma than in those with invasive
carcinoma. Positive infiltrates were also more commonly seen in patients who
had regional nodes displaying positive sinus histiocytosis indicating that
these cryostat sections might have some degree of prognostic correlation.
Studies of cross-reactivity are precluded using this technique for reasons of
safety, and conclusions regarding the specificity and hence immunological
nature of such observations cannot be made.
In summary, cutaneous testing using tumour or tumour extracts has
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never been wholly satisfactory in that both patients and controls react in a
somewhat arbitrary fashion. Interpretation is often difficult because of the
subjective element attached to it, there is occasional bacterial contamination
of the tumour extracts, and also a lack of appropriate normal control
tissue extracts (Currie 1980).
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2.3. Tumour Associated Antigens
2.3.1. Historical background
Work in the late nineteenth and early years of this century, as a
result of observations that transplanted tumours frequently showed spontaneous
regression, demonstrated that animals rechallenged with the same tumour
displayed increased resistance. These observations resulted in many attempts
at immunotherapy but with little success. The reason for this failure was
acidly pointed out by Woglom (1929) who demolished the work of many who had
laid the foundations of the existence of tumour-specific immunological
responses by indicating the lack of genetic homogeneity in the experimental
animals. These experiments were not examining immunity to tumour antigens
but to allografts.
The existence of tumour antigens could only be satisfactorily decided
when inbred genetically homogeneous strains of experimental animals became
available. Gross (1943) induced sarcomas in the C^H strain of mice using
methylcholanthrene, and showed that these tumours could be transferred from
one mouse to another by intradermal inoculation. However, a proportion of
these tumour transplants regressed and regressor mice subsequently showed
increased resistance to further rechallenge with the tumour. Interestingly,
spontaneous tumours developing in these mice were unaffected by this
immunity and he was thus able to conclude that the resistance to tumour
growth was immunologically specific, and by inference, that these tumours
carried antigens specific for the tumour. A decade later it was shown
(Foley 1953) that increased resistance could be demonstrated following
surgical excision of the tumour. These experiments continued to be criticised
because of the possible influence of residual heterozygosity. Prehn and Main
(1957) demonstrated, however, that antigens produced by methylcholanthrene
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were peculiar to the tumour produced and were not present in cells from normal
tissues of the animal. There did appear to be evidence of seme degree of
cross-reactivity between some of the tumours although, in the main, the
tumours tended to be immunologically distinct. Using the same model
Klein et al. (1960) demonstrated that methylcholanthrene-induced tumours
were each antigenetically different even in the same animal. The same findings
were obtained in rats and guinea pigs. Because of such clear cut specificity
and the experimental methods used to show this, these antigens were termed
'tumour specific transplantation antigens' (TSTAs). Since then, many have
shown that tumours produced in the laboratory by viral, chemical and physical
agents have TSTAs (reviewed by Old & Boyse 1966).
Such experiments are ethically unsuitable for humans, and other
in vitro methods to detect tumour specific antigens (TSAs) have been
used in both human and animal experiments. Such antigens should not be called
TSTAs as it is not known if they are those responsible for tumour transplant
rejection. Methods used to demonstrate these antigens have been assays of
cell-mediated immunity, humoral immunity and monoclonal antibody.
Hellstrom and Sjogren (1965) showed that cells taken from tumour
irrmune animals could inhibit or lyse tumour cells in vitro. This colony
inhibition test proved the basis of many further cytotoxicity assays used
in studies of human tumour immunity. The first development of it was a micro-
cytotoxicity assay (Tagasugi & Klein 1970) for studying lymphocyte cyto¬
toxicity. Numerous studies of human tumour patients were performed using
these assays and the principal finding was that lymphocytes from these
patients could kill target cells derived from their own tumours or other
tumours of the same histologic type (reviewed by Currie 1976), a surprising
outcome in the face of a large body of animal data which had shown chemically
and physically induced tumours to carry transplantation antigens specific
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to that tumour alone, but not shared by tumours of similar histology. Other
assays of CMI to tumour antigens have been those using lymphoblastogenesis,
leukocyte migration inhibition, leukocyte adherence inhibition and antibody-
dependent cellular cytotoxicity, all which have been well reviewed
(Currie 1980; Gupta & Morton 1983; Heppner & Hager 1980) and all of which
appear to suggest the existence of tumour antigens. However, there are
problems with all of these tests with regard to technique, interpretation,
cross-reactivity and specificity, and none have, as yet, shown unequivocally
the presence of antigen specific only for a specific tumour.
Antibodies are not difficult to detect in cancer serum but proving
their specificity is extremely difficult. However, using autologous,
allogeneic and xenoantibody, attempts have been made to find tumour associated
antigens (TAAs) serologically. Gupta and Morton (1983) stated "Using
hetero-antisera a number of tumour antigens other than CEA and AFP, have
been detected in various human malignancies including melanoma, sarcoma,
and carcinomas. However, many of these antigens have been shown to be
expressed by fetal tissues as well.". To date there is no conclusive
evidence that these antigens are immunogenic in the cancer host. Autologous
and allogeneic assays in humans have been beset with problems of specificity
and technique, cross-reactivity between different tissues occurring commonly
and antibody to cytoplasm and nuclear factor further masking the situation.
Some success has occurred with serological assays in Burkitt's lymphoma and
sarcomas, i.e. tumours with possible viral aetiologies, and Currie (1980) has
suggested that these antibodies may be directed against viral antigen. The
serological literature on human tumour antigens was reviewed by Currie (1976)
and can be summarised by stating that many laboratories have shown tumour
antigen systems identified by many methods and that there are many
discrepancies between laboratories. Most of these have been due to the fact
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that no two polyclonal sera, whether from a tumour bearing patient or
immunised experimental animal, are ever identical.
Monoclonal antibodies, developed by Kohler and Milstein (1975), are
extremely specific but they too have been beset with the problem of
specificity, and the more carefully a TSA is investigated, the less likely
it appears to be specific to the tumour cell, certainly outside the rather
artificial world of highly immunogenic animal models.
2.3.2. Aetiology of tumour associated antigens
"In general the type of antigen that appears on a tumour depends
on the agent that induces the tumour." (Old & Boyse 1966). In animals
and man we know that chemicals, physical agents and viruses can bring
about tumour induction. There is usually no obvious aetiological factor
in humans and such tumours are termed spontaneous.
TSTAs induced in laboratory animals are unique in that they are
specific for a specific tumour and have no strong cross-reactivity, although
the tumours also appear to have weaker associated antigens which do have
sane degree of cross-reactivity (Gupta & Mbrton 1983). There is evidence that
these weaker antigens may be due to viral contamination of the laboratory
animals but it seems more likely that they are embryonic or foetal antigens,
demonstrated as a result of derepression of an inactive gene coding for their
synthesis. Chemically induced TSTAs in laboratory animals tend to be
strongly immunogenic but the strength of the immunogenicity varies with
other factors. Tumours induced by low doses of chemical carcinogen take
longer to develop and possess little or no immunogenicity whereas large
doses of carcinogen rapidly induce tumours of high immunogenicity
(Prehn 1975). This phenomenon appears to be related to the associated
immunosuppressive activity of the carcinogen (Prehn 1963). The host
immune status is also related to the strength of TSTAs, Lappe (1968)
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demonstrating that immunosuppressed animals quickly developed tumours
of high immunogenicity, whereas animals with stimulated immunity took
longer to develop tumours which had weak TSTAs.
Physically induced TSTAs behave as their chemical counterparts, but
tend to be rather weak in comparison (Gupta & Morton 1983).
Virally induced TSTAs were first demonstrated on tumour cells by
Sjogren et al. (1961) who showed that polyoma virus-induced mouse tumours
contained TSTA which would cross-react with other tumours induced by the
same virus; very different to the type of specificity displayed by chemical
and physically induced tumours. It was subsequently demonstrated
(Smith 1968) that sarcomas, carcinomas, and embryomal tumours induced by a
specific virus shared the same TSTA, this cross-reactivity being therefore
independent of histological tumour type and indeed of animal species, but
dependent on the oncogenic virus. There was no cross-reactivity between
tumours induced by different strains of virus however. Viral tumours, like
physical and chemically induced tumours, are known to express weaker foetal
or embryonic antigens (Gupta & Morton 1983; Coggin et al. 1970). TSTAs
specific to viruses differ in immunogenicity depending on the strain of
virus (Old & Boyse 1966), but are of similar antigenic strength as those
induced by chemical carcinogens (Gupta & Morton 1983), the spectrum which
ranges from no detectable antigenicity to very strong antigenicity (Prehn
1975).
Spontaneous neoplasms appear sporadically and infrequently in certain
animal strains, leukaemia in AKR mice and mammary cancer in C^H mice
being examples. They are different to artificially induced tumours, most of
which are strongly immunogenic, in that they tend to be only weakly or not
at all irrmunogenic (Hewitt et al. 1976). Most human tumours are at best
possessed of weakly immunogenic TAAs, metastasise early and extensively, and
29
in this fashion behave differently to animal tumours in which this behaviour
is exceptional. Hewitt et al. (1976) made a plea for more research using
animals with spontaneous neoplasms as these were more akin to human
malignancies. They believed that because the majority of animal models were
chosen for their strong TSTAs and IR genes inducive of strong immune
responses, research involving such models was artificial and consequently
counter productive in the understanding of the relationship between cancer
and immunity in humans. Currie (1980), on the other hand, argued that
animal models with spontaneous tumours were also imperfect as they displayed
entirely predictable behaviour, and did not exhibit the episodes of partial
regression, dormancy and clinical unpredictability which is seen in humans.
Tumours developed in laboratory animals and spontaneous animal and human
tumours are not entirely independent of each other however; there being
evidence that some spontaneous tumours have viral aetiology (Kinlen 1982;
Weiss 1984), and others occur as a result of exposure to low levels of
chemical carcinogens present in the environment (Prehn 1975). Prehn's
suggestion is in accord with human tumours expressing weak antigenicity and
with the concept that 70 - 90% of human cancers are induced by environmental
factors (Higginson 1972).
2.3.3. Role of tumour associated antigens in humans
Artifically induced animal tumours invariably have strong TSTAs with
powerful rejection reactions to them, unless the animals are immuno-
suppressed or given too great a tumour burden to cope with, and it would
appear that the development of these neoantigens is an essential ingredient
of the malignant transformation process (Old & Boyse 1966). However, in
animals and humans with spontaneously occurring tumours no conclusive
evidence has been presented that TSAs exist despite serological (both
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monoclonal and polyclonal) and cell-mediated responses to antigens associated
with tumours having been demonstrated. Are these tumour associated immuno¬
logical responses important in the sense of host rejection activity, or, are
spontaneously occurring tumours antigenic but not immunogenic, possessing
membrane determinants capable of specific interaction with one element or
another of the immune response but not inducive of cell killing? In answer
to this, the degree of cross-reactivity in tumours arising spontaneously,
suggests that malignant transformation may be associated with exposure of
either, cell surface antigen hitherto shielded on the membrane, or intra-
cytoplasmic antigen not previously expressed on normal tissue, that is,
malignant change comprises the expression of a normally existing and non-
immunogenic macromolecule to the host immunological apparatus and not the
synthesis of neoantigen. On the other hand cross-reactivity occurring in
viral tumours can still be explained by common viral neoantigens.
Cochran (1982) has suggested that TAAs are possibly differentiation
markers, organ specific markers, re-expressed embryonic or foetal antigens
such as CEA and AFP, or antigens of classes not yet identified, and are
not specific for tumours. For instance, antigen belonging to normal tissue
may appear initially to be a TSA because it is expressed on tumour cells
in quantitatively larger numbers than on the normal cells from which the
tumour is derived (Woodbury et al. 1981). Similarly, where the normal
body cell population is very small, its malignant counterpart will be
present in relatively greater numbers and antigens common to both will
initially appear tumour specific. An example of this is the CALLA antigen
initially thought to be specific for the common (nonT) ALL (Ritz et al.
1980), but later found in normal bone marrow probably on an early stage B
cell (Greaves et al. 1981). Antigenic expression may also be cell cycle
dependent as is the receptor for transferrin, normally present on cells
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in the bone marrow and thymocytes, but which has been found also on
rapidly growing tumour cells in culture (Omary et al. 1980). These are
examples of the problems confronting those searching for TSAs, and
certainly to date, it appears that the more critically one evaluates an
apparent TSA the less likely it is found to be specific for the tumour
concerned.
Although their presence has never been unequivocally proven it is
possible that TSAs exist in all of us perhaps for a transient period of
time during which they are recognised as foreign and the tumours carrying
them rejected by our immunological apparatus, this being in accord with
the theory of immune surveillance. Such supposition would permit tumours
to grow successfully only where these antigens are too weak to invoke
such a response although Prehn (1976) has argued strongly against this
possibility. Our present knowledge of TAAs is insufficient to permit
critical evaluation of their importance with regard to the host immuno¬
logical response to tumour. They have, however, been useful in the
understanding of the host effector systems in immunity, and are presently
in use as measures of disease activity and response to treatment, examples
being CEA in large bowel tumours and AFP in primary hepatomas and
teratomas of the testis and ovary.
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2.4. Immune Effector Systems Against Tumours
The effector systems responsible for tumour rejection are
ill-defined in laboratory animal tumours and even more so in the
spontaneous cancers arising in man. Host attack on tumour cells can be
implemented immunologically through either the humoral or cell-mediated
arms, or a combination of both. If TSAs exist there should be specific
immunological responses to the cells carrying them but this does not
preclude the occurrence of other non-specific responses to these cells.
Lewis et al. (1969) found specific antibodies to malignant melanoma
cells, and Thompson and Linna (1973) showed that humoral immunity, as well
as cell-mediated immunity, protected chickens from viral oncogenesis.
Currie (1980), reviewing the role of antibody in resistance to tumour
stated "As a general rule tumour-specific antibodies develop in early
disease and following tumour excision; and such antibodies can be made
to lyse tumour cells under a variety of artificial conditions.". He also
noted that antibody may act not only in a cytolytic fashion but also by
inhibiting tumour growth especially when present in lower concentrations.
He warned that although antibody appeared present in seme cancers,
in vitro assays of their activity contained many technical pitfalls,
thereby calling into question the importance or even relevance of that
presence. Antibody also appears, in vitro, to act by causing inhibition
of tumour cell motility (Currie & Sime 1973) and may work in concert with
unsensitised lymphocytes to lyse target tumour cells in vitro, this
phenomenon being known as antibody dependent cell cytotoxicity (ADCC),
the specific cells involved being killer (K) cells. Other cells capable
of antibody dependent killing are macrophages and granulocytes which, like
K cells, have Fc receptors on their surface membranes. The specific antibody
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involved is usually IgG and the process is independent of phagocytosis and
complement. The first person to demonstrate such co-operation between
antibody and cellular mechanisms was Moller (1965) who noted that the antibody
was only detectable during early tumour growth and also that it was capable
of 'blocking' the effect of specific cell-mediated cytotoxicity, as prior
treatment of target cells with antibody abrogated the effect. Moller's
suggestion of 'blocking' by antibody received support from the Hellstroms
(1969) who showed that serum from tumour bearing animals could abrogate
in an immunologically specific manner the antitumour effect of specifically
sensitised lymphocytes, and for a time it was held that antibody was bad
in that it prevented cell-mediated tumour damage, even though there was
never proof that it was antibody itself which did the 'blocking'.
In addition to specific antibody, non-specific auto-antibody has been
noted in patients with cancer (Whitehouse & Holborow 1971), to cellular
components, presumably as a response to tumour cell necrosis, but this is
also seen in normal people and increases with age and may, therefore, be a
mechanism for clearing up debris from dead or dying cells. Currie (1980)
has, however, suggested that tumour cells may have 'natural' antibody
directed against them, perhaps by expression of surface determinants not
detectable on normal cells, through defective glycolisation, in a similar
manner to the opsonisation of effete red cells by immunoglobulin in normal
autologous serum.
Shuster (1984) and Campbell et al. (1986) have suggested the reason
that specifically directed antibodies to tumours have not to date been
isolated is because the humoral response to tumour may be very limited
when compared to that of cellular immunity. Further, any specific humoral
response may be masked by the much greater non-specific antibody responses
in the serum directed against common tissue antigens released by normal
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cell destruction.
Whether or not specific or non-specific humoral responses to cancers
do occur and play a part in the process of tumour rejection remains
inconclusive. Indeed it is possible that their role may be a negative
one because of their ability to 'block' specific cell-mediated responses,
and further, there is evidence to suggest that such antibodies could
even be stimulatory to tumours under certain conditions (Murasko & Prehn
1983).
It is generally held that CMI is more important in tumour rejection
than its humoral counterpart, and indeed tumour specific immunity can be
adoptively transferred by lymphocytes much more readily than antibody
(Southam et al. 1966; Morton et al. 1983).
From allograft work it was assumed, though never proven, that the
effector cells in tumour rejection were thymus-derived lymphocytes
(Cerottini & Brunner 1974) and there was some evidence from animal work
to suggest an in vivo role for these lymphocytes in the prevention
of tumour development. Allison and law (1968) showed that thymectomy or
giving antilymphocyte serum (ALS) enhanced the incidence of virally
induced tumours in neonatal mice. Grant and Miller (1965) found a decrease
in the latent period for development of chemically-induced tumours in
neonatally thymectamised mice, although, following tumour development,
there was no difference in tumour growth rate between thymectamised
animals and controls. Thymectomy in adult mice had no effect on tumour
development. Allison and law (1968) stated "Animals treated with chemical
carcinogens sometimes show increased incidence of tumours after neonatal
thymectomy but usually not.", and Currie (1980) in summarising the
literature suggested that tumours induced by carcinogenic hydrocarbons
were little influenced by immunosuppression and their incidence in
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thymectomised or nude mice was no greater than in normal control mice.
Such data appears to indicate that chemically-induced tumours and, by
inference, spontaneous tumours are independent of T lymphocyte function but
that virally induced tumours are influenced by these lymphocytes.
Hellstrom et al. (1968), however, demonstrated cellular (and humoral)
immunity in humans which indicated specificity, as only autochthonous
tumour cells were killed by the effectors. This supported the concept of
necessary effector stimulation by prior inmunisation, and hence a role
for the T lymphocyte, a prerequisite for its generation being previous
contact with the antigen. This finding was upset later in 1973 by
Tagasugi et al. who showed that prior immunisation was not necessary,
by demonstrating that cells from normal individuals appeared to exert the
same, or even greater, cytoxicity than lymphocytes from cancer patients.
Tagasugi's work has been amply confirmed by other authors since then.
The search for effector cells against tumours was aided by the use
of alloantisera in mice which allowed better definition of lymphocytes
and particularly T lymphocytes (reviewed by Simpson & Beverley 1977)
showing that various subsets had different functions, e.g. help and
suppression of antibody responses were mediated by different T cell types.
The use of monoclonal antibodies specific for these subsets further
enhanced investigation of their definition and function (Reinherz &
Schlossman 1980; Ballieux & Heijnen 1983). Further, a number of researchers
have defined and characterised the small subset of apparent lymphocytes
responsible for non-specific, antibody-independent tumour cell cytotoxicity.
These natural killer (NK) cells have been well reviewed (Santoli &
Koprowski 1979; Kiessling & Wigzell 1979; Herberman et al. 1979;
Herberman 1983a). In summary they are non-adherent, non-phagocytic,
complement-independent and carry surface markers compatible with macro-
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phage or lymphocyte lineage, though Herberman and colleagues feel they
are early T cells. They may be involved in ADCC through their Fc - IgG
receptors, as well as having the ability to achieve tumour cytotoxicity
non-specifically through tumour antigen receptors, and as such may indeed
be K cells. Their activity is augmented by viruses, BCG, Corynebacterium
parvum and tumour cells susceptible to their action, probably through
the production of Interferon to which NK cells are very responsive.
Natural killer cell activity is depressed by immunosuppression, high dose
radiotherapy, chemotherapy, hydrocortisone and large tumour burden.
Natural killer cells, when stimulated by Interferon, are highly cytotoxic
to virus-infected cells and to tumour cells but do not damage normal cells.
It is thought that they are the cells responsible for the low incidence
of spontaneous and chemically-induced tumours in nude and neonatally
thymectomised mice as NK activity in these animals is very high.
Interestingly, this resistance to tumour can be broken in nude mice by
irradiating the animals (personal communication from Rygaard to Kiesling &
Wigzell 1979) which is known to depress NK activity. These cells seen to
meet the criteria necessary for tumour surveillance in that they "have
high spontaneous activity or can rapidly develop high activity (through
Interferon) in response to tumour cells or other stimuli", whereas immune
T lymphocytes and activated macrophages take longer to respond
(Herberman et al. 1979) by which time the tumour may have developed
sufficiently to overcome further immunological attack. It is possible
that NK cells may be more important in tumour rejection than T lymphocytes
but because they are present in the peripheral blood of controls as well
as in cancer patients, it is almost impossible to assay for the specific
cytotoxicity of T cells with any certainty.
Macrophages are also apparently capable of reacting in non-specific
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fashion to tumour cells. When activated they kill tumour cells in vitro
by direct contact and transfer of lysosomal contents and can also act to
inhibit tumour growth (Alexander & Evans 1971). These processes affect
tumour cells only and macrophages do not harm normal viable host cells
(Currie & Basham 1975) or cells with normal surfaces (Hibbs 1973). Macro¬
phage activation can be non-specifically effected by BCG, Corynebacterium
parvum, endotoxin and other microbial products (Parr et al. 1973;
Currie 1980) but they can also be specifically armed to kill tumour cells
by exposure to a supernatant factor released by immune lymphoid cells
(Evans & Alexander 1970), these being now recognised as lymphokines and
T lymphocytes respectively. Macrophages may further play a part in tumour
rejection through their ability to process antigen and present it in a
highly antigenic form to other lymphoid cells (Currie 1980). It has been
noted that lower vertebrates and invertebrates appear to succeed in achieving
good tissue surveillance to foreign material without the sophisticated
apparatus associated with elaborate immunological responses. Cells involved
in the performance of such allograft reactions have many features in common
with human macrophages (Currie 1980).
Because of such attributes it was postulated that antitumour resistance
in nude mice and T lymphocyte-depleted mice was the result of the possession
of a highly activated macrophage system compensating for the lack of
T lymphocytes. However, the discovery that macrophage activating substances
such as BCG and Corynebacterium parvum also stimulate NK cell activity
brought this theory into question (North et al. 1980). Evidence for the
the role of macrophage resistance to tumour in vivo has been presented
by Eccles and Alexander (1974) who showed that immunosuppressed rats had
lower macrophage content in their tumours than controls and that non-specific
immunological stimulation resulted in a slight increase in tumour macro-
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phage content and a decrease in the number of tumour metastases. They
postulated that the macrophage content of tumours was inversely proportional
to the tumour's ability to metastasise. Keller (1980) demonstrated, by
inducing fibrosarcomas in DA rats with Dimethylbenz(a)-anthracene, that
resistance to tumour induction was least in animals with lower macrophage
activity, that is, young and old rats. He further showed that macrophage-
stimulating agents such as BCG and Corynebacterium parvum increased the
resistance to tumour induction in young and old animals, and age-diminished
resistance could be restored by adoptive transfer of Corynebacterium parvum-
induced peritoneal cells. However, Eccles and Alexander (1974) suggested
that tumour macrophages might be "ineffectual bystanders brought in by
lymphokines released in an immune process effected entirely by lymphoid cells
interacting with the tumour.". North et al. (1980) who demonstrated
significant systemic macrophage activation in response to tumour growth, and
interestingly, local suppression of both T lymphocyte and macrophage
activation by the tumour itself, argued strongly that this systemically
acquired macrophage activation was a consequence of the generation of
concomitant T lymphocyte-mediated antitumour immunity. These authors
further called into doubt the validity of much of the previous in vitro
work demonstating macrophage-induced tumour inhibition because of many and
various technical pitfalls not appreciated by the researchers. The role of
the macrophage in defence against tumour therefore remains unclear at the
present time.
Despite all, we ranain unsure of the effector mechanisms against
spontaneous cancers. The consensus of opinion appears to have swung towards
the role of 'natural' cellular cytotoxicity as being of importance, and
perhaps even rescuing the theory of immune surveillance, but whether these
cells are NK cells, macrophages, cells of the granulocyte series or some,
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as yet, undiscovered cell, is unknown. It would seem more likely, however,
that immune resistance to tumour is a combination of humoral and cellular
immunity; these two arms and the various cell types interreacting with each
other in the complex fashion with which they resist foreign materials and
infection. There is, however, evidence that sane particular effector
mechanisms are more important than others with regard to certain cancers,
that is, the relationship between cancers of possible viral aetiology and
T lymphocyte function.
The study on nude mice by Rygaard and Povlson (1976) and studies of
immunosuppressed humans (reviewed by Kinlen 1982) showed no increase in the
incidence of the common cancers but noted a large rise in the numbers
of lymphoid and other possibly virus-related tumours. Together with the
fact that immunosuppressed animals and humans are prone to viral infections,
these findings have led to the view that T lymphocytes defend against
viruses and not tumours; therefore, as some viruses are oncogenic, one
would expect an increase in virally induced tumours in the immunosuppressed.
Added support comes from the study of Simpson and Nehlsen (1971) who
found no general increase in tumours in mice immunosuppressed with
antilymphocyte serum (ALS); but did find a group who developed polyoma-
virus-induced cancers. This virus was found to have been administered in a
batch of ALS. There is compelling evidence that some cancers, and especially
those which are commonly found with increased incidence in immunosuppressed
individuals, are of viral aetiology. Epstein Barr (E.B.) virus has been
implicated as the cause of lymphomas in the immunosuppressed (Crawford et
al. 1980; Kinlen 1982), in Burkitt's lymphana and nasopharyngeal carcinoma
(Klein 1975). Human T cell leukaemia retrovirus, was first isolated
from a patient with Sezary T cell leukaemia by Poiesz et al. (1981);
hepatitis B virus is strongly suspect in the aetiology of hepatocellular
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carcinoma (Lancet editorial 1981a) and herpes simplex type II and papilloma
virus types 6 and 11 may be implicated in squamous cell carcinoma of the
cervix (Weiss 1984). More topically, there is a link between cytomegalovirus
(CMV) and Kaposi's sarcoma (Lancet editorial 1981b), a common tumour in
Africa but now seen in patients with acquired immune deficiency syndrome
(AIDS). Gottlieb et al. (1981) and Masur et al. (1981) demonstrated
evidence of CMV infection in homosexuals and drug abusers who were anergic
to a battery of delayed hypersensitivity recall antigens, had poor
in vitro lymphocyte function and profound depletion of T helper
lymphocytes with reversal of helper/suppressor ratio but with preservation
of B cell function. The CMV is probably permitted to exert its oncogenic
effect as a result of this T lymphocyte immunosuppression (Weiss 1984),
the virus responsible for the latter being retrovirus human T lymphotrophic
virus type III (HTLV-III) also know as lymphadenopathy associated virus (LAV),
AIDS associated retrovirus (ARV) and more recently human immunodeficiency
virus (HIV) (reviewed by Curran et al. 1985; Melbye 1986).
Such evidence together with previously discussed data (showing that
virally-induced tumours can be affected by changes in T cell function
whereas chemically-induced tumours tend not to be, indeed Greenberg and
Greene (1976) showed the latter to be independent of adaptive immunity)
suggests that T lymphocytes, by their immunosurveillance against viruses,
may prevent the formation of virally-induced tumours. It may be that a
period of immunosuppression is necessary for induction of such tumours,
at least until the cancer grows to sufficient size to defy rejection.
It is indeed possible that virally-induced tumour surveillance is
the only form of immune surveillance in man and that there is no adequate
effector system working against the more common spontaneous tumours. The
Mollers (1976) argue that because most tumours are monoclonal, genetic change,
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with failure of repair of such mutation occurring in one cell, is the
most likely explanation for in vivo carcinogenesis. They further
argue that carcinogens only accelerate the appearance of these rare genetic
changes leading to neoplasms and therefore host resistance to carcino¬
genesis is more likely to involve genetically determined repair mechanisms
rather than hypothetical immunological surveillance mechanisms. Such
criticism of the immune surveillance hypothesis in relation to spontaneous
cancers has received wide support, some of the best evidence coming from
Prehn (1970; 1976) and Rygaard and Povlsen (1976). Despite the fact that
spontaneous tumours may therefore not require to modify themselves to
escape hypothetical effector mechanisms, there is evidence - some theoretical
and sane real - that tumours can modify both themselves and the immunological
reactions of the host. This is discussed in the following sections.
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2.5. Immunological Escape of Tumours
If we accept that the host immunological apparatus is able to recognise
and respond to TSAs, it must be asked why tumours, even strongly immunogenic
ones such as those induced in animals, can grow and metastasise in the face
of such an attack.
Insufficient tumour immunogenicity; If TSAs are absent or very weak,
as is probable in the case of spontaneous tumours, cancers would not be
recognised as foreign and there would be no immunologically directed
response raised against them. The tumours would not have to escape as
there is nothing to escape from. However, cancer patients are able to
display reactivity to autologous tumour cells and show evidence of cellular
and humoral cytotoxicity to tumour cells thereby demonstrating that there
is some degree at least of tumour immunogenicity in spontaneous cancers.
Immunological tolerance; Same animals associated with vertically
transmitted viruses such as the Gross leukaemia virus in AKR mice, appear to
raise no immunological response to the virus or to the induced tumour cells
whereas they can respond immunologically to other viruses and tumours.
It may be that this is due to exposure to the virus during embryonic or
foetal life when surveillance systems do not afford protection. Similarly,
mice infected with mammary tumour virus (MTV) as neonates become tolerant
and cannot be immunised against MTV-induced tumours (Morton 1969). However,
this phenomenon, which is akin to insufficient tumour immunogenicity,
has not yet been demonstrated in man.
'Sneaking through' was the term devised by Klein (1966) to explain the
phenomenon first noticed by Old et al. (1962) who showed that small inocula
of tumour cells would grow whereas intermediate doses were rejected by mice
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suggesting that low doses were too small to provoke an immune response. This
hypothesis only provides a mechanism of escape during the earliest phase of
tumour growth and offers no explanation for the successful growth of the
tumour at a later time.
Immunoselection: Resistant tumours might occur in the presence of a
host response because immunogenic tumours are gradually deleted. Thus,
surveillance mechanisms would eliminate all but a small minority that would
constitute the spontaneous tumour population. Surveillance could thus be
postulated to be the reason for the low immunogenic!ty of spontaneous
tumours. This hypothesis was reviewed by Prehn (1976) who noted that
spontaneous tumours arising in tissue cultures or in diffusion chambers,
and hence not in contact with surveillance mechanisms, were also of low
immunogenic!ty. He concluded "that the immunogenicity of a tumour is the
result of the direct action of the oncogen on the tumour cells. When little
or no action is present, as in spontaneous tumours, there is little or no
immunogenicity upon which surveillance can act.". It appears unlikely,
therefore, that irrmunoselection of tumours is a method of tumour escape
in man.
Antigenic modulation: Tumours appear to have an ability to change
their presenting 'face' to the immunological environment. This, antigenic
modulation was first described by Boyse and Old (1969) and originally
detected in the case of thymus leukaemia (TL) antigen in mice. It was
noted that when murine lymphoma cells were transplanted into tissue culture
containing specific antibody or into an immunised host they lost their TL
antigen. The antigen reappeared on transplantation back into tissue cultures
containing no antibody or into the unimmunised host. The mechanism whereby
this occurs is unclear and the phenomenon has not yet been demonstrated
44
in human tumours.
Immunostimulation; This hypothesis was first presented by Prehn and
Lappe (1971) who suggested that low levels of immune reactivity had the
potential to stimulate growth of both normal and tumour tissues. They
reasoned that tumours in nude mice grew poorly, tending to regress or to
remain localised because there is a lack of inmune stimulus to growth.
Prehn (1976), by manipulating the immunity of normal adult mice was able
to show that tumours developed more quickly in partially immuno-
suppressed mice than in either fully immunosuppressed mice or mice with
fully restored immunity. He went on to suggest that spontaneous tumours,
being weakly immunogenic, were prone to stimulation rather than rejection
by the host immune system. The actual mechanism of the stimulatory activity
is still unknown (Murasko & Prehn 1983) but suppressor cell activity,
'blocking' factors or direct tumour cell stimulation by T cells, macrophages
and antibody, have all been implicated.
Antigen shedding: The glycocalyx of all nucleated mammalian cells
is constantly being shed and resynthesised and the normal transplantation
antigens - HLA in man and H2 in mice, are found in the serum in soluble
form. Davey et al. (1976) demonstrated that mouse lymphoma cells shed
their H2 antigens with increased frequency, suggesting that tumour cells
shed their surface components more extensively and rapidly than normal
cells. Gold and Freedman (1965) described CEA in patients with colonic
carcinoma, showing that this antigen which is a component of the tumour cell
glycocalyx, is shed in large quantities and can be demonstrated in the
serum of the patients. The cancers of experimental animals with readily
metastasising in vivo tumours, rapidly shed TSTA also in vitro,
whereas non-metastasising or poorly metastasising tumours do not (Currie &
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Alexander 1974). "A lethal interaction between a cytotoxic effector cell
or an inmunoglobulin molecule plus complement and a tumour cell necessitates
seme local stability of the target antigen on the cell surface." (Currie
1980), and it is tempting to correlate the evasive and metastasising
behaviour of tumours of low immunogenic!ty with their capacity to shed
surface antigen so readily. Furthermore, such shedding will create an
antigen 'smoke screen' in the vicinity of the tumour, attractive to host
inmune effectors and distracting them from the appropriate target. The
resulting complexes between antigen and effectors are thought to be
responsible for the phenomenon of 'blocking' which will be discussed in
greater detail in the next chapter.
Host immunodeficiency; Immunosuppressive manipulations using steroids,
ALS, radiotherapy and chemotherapy, can modify graft rejection. Tumours
are more easily induced in animal models when these manipulations or
thymectomy are performed in neonates. Patients with cancer and concomitant
general immune hyporeactivity have more rapidly growing tumours and
following surgical procedures have a poorer prognosis. However, with the
exception of the immunologically compromised, those with disease of the
lymphoid or reticuloendothelial systems, and patients with bronchogenic
or head and neck cancer (Hersh et al. 1976), depressed immunity tends to be a
feature of advanced cancer only. When other features such as age are taken
into consideration, patients with early cancer have almost normal immunity.
It, therefore, appears that tumour dissemination appears to be the cause
rather than the result of immune depression (Stein et al. 1976) and this will
be discussed more fully in the next chapter.
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2.6. Summary
There is evidence of a relationship between host immunity and cancer
in humans but much of this can be explained on non-immunological grounds,
for instance, on the basis of physiological or hormonal events.
There is growing evidence that seme human tumours are virally induced
but it is probable that the majority of spontaneous tumours are a result of
chronic exposure to physical and chemical agents.
Tumours carrying TSAs can be induced in laboratory animals and the
strength of these antigens is dependent on the dose and method of
application of the inducing agent. Definite host immunological reactions
resulting in tumour rejection can be demonstrated in these animals but
these reactions can also be overcome permitting tumours to thrive.
The occurrence of TSAs in spontaneous tumours have never been
unequivocally shown in animals or man. These tumours have no, or at best,
weak, immunogenicity and it seems improbable that specifically directed
immune surveillance acts against thorn. Further, spontaneous tumours nearly
always predate the appearance of measurable depression of immunity,
making it unlikely that they arise because of defective immunity. On the
other hand, tumours of probable viral aetiology occur reasonably often in
hosts with depressed T lymphocyte function and it seems likely that such
tumours are rare in normal individuals because viruses and their induced TSAs




3. The Effect of Cancer on Innmune Function
3.1. Introduction
There is general acceptance that host immunity is impaired in
tumour bearers and that CMI is more affected than humoral immunity.
In this chapter the evidence for this will be reviewed with regard to the
more common spontaneous neoplasms of man, evidence which also indicates
that the impaired immunity in such cancers is a secondary phenomenon rather
than the primary event by which immunodeficiency permits the development
of virally-linked cancers for instance. Evidence will also be presented
which suggests that this effect on the host immune system is a result
of the action of serum blocking or inhibitory factors which are products
of the tumour and host immune responses.
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3.2. Tests of Immune Function in Cancer
3.2.1. Humoral immunity
Humoral immunity may be assessed by measuring circulating antibodies,
complement and its components and possibly 'blocking' or 'inhibitory'
serum factors. These 'blocking' factors will be discussed later.
As previously noted, apparent tumour-specific antibodies have been
demonstrated in patients with Burkitt's lymphoma, some sarcomas, malignant
melanoma and other tumours (Ioachim 1980). It is not surprising that
this may be the case where tumours linked with a viral aetiology are
concerned, Thompson and Linna (1973) having demonstrated the protective
role of antibody against oncogenic viruses in chickens. However, with
regard to other tumours, the specificity of such antibodies is not clear
(Heppner & Hager 1980). Tests of humoral immunity in the context of
measuring serum antibody levels in cancer patients have, therefore,
for the most part, comprised the measurement of immunoglobulin levels
in the serum, most commonly IgG, IgA and IgM.
Teasdale et al. (1979a) on examining these immunoglobulins
in various cancers found no significant differences between cancer
patients and controls, and similar conclusions have been published
by others concerning patients with breast cancer (Bolton et al. 1976;
Wanebo et al. 1978; Toivanen et al. 1984; Shukla et al. 1986a).
Hughes (1971) however, found changes in seme immunoglobulin levels in
patients with epithelial cancers but concluded that these were explained
by bacterial invasion through the malignant epithelium. Roberts et al.
(1975), on the other hand, reported significantly raised levels of IgA
and depressed levels of IgG in all stages of breast cancer but their
numbers were small and their control group much younger than the cancer
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patients; Bolton et al. (1976) having demonstrated that IgA levels
increase with age, and when this factor is taken into consideration,
that previously significantly elevated levels in patients with metastatic
disease, become insignificant. Toivanen et al. (1984) found no changes
in immunoglobulin levels relating to treatment or outcome of breast cancer
but Webster et al. (1979) and more recently others (Shukla et al. 1986b),
reported a drop in IgM levels following treatment in all breast cancers
irrespective of treatment modality and outcome. Shukla et al. (1986b)
further noted a rise in IgG levels in these patients just prior to, or
at development of, breast cancer recurrence.
In short, immunoglobulin levels do not appear to be altered
dramatically by cancer itself but when levels do change this may be a
reflection of age, infection or malnutrition, making interpretation of
results difficult, if not impossible (Cochran 1982).
A humoral response to tumour should result in the consumption of
complement components and although abnormalities have been detected
in cancer patients they are by no means uniform, perhaps because of the
activation of the alternate pathway by endotoxin from intercurrent
infection or the effects of tumour necrosis (Cochran 1982).
In conclusion, there is no substantial evidence at present
to indicate that patients elicit specific antibody responses to malignant
cells of the more common solid tumours occurring spontaneously in man.
The measurement of non-specific immunoglobulins or complement does not
appear to be of any significant benefit in assessing these tumours.
3.2.2. Cellemediated immunity
Much of the investigative work on the relationship between the
immune system and cancer has been based on in vitro studies using
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tumour cells or cells from tumour cell lines and peripheral blood
lymphocytes, the supposition being that tumour cell destruction was
mediated by cytotoxic T cells. Serious doubt presently exists about
this interpretation as it is now recognised that cytotoxicity tests
detect a range of cell-mediated responses including those affected
by NK cells. Nevertheless, both lymphocyte numbers and lymphocyte
function appear to be affected in patients with neoplasms; the most
commonly used tests being those relating to T lymphocytes; skin testing
to recall or primary antigens, in vitro blastogenesis of lympho¬
cytes and enumeration of their numbers.
3.2.2.1 Delayed hypersensitivity testing
The logic behind delayed hypersensitivity testing to dermal
antigens was that if a patient were able to respond to an antigen to
which he had previously been sensitised, he should be able to mount
an effective response to TSA and hence against tumour. This indirect
assay of host response to tumour has followed two major approaches.
The earlier approach utilised common antigens to which there was a
high probability of the patient having had previous exposure, examples
being purified protein derivitive (PPD), Candida, varidase (strepto-
kinase-streptodornase), mumps, diptheria toxoid, etc. There are,
however, difficulties in interpreting responses to recall antigens
because of variables such as age and ill health, and that there may be
doubt as to whether or not the patient has had previous exposure to the
antigens being tested, how long previously and how intense the exposure.
A second approach was, therefore, developed which utilised the generation
of a primary immune response against an antigen to which the patient had
had no previous exposure, such as 3,4-dinitro chlorobenzene (DNCB),
an antigen which can sensitise a patient upon contact and will cause
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approximately 90% of controls to display a positive skin hypersensitivity
reaction on rechallenge two weeks later (Bolton 1975b), i.e. a delayed
hypersensitivity reaction (DHR).
Recall antigens; Testing with recall antigens has been demonstrated
to be of little use in assessing cancer status and prognosis by some
(Eilber & Morton 1970; Wanebo et al. 1978; Webster et al. 1979;
Shukla et al. 1986a). Others have found depressed DHR to recall antigens
only in women with terminal breast cancer (Nemoto et al. 1974) commenting
that this was most significant when a battery of antigens was used rather
than just one. Kopersztych et al. (1976) in a comparison of various
tumours with controls also found depressed DHR in patients only with
metastases using tuberculin; however, reactivity to Candida albicans
was depressed in all stages of cancer, and varidase although depressed
in both, was able to discriminate between local and disseminated tumours.
Depressed DHR has been reported throughout all stages of breast, gastric
and colonic cancer (Bolton et al. 1975) although it was noted that
reactivity was most depressed in colonic tumours and least affected in breast
cancer apart from Stage IV disease where it was also markedly depressed.
Reports of depressed DHR to recall antigens in early cancer have been
published by Hughes and MacKay (1965), Roberts and Jones-Williams (1974),
Stein et al. (1976), Mandeville et al. (1982), and further, that
impairment increased with advancing disease in a stage related manner.
Hortobagyi et al. (1981) shewed that recall antigen reactivity was weakly
predictive of response to chemotherapy and survival time in breast
cancer patients but interestingly this did not correlate with other
prognostic factors such as age, menopausal status, tumour load, previous
irradiation therapy, absolute lymphocyte count or performance status.
The relationship to prognosis has also been noted by Mandeville et al.
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(1982) who reported that recall antigens were more favourable in this
instance than DNCB reactivity. Sequential testing with recall antigens
has been said to be unhelpful in assessing treatment efficacy (Webster
et al. 1979; Hortobagyi et al. 1981; Shukla et al 1986b) although
Shukla et al. (1986b) using PPD, and Roberts and Jones-Williams (1974)
using varidase, noted that seme patients became less reactive as
disease spread, but not before this was clinically obvious. Roberts
and Jones-Williams (1974) further described a sharp drop in DHR in
patients just prior to death. On the opposite side of the coin, depressed
PPD responses have occasionally been reversed following curative surgery
(Hughes & MacKay 1965).
Primary antigens: Wanebo et al (1978) reported that patients with
node negative operable breast cancer had no impairment of DNCB response and
that those with four or more involved nodes had only slight impairment.
Bolton (1975) also noted only slight impairment in early breast cancer,
and others have shown on testing patients with many different solid
tumours that those with localised disease have normal DHR (Simo-Camps
et al. 1976; Kopersztych et al. 1976). However, Stein et al. (1976)
found impaired DHR in a significant number of women with early breast
cancer and Teasdale et al. (1976b) observed that depressed reactivity
to DNCB was the only consistent marker of immunodepression in early
breast, gastric and colonic cancer, especially when corrections were made
for age and ill health. Impairment of DHR with increasing stage of disease
has been demonstrated in patients with breast cancer (Bolton et al. 1975;
Bolton 1976) with the exception of Stage III disease in which DHR is
virtually normal. These authors, however, found that all stages of stomach
cancer and even more profoundly, colonic cancer, had markedly depressed
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reactivity to DNCB, this being most severe in cases with disseminated
disease. Similar findings with regard to Stage III breast cancer were
published by Teasdale et al. (1979b) but Stein et al. (1976) found
straight forward increasing depression of DHR with increasing stage
of the disease, and most authors have agreed that this depression is
greatest in patients with metastases (Stein et al. 1976; Teasdale
et al. 1979b; Shukla et al. 1986a) and in those with shortest survival
times (Shukla et al. 1986b), reflecting perhaps a relationship between
DHR and tumour load. Other authors, although finding normal DHR in a variety
of localised cancers, also concurred that impairment appears with
disseminated disease (Simo-Camps et al. 1976; Kopersztych et al. 1976).
Mandeville et al. (1982) however, found no such stage relationship even in
patients with metastatic cancer. It has been reported that pre-treatment
DNCB reactivity has no prognostic significance (Wanebo et al. 1978;
Teasdale et al. 1979a; Mandeville et al. 1982; Shukla et al. 1986a) in early
breast cancer. Similarly, Stein et al. (1976) noted no difference in DHR
response between patients with early breast cancer who remained disease
free and those developing metastases within two years, and Davies et al.
(1978) found no correlation of DHR with either early treatment failure
or axillary node metastases. Other authors, however, have found DNCB
responses to be predictive of outcome in advanced breast cancer treated
with chemotherapy or hormonal manipulation (Webster et al. 1979);
anergy usually being associated with poor prognosis. Eilber and Morton
(1970) also noted on pre-operative testing of 83 patients with a wide
variety of tumours, a highly significant correlation between DNCB
reactivity and disease outcome, although later follow-up of these patients
demonstrated that much of this significance was lost (Bolton 1975).
Hortobagyi et al. (1981), using the primary antigen KLH, reported that
54
reactivity to this was predictive not only of survival but also of response
to subsequent chemotherapy. These authors noted that serial measurements
of DHR, using both primary and recall antigens, were no more advantageous
than pre-operative testing alone. Webster et al. (1979) however, have
shown that DNCB responses can parallel clinical course, anergic patients
becoming reactive with successful therapy and becoming anergic again
on recurrence of their advanced breast cancer.
Not all cancers affect DHR to the same degree, impairment being
greatest in lymphomas such as Hodgkin's disease and in squamous cell
carcinomas, and varying in different adenocarcinomas (Bolton 1975).
For instance, DHR is impaired, stage for stage, less in breast carcinoma
than in gastrointestinal cancer, and colonic carcinoma patients have more
depressed DHR than those with gastric cancer. This seems somewhat
anomalous when it is considered that those with colonic tumours have a
better prognosis than those with gastric cancer.
Other influencing factors on DHR which complicate the issue
may be external ones such as the depressant effect of radiotherapy
(Shukla et al. 1986b) or those which are an integral part of the patient's
physiology. Although there is no sex difference in DHR responses to
primary or recall antigens (Whitehead et al. 1979b), increasing age is
associated with diminishing DHR to primary antigens (Gross 1965;
Bolton et al. 1976; Davies et al. 1978; Teasdale et al. 1979b) and recall
antigens (Roberts-Thomson et al. 1974; Roberts & Jones-Williams 1974;
Teasdale et al. 1979b). There is, however, considerable evidence to
suggest that this age related depression is a reflection of the associated
general debility of age, rather than age per se. For instance,
Roberts-Thcmson et al. (1974) showed that elderly people who were
hyporeactive compared with others in the same age group had significantly
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higher mortality over the ensuing two years, indicating perhaps poorer
health in these particular people. Teasdale et al. (1979b) also noted
that healthy controls had no age related impairment of DHR but that those
with benign disease did; patients with gastrointestinal disease who
tended to be more ill, being worse affected that those with benign breast
disease. Further, in the communication published by Gross (1965) noting
age related hyporeactivity, young healthy adults were compared with
older patients who had 'chronic active disease ' and it is likely that
illness and not age influenced the DNCB responses in that study (Bolton
1975). That debility itself can cause impaired DHR is beyond doubt,
an example being the depressed tuberculin responses seen in severely
protein deficient children (Sinha & Bang 1976).
In summary, tests of DHR have been found to be of varying
usefullness in the assessment of disease status and prognosis in patients
with solid tumours. The consensus opinion appears to be that impairment
varies with the type of tumour; that DHR is often depressed in early cancer
and this depression, to some extent, parallels advancing stages of disease.
Nutritional status and general debility affect DHR in a substantial manner
and accordingly the degree of impairment seen in many cancer patients
may be due to a combination of the effects of tumour and these factors.
Consequently it may be difficult to discriminate between early and
advanced neoplasia and even between benign and malignant conditions and
because of this lack of specificity the place of delayed hypersensitivity
skin testing in assessing cancer patients has perhaps become less
apparent.
3.2.2.2. In vitro lymphocyte blastoqenesis
Contact between a lymphocyte coded for a particular antigen and
that antigen results in transformation of the lymphocyte into a blast cell
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which undergoes mitosis, forming a clone of lymphokine producing
lymphocytes specifically directed against the antigen. By stimulating
lymphocytes in this way, their functional ability can be assessed
either by measuring lymphokine production or the number of blast cells
formed. Stimulation can be affected specifically by using common recall
antigens, tumour cells or foreign lymphocytes, or non-specifically
by extracts from various bean species known as mitogens, the three
most commonly used being phytohaemagglutinin (PHA), concanavalin A
(Con A) and pokeweed mitogen (PWM), the first two which stimulate T
lymphocytes and the last, mainly B lymphocytes.
Breast cancer patients have been reported to have normal PHA responses
(Roberts & Jones-Williams 1974; Bolton et al. 1976) and normal PHA and
Con A responses in all but elderly patients with disseminated disease
(Ludwig et al. 1985). It has been demonstrated that gastric, colorectal and
breast cancer patients have normal PHA and Con A responses but that patients
with Stage III breast cancer have impaired blastogenic responses to PHA
(Teasdale et al. 1979b). Other authors have demonstrated depressed PHA
responses in many solid tumours but only in those which have metastasized
(Simo-Camps et al. 1976; Kopersztych et al 1976) whereas Nemoto et al. (1974)
reported hyporeactivity solely in patients who were terminally ill. Yet
others have demonstrated impaired responses to PHA in various solid
cancers (Gatti et al. 1971; Whittaker et al. 1971a; Suciu-Foca et al. 1973;
Semenzato et al. 1980) including early disease (Whitehead et al. 1975;
Stein et al 1976; Mandeville et al. 1982), and reports of abnormal PHA
responses in early disease becoming more obviously depressed in disseminated
disease have also been published (Whittaker et al. 1971b; Stein et al.
1976). Such stage related depression has also been noted by Bolton et al.
(1976) using suboptimal doses of PHA but this discriminatory ability was lost
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when correction was made for the age of the patients. Mandeville et al.
(1982) have reported stage related lymphocyte response depression to Con A,
and recall antigens as well as to PHA, and Suciu-Foca et al. (1973) depressed
stage related, mixed lymphocyte culture (MLC) responses. Wanebo et al. (1978)
examining risk groups in early breast cancer noted significant depression
of PHA responses only in the high risk group, but surprisingly, increased
responses to PWM, Con A and recall antigens also in this group,
suggesting that lymph node metastases might be associated with stimulation
of certain lymphocyte responses. Using suboptimal doses of PHA, Whitehead
et al. (1975) reported that pre-treatment responses correlated well with
prognostic groups in breast cancer, and similar findings using both
PHA and recall antigens have been published by Mandeville et al. (1982),
though neither group used corrections for patient age differences.
Teasdale et al (1979a) on the other hand found no correlation between
prognosis and blastogenic responses. PHA responses have not been found
predictive of response to chemotherapy or hormonotherapy in advanced
breast cancer (Webster et al. 1979) and although these authors found
no associated changes in PHA responsiveness with clinical outcome,
Braun et al. (1983) did so having demonstrated increased PHA responsiveness
following successful surgery for lung tumours, this diminishing prior to
disease recurrence, remaining low or dropping even further as disease
progressed, and appearing therefore to correlate with tumour burden.
Lymphocyte stimulation is also affected by factors other than
cancer and although there are no sex related differences (Teasdale et al.
1979b) responses are profoundly affected by ageing (Roberts-Thomson et al.
1974; Weksler & Hutteroth 1974; Bolton et al. 1976; Teasdale et al. 1979b;
Mascart-Lemone et al. 1982). General ill health also depresses blastogenic
responses (Whitehead et al. 1975; Teasdale et al. 1979b) as do many
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specific disease states such as tuberculosis, multiple sclerosis, hepatitis,
chronic mucocutaneous candidiasis, ataxia telangiectasia and syphilis
(Gatti et al. 1971). Various forms of therapy such as surgery, irradiation
and cytotoxic drugs have been reported to have no effect on lymphocyte
stimulation (Whitehead et al. 1975) but Espanol et al. (1974) have shown
transiently reduced PHA responses following anaesthesia, and longer
lasting depression following radiotherapy has been demonstrated by others
(Stjernsward et al. 1972; Toivanen et al. 1984).
In essence, lymphocyte blastogenesis appears to be depressed in
patients with disseminated cancer and occasionally, to a lesser degree,
in those with early disease, where it may have some prognostic
implications. Further there is seme evidence that responses may change
in line with clinical responses to treatment and occasionally precede
objective evidence of such changes in disease status, implying a
relationship between lymphocyte reactivity and tumour burden. However,
the influencing effects of age, ill health, and therapeutic manipulations
on in vitro lymphocyte stimulation, the complexity of the techniques,
and the different methodologies used between laboratories, make it
necessary to interpret results with extreme caution.
3.2.2.3. Lymphocyte counts
The white blood cell count (WBC), as a whole, does not seem much
influenced by cancer (Teasdale et al. 1979a; Bolton et al. 1976) and has
no stage related or prognostic significance (Shukla et al. 1986a)
although it is depressed following radiotherapy (Toivanen et al. 1984;
Shukla et al. 1986b) and chemotherapy (Webster et al. 1979). With regard
to the cell populations of the WBC, a negative correlation between the
peripheral neutrophil count and the curability of various cancers has
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been noted by Riesco (1970) but no correlation with monocyte, eosinophil
or basophil counts was seen. The monocyte count has been reported to
increase in patients with metastatic breast cancer (Ludwig et al. 1985)
and non-significantly in recurrent lung cancer (Braun et al. 1983). Most
authors however, have demonstrated changes only in the lymphocyte
population in relation to cancer.
1. Total lymphocyte count; The total lymphocyte count is an
inexpensive, readily available test which is also a rough reflection
of T lymphocyte numbers. There have been reports of normal lymphocyte
counts in cancer patients (Nemoto et al. 1974; Teasdale et al. 1979b;
McCluskey et al. 1983; Ludwig et al. 1985), of depressed counts only
in patients with disseminated tumours (Stein et al. 1976; Bolton et al.
1976; Kopersztych et al. 1976; Ownby et al. 1983; Shukla et al. 1986a),
and of stage related depression in colorectal cancer (Slater et al. 1979)
although Dukes' C tumours in these patients had higher lymphocyte counts
than Dukes' B cancers. This increase in lymphocyte counts in bulky local
colorectal disease is similar to the elevated counts noted in breast cancer
patients with three or more axillary nodes involved (Rotstein et al. 1985)
and reminiscent of the normal DHR (Bolton et al. 1975; Teasdale et al.
1979b) and T lymphocyte counts (Whitehead et al. 1976) seen in Stage III
breast cancer. Total lymphocyte counts do not appear affected in early
breast cancer although Wanebo et al. (1978) have reported a small but
insignificant depression with increasing risk factors and Bainbridge
et al. (1978) have shown significantly low counts in Stage II disease but
similar counts to controls in all other stages. In gastrointestinal
cancers however, counts are depressed both in operable and inoperable
disease (Shukla et al. 1979), counts remaining constant following surgery
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in operable patients but falling steadily as disease progresses in
inoperable cancer. Some authors have reported a positive correlation
between total lymphocyte counts and improved prognosis in various cancers
(Riesco 1970) and breast cancer (Papatestas et al. 1976; Ownby et al. 1983)
but Shukla et al. (1986a) surprisingly have found that elevated total
lymphocyte counts in early breast cancer were more likely to indicate
future recurrence. The total lymphocyte count has been reported to be both
predictive of response of disseminated breast cancer to endocrine
manipulation (Franks & Williams 1978), and to be unhelpful in this regard
(Webster et al. 1979). Serial total lymphocyte counts have been shown
(Shukla et al. 1986b) to rise slowly post-operatively in patients whose
breast cancers do not recur but to drop as patients develop systemic
recurrence. Total lymphocyte counts also increase on serial testing in
patients with advanced breast cancer who respond to endocrine treatment
(Franks & Williams 1978) but decrease following successful chemotherapy
(Webster et al. 1979). It has also been noted that recurrence of lung
cancer is often heralded by a decrease in total lymphocyte count, and death,
preceded by a sharp fall (Anthony et al. 1975b).
Factors other than cancer also affect the total lymphocyte count,
for instance, with increasing age the count falls (Bolton et al. 1976;
Alexopoulos & Babitis 1976; Teasdale et al. 1979b) although there are
reports that no age related changes in total lymphocyte counts exist
(Weksler & Hutteroth 1974; Smith et al. 1974; Nagel et al. 1981; Mascart-
Lemone et al. 1982). The total lymphocyte count is unaffected by the
sex of the patient (Smith et al. 1974; Alexopoulos & Babitis 1976) but
general ill health causes elevated counts (Teasdale et al. 1979b) and
physical exercise transiently increase the number (Steel et al. 1974a)
probably through an increase in the B cell population. Chemotherapy
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(Petrini et al. 1984; Sheard et al. 1986) and, more chronically, radio¬
therapy (Stjernsward et al. 1972; Shukla et al. 1980; Shukla et al. 1986b;
Petrini et al. 1983; Toivanen et al. 1984) both depress the total lymphocyte
count, but the depressive effect of surgery is transient (Shukla et al. 1980;
Rotstein et al. 1985) recovering fully within a week (Lynch & Kirov 1986).
The anti-oestrogen, tamoxifen, on the other hand, elevates the total
lymphocyte count and indeed counteracts the depressive effect of chemotherapy
(Sheard et al. 1986).
In summary, the total lymphocyte count is not absolutely stage
related but is usually depressed in disseminated cancer. It may be decreased
or increased in locally advanced cancer and although the prognosis
of a tumour is sometimes improved if the count remains elevated this is
certainly not always the case. Such variability may be due to other factors
e.g. age and ill health, and difficulties with serial testing are exacerbated
by the effects of chemotherapy, hormonotherapy and radiotherapy.
2. T Lymphocytes; The thymus-dependent proportion of the lymphocyte
population (T lymphocytes) accounts for between 52 and 81% of peripheral
blood lymphocytes in the control population (Jondal et al. 1972). More
recently this group of cells has been recognised using monoclonal surface
markers which are particularly useful in enumerating the subsets of
T lymphocytes (Reinherz & Schlossman 1980) but initially they were defined
by their ability to bind sheep red blood cells (SRBC) in a specific but
non-immunological manner (Bianco et al. 1971; Jondal et al. 1972) and
most research pertaining to the relationship between these cells and
cancer has been performed using this particular method (E-rosetting).
Some laboratories have attempted to achieve finer degrees of
discrimination using the E-rosetting technique by modifying the methods
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such that only lymphocytes with higher affinity for SRBC are counted
('active' T lymphocytes). Using this technique Braun et al. (1983) found
no difference in 'active' T counts between controls and lung cancer patients
and between stages of the disease. However, Wybran and Fudenberg (1973)
reported depressed 'active' T counts even in early tumours and this
depression became more profound the more advanced the stage of disease.
This correlation with the tumour load in various cancers was made more
apparent when on sequential testing 'active' T counts increased in those
patients responding to treatment. Furthermore, Semenzato et al. (1980)
demonstrating 'active' T count depression in glioblastomas and oesophageal
and lung cancers, showed that this depression correlated well with depressed
PHA responses in these patients suggesting that these particular T cells
were important functionally against cancer. Djeu et al. (1977), using
a different method of 'active' E-rosetting, were also able to show in
several types of cancer a stage related fall in 'active' T counts, workers
from the same laboratory having previously reported that clinical relapse
of disease was often preceded by a fall in 'active' T counts by as much
as three months (Oldham et al. 1976).
There is no uniform agreement on the relationship between total
T lymphocyte counts and cancer, seme authors having reported no change in
percent or absolute counts in untreated tumours (Stjernsward et al. 1972;
Nemoto et al. 1974; Wanebo et al. 1978; Mandeville et al. 1982; Brown
et al. 1983; McClusky et al. 1983; Ludwig et al. 1985). However, depressed
T lymphocyte counts have been reported in early cancers of lung (Gross
et al. 1975a; Dellon et al. 1975), stomach, colon and rectum (Shukla et al.
1979), breast (Stein et al. 1976; Keller et al 1976), oesophagus and
gliomas (Semenzato et al. 1980) as well as in early head and neck tumours
(reviewed by Katz 1984) but other authors have only noted this depression
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in advanced disease (Anthony et al. 1975a; Bolton et al. 1976; Kopersztych
et al. 1976). There have also been claims that T lymphocyte counts correlate
with extent of disease in lung cancer (Gross et al. 1975a; Dellon et al.
1975) but not in lung adenocarcinomas (Dellon et al 1975), and in breast
cancer (Whitehead et al. 1976) apart from advanced locoregional disease
where T counts like DHR are virtually normal. Conflicting reports exist
on the prognostic value of T lymphocyte counts. Anthony et al. (1975a)
showed that squamous cell lung cancer patients with depressed counts
had a poorer prognosis, whereas Rotstein et al. (1985) surprisingly
found that patients with breast cancer had a worse prognosis if T counts
were elevated. Others have suggested that the pre-treatment T lymphocyte count
has no prognostic significance (Stein et al. 1976; Teasdale et al. 1979a).
Serial T lymphocyte counts, however, do appear to change in relation to
clinical outcome, increasing or remaining stable with successful treatment
(Gross et al. 1975a; Dellon et al. 1975) and falling as disease progresses
(Anthony et al. 1975b; Dellon et al. 1975). Indeed changes in T counts may
precede clinical evidence of outcome, increasing prior to objective
response (Yonemoto et al. 1977) and falling by as much as three months
prior to obvious recurrence (Anthony et al. 1975b; Dellon et al. 1975).
It is well appreciated that the results of T lymphocyte assays,
especially those using the E-rosetting properties of lymphocytes, are to
seme extent dependent more on the techniques used to perform the assay
rather than the status of the cancer patient and it is probable that
much of the conflicting data presented here is the consequence of variation
in technique between laboratories. Other factors, however, also compound
this problem.
The sex of the patient does not affect T counts (Smith et al. 1974;
Alexopoulos & Babitis 1976) but with increasing age, percentage counts
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become depressed (Smith et al. 1974; Holland et al. 1975; Whitehead
et al. 1978, Nagel et al. 1981; Mascart-Lemone 1982) although not all
agree that there is an age associated relationship (Weksler & Hutteroth
1974; Alexopoulos & Babitis 1976; Djeu et al. 1977). Wybran and
Fudenburg (1973) reported that viral but not bacterial infection depressed
'active' T counts and illnesses such as myocardial infarction, cirrhosis,
sarcoidosis and vasculitis had no effect. Viral illness has also been
demonstrated to depress total percentage T lymphocyte counts (Anthony
et al. 1975a; Chisari & Edgington 1975; Niklasson & Williams 1974) as
do benign diseases such as 'Crohn's' when in an 'active' state (Whitehead
et al. 1978). Cancer therapies have widely differing effects, surgery
having a short lived depressive effect of between four days to two weeks
(Hamid et al. 1984; Lynch & Kirov 1986; Shukla et al. 1980), radiotherapy
depressing T counts for at least one to ten years (Stjernsward et al.
1972; Toivanen et al. 1984; Petrini et al. 1983) when applied to the
chest, and chemotherapy for two to three years (Petrini et al. 1984).
On the other hand, hormonal manipulation with tamoxifen increases
T lymphocyte counts and will, to seme extent, neutralise the depressive
effect of chemotherapy (Sheard et al. 1986). Indeed, hormonally induced
increases in T lymphocyte counts have been claimed to be the cause of
treatment success in breast cancer through immune mechanisms (Yonemoto
et al. 1977).
It has been shown that markers for Fc - lg receptors, used to
differentiate T helper (Th) from T suppressor/cytotoxic (Ts) lymphocytes
(Moretta et al. 1977), give an inaccurate picture and that monoclonal
markers reflect the situation more truly (Reinherz et al. 1980) although
even these do not accurately reflect subset function completely (Robbins &
Fudenberg 1983). Using monoclonal antibodies, researchers have reported
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T lymphocyte subsets to be the same in all stages of breast cancer as in
controls (Petrini et al. 1984; Ludwig et al. 1985) although McCluskey
et al. (1983) were able to demonstrate a difference between disseminated
breast cancer and the other stages of disease and control patients,
those with metastases having decreased numbers of Th and increased
numbers of Ts lymphocytes with consequent reduction in the Th to Ts
ratio.
Measurement of T lymphocyte subsets is unfortunately also prone
to the complicating effects of other variables. For instance, Nagel et al.
(1981) have reported that increasing age affects the Th population only
slightly but that Ts lymphocytes decrease significantly, resulting in
elevated Th/Ts ratios and this is especially so in men. Very different
findings have been published by others (Mascart-Lemone et al. 1982) who
found that with increasing age in men the ratio falls, due mainly to a
striking reduction in Th cells and a less pronounced increase in Ts
lymphocytes, but no such changes occur in women. The Th/Ts ratio
has been reported to be decreased for up to ten years following radiotherapy
due to a fall in Th lymphocytes (Petrini et al. 1983) but Toivanen et al.
(1984) have demonstrated that the Ts population also falls and at three years
post-treatment, although both subsets are reduced, the ratio remains constant.
The effect of chemotherapy appears to be to reduce both subpopulations
but more so, Th lymphocytes, with consequent reduction in ratio even
two to three years after treatment (Petrini et al. 1984). Tamoxifen,
however, increases both subpopulations, especially Th cells, and also
counteracts the depressive effects of cyclophosphamide (Sheard et al. 1986).
Surgery is reported to depress both subpopulations equally without
disturbance of the ratio (Sheard et al. 1986) but this effect returns
to normal within a week (Hamid et al. 1984; Lynch & Kirov 1986).
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It is apparent that T lymphocyte counts bear a relationship to
cancer, most authors agreeing on depressed absolute and percentage
counts in patients with disseminated disease but there is less consensus
regarding early tumours. Seme evidence points to stage related changes
in T lymphoycte counts and even that variation in counts may precede
clinical evidence of change in disease status. Data supporting T subset
fluctuations in cancer is however, poor. The changes in T lymphocytes
may be masked by other variables such as age, illness and the effects
of treatment directly on the immune system but more profoundly by the
variation in techniques used by different laboratories, some of which
may nullify the discriminatory value of this test and which will be
discussed fully in the following chapter.
3. B Lymphocytes: comprise 20% (Anthony et al. 1975a) to 28%
(Jondal et al. 1972) of the lymphocyte population. There have been
reports of decreased B cell counts in patients with locally advanced
breast cancer (Rotstein et al. 1985) and of increased counts in
disseminated tumours (Kopersztych et al. 1976) but the consensus of
opinion is that B lymphocyte proportions remain unaffected by cancer
(Stjernsward et al. 1972; Gross et al. 1975a; Teasdale et al. 1976;
Whitehead et al. 1976; Shukla et al. 1979, Shukla et al. 1980;
Mandeville et al. 1982). Neither age nor sex differences affect B cell
numbers (Teasdale et al. 1979b) but exercise transiently increases the
B cell population (Steel et al. 1974a) as does surgery (Lynch & Kirov
1986), the effect of the latter lasting for less than a week. Hamid et al.
(1984) have suggested that these stress induced changes are due to
redistribution of lymphocytes from blood to tissues by cortisone. Radio¬
therapy reduces absolute numbers but not the proportion of B lymphocytes
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(Shukla et al. 1980; Toivanen et al. 1984) although Stjernsward et al.
(1972) have found a percentage increase for at least one year following
this treatment.
In short, B lymphocytes appear to be a fairly constant proportion
of the lymphocyte population and changes in absolute numbers in cancer
or following therapy are really a reflection of the variation in total
lymphocyte counts. They are, therefore, not particularly useful in
assessment of the cancer patient.
4. Null cells: the null cell compartment comprises the third
component of the total lymphocyte population. Null cells probably contain
myeloid precursors (Richman et al. 1978), erythroid precursors (Nathan
et al. 1977) and the major effector cells of ADCC and NK activity
(Reinherz et al. 1980). As such, cells of the null compartment may not
be lymphocytes at all but whether K cells and NK cells, which are probably
the same cell anyway (reviewed by Herberman 1983a), are lymphocytes,
monocytes, immature forms of either, or totally different cells is
controversial. More recently it has been suggested (Lanier et al. 1986)
that NK activity is mediated by non-lymphocytes, i.e. NK cells proper,
accounting for approximately 10% of the total peripheral blood lymphocyte
population, and by non-MHC-restricted lymphocytes which make up about
5% of the peripheral blood lymphocytes. It certainly seems that NK cells
straddle both null cell and T lymphocyte populations, with 50% of NK cells
having low affinity receptors for SRBC (Herberman & Ortaldo 1981;
Timonen et al. 1981) as do K cells (West et al. 1978). The method of
E-rosetting is, therefore, of crucial importance in assessing the true
number of null cells, the presence of neuraminidase (Sandilands et al.
1975), bovine serum albumin (BSA) (Anthony et al. 1975a), foetal calf
serum (FCS) (Whitehead et al. 1976; Byrom et al 1978) and prolonged
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incubation of lymphocytes (Whitehead et al. 1978) increasing the number
of E-rosetting lymphocytes, perhaps by providing optimal conditions for
low avidity receptors to combine with SRBC (see Chapter 4).
The null cell population changes which occur in cancer patients
(Byron et al. 1978) tend to reflect in an inverse manner the changes
in the proportion of T lymphocytes (Whitehead et al. 1976; Shukla et al.
1979; Shukla et al. 1980) and increases proportionally with the decrease
in T cells related to age, debility, treatment regimes and disease
(Whitehead et al. 1978). This relationship may be due to part of the
null cell population being converted into T lymphocytes and vice versa
(Whitehead et al. 1976) through blocking mechanisms present in the sera
of the aged, the ill and the cancerous (Whitehead et al. 1978; Shukla
et al. 1980).
These common tests of immune competence show in most solid neoplasms
of man that host immunity in early disease is usually normal or only
slightly impaired. However, as disease advances this impairment becomes
more profound affecting most severely those with disseminated tumours
and those in the terminal stages of cancer. It therefore appears that cancer
precedes depressed immune function, unlike the situation with virally
linked tumours, and that the degree of immunological impairment parallels
the extent of disease. That impaired host immunity appears to be a
secondary phenomenon rather than a primary event allowing cancer to develop,
is in accord with the observation that the common solid neoplasms such as
carcinoma of the breast do not occur with any greater frequency in the immuno¬
compromised population. Why then do tests of immune function became depressed
and why does such impairment become more obvious in patients carrying greater
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tumour loads?
Possible mechanisms for this (reviewed by Herberman 1983b) are:
suppressor T cells, suppressor macrophages, inrmunosuppressor products of
tumour cells, prostaglandins, corticosteroids and serum inhibitory factors,
and these may be interlinked, for instance, immune complexes (ICs), a
putative serum inhibitory factor, may also stimulate suppressor cell
activity (Gershon et al. 1974; Moretta et al. 1977). There is good evidence
that serum inhibitory factors directly affect the tests of host immunity




3.3.1. The effects of cancer sera on immune function
Control lymphocytes incubated in cancer serum have diminished
blastogenic responses compared with those incubated in control serum, this
depression being most marked in serum from patients with advanced disease
(Whittaker et al. 1971a) and recurrent disease, whilst PHA responses
are normal in patients remaining clinically free from tumour (Whittaker
et al. 1971b). These authors and others (Suciu-Foca et al. 1973) also
showed that PHA responses of cancer patients' lymphocytes improved
following incubation in control serum. Allogeneic inhibition of control
lymphocytes by cancer sera has also been demonstrated by Gatti (1971),
Tanaka et al. (1978) and Suciu-Foca et al. (1973) who reported that the
depth of depression was related to the extent of disease, and further,
repeating these experiments using mixed lymphocyte culture (MLC) instead
of PHA to induce blastogenesis, that cancer sera mediated depression
of MLC responses was even more pronounced and bore a remarkable
relationship to stage of disease. Both specific and non-specific 'blocking'
has also been demonstrated using autochthonous and allogeneic cancer
sera in an assay in which tumour cells were used to stimulate autochthonous
lymphocytes (Vanky et al. 1971) and, as a rule, this 'blocking' effect
tended to decrease or to disappear after tumour removal or regression.
With this form of assay it was also shown that the 'blocking' factor could
be removed from the lymphocyte surface by washing (Hattler & Soehnlen 1974)
with resultant improvement of lymphocyte function. A note of caution was
introduced about the use of allogeneic sera in such experiments when it
was demonstrated that non-autologous sera have a non-specific depressive
effect on PHA responses in general (Whitehead et al. 1974). However,
71
Suciu-Foca et al. (1973) using PHA and MLC, and Vanky et al. (1971)
using autochthonous tumour, to induce lymphocyte blastogenesis, reported
that although such an effect was seen it was much less obvious than
the changes induced by cancer sera.
The fact that cancer sera depress control lymphocyte function and
that incubation of cancer lymphocytes in control sera improves their
blastogenic capability, taken together with the observation that the
inhibitory factor can be removed from the lymphocyte surface by washing,
implies that the cancer associated defect lies in the serum and not with the
lymphocyte itself. Roberts and Jones-Williams (1974) suggested that this was
the case when they noted that patients with impaired DHR to varidase
surprisingly had normal PHA blastogenesis when the lymphocytes were incubated
in foetal calf serum (FCS) instead of autologus serum, that is, although
lymphocyte function was obviously impaired as measured by DHR, removing
these cells from their serum permitted normal function as measured by
blastogenic response to PHA. This loss of PHA response impairment
following removal of lymphocytes from autologous plasma and placement in
normal AB plasma has also been shown in patients with colonic cancers
(Shafir et al. 1980). Correlation between skin reactivity and lymphocyte
blastogenesis has been observed (Nemoto et al. 1974; Simo-Camps et al. 1976;
Kopersztych et al. 1976) and it has been demonstrated that the link may be
due to a serum factor, Nimberg et al. (1976) having shown that 66% of the
sera of cancer patients who lacked DHR were capable of inhibiting PHA
stimulation of normal lymphocytes.
Finally, however, it must be remembered that serum depression
of lymphocyte blastogenesis is not cancer specific, and PHA responses
for instance, have been shown to be inhibited by sera from patients with
tuberculosis, multiple sclerosis, hepatitis, candidiasis and syphilis,
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as well as from healthy multigravida women (Gatti 1971).
Serum from patients with benign and malignant disease also has
the ability to prevent T lymphocytes forming E-rosettes with SRBC, for
instance, sera from patients with active systemic lupus erythematosis (SLE)
were able to 'block' in a non-specific manner the formation of rosettes by
a proportion of T lymphocytes (Popovic et al. 1974) and further, the
extent of this inhibition was related to the degree of disease activity
as measured by DNA antibody activity. Such disease related inhibition
of rosette formation was also reported in lung cancer (Gross et al. 1975a)
and in patients with untreated Burkitt's lymphoma (Gross et al. 1975b),
the inhibition disappearing following treatment induced remissions in
the latter disease. The 'blocking' factor is removable from the lymphocyte
surface by brinase (Holland et al. 1975), papain (Whitehead et al. 1976;
Whitehead et al. 1977; Shukla et al. 1979; Shukla et al. 1980),
washing (Holland et al. 1975; Whitehead et al. 1976; Whitehead et al. 1977),
or plasmapheresis (Browne et al. 1976) and can be replaced by reincubation
in autologous cancer serum (Whitehead et al. 1976; Whitehead et al. 1977).
Further, incubation of control lymphocytes in allogeneic cancer sera results
in inhibition of E-rosetting (Whitehead et al. 1977; Shukla et al. 1979;
Shukla et al. 1980), the degree of depression being related to the tumour
load of the donor patient (Shukla et al. 1979). It has also been observed
that there is a high degree of correlation between depressed control
percentage T lymphocyte counts when control lymphocytes are incubated
in cancer sera and the percentage T lymphocyte counts of the cancer patients
from whom the sera is taken (Shukla et al. 1979; Shukla et al. 1980).
Whitehead et al. (1977) also noted this correlation stage for stage in
patients with breast cancer. It has further been reported that 'blocking'
factor, measured by T lymphocyte rosetting inhibition decreases significantly
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in those with Stage III breast cancer following mastectomy (Shukla et al.
1980) and in those with early breast cancer, who do not recur, following
mastectomy (Haffejee et al. 1983). It has been further shown that patients
with little post-operative serum inhibitory factor are unlikely to develop
recurrent disease whereas 50% of those with significant post-operative
inhibitory levels recur within four years (Haffejee et al. 1983). The
inhibitory effect of allogeneic control sera on lymphocyte blastogenic
function has also been demonstrated in T lymphocyte rosetting but this
appears to be limited at most to 15% of T lymphocytes (Shukla et al. 1980),
cancer sera invariably causing greater depression.
Evidence that the link between the depression in DHR and percentage
T lymphocyte counts in cancer patients may be a lymphocyte inhibiting
serum factor has been produced by Holland et al. (1975) who showed that
slow infusion of brinase, which removes inhibitory factor from the
lymphocytes in vitro, into patients with malignant disease, results
in increased T lymphocyte counts paripassu with a restoration of skin
allergy.
The serum factor which inhibits E-rosetting is, like that affecting
blastogenesis, not specific to cancer, and has been demonstrated
in patients with SLE (Popovic et al. 1974), acute viral hepatitis (Chisari
& Edgington 1975), and in the elderly, and in those with chronic benign
disease (Whitehead et al. 1978).
Added evidence that cancer sera contains inhibitory factors
affecting lymphocyte function comes from the work using assays of lymphocyte
cytotoxicity against tumour target cells, much of it undertaken by the
Hellstroms who, following Moller's demonstration in 1965 that autologous
antibody was capable of 'blocking' cell mediated cytotoxicity, were able
to show that serum from tumour bearing animals could abrogate, in an
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immunologically specific manner, the antitumour effects of specifically
sensitised lymphocytes (Hellstrom & Hellstrom 1969). They and others
later demonstratead that the 'blocking' capacity of the serum in animals
and humans was lost following complete excision of the tumour (Hellstrom
et al. 1970; Hellstrom 1971; Hellstrom & Hellstrom 1974a, Hellstrom
& Hellstrom 1974b; Baldwin et al. 1972; Baldwin et al. 1973a; Currie 1973)
but not on partial excision. Serum from such tumour-free individuals was
shown to have the capacity to neutralise the inhibitory activity of
tumour bearer serum, this 'unblocking' phenomenon having previously been
reported by Hellstrom and Hellstrom (1970) and Bansal and Sjogren (1971).
It was also demonstrated that lymphocyte mediated cell cytotoxicity was
more pronounced in patients with small tumours than in those with large
tumours and that the sera of patients with growing neoplasms could 'block'
cytotoxicity against tumours of the same histologic type (Hellstrom &
Hellstrom 1974a) and even that such 'blocking' activity was often detectable
before clinically overt tumour recurrence (Hellstrom & Hellstrom 1973;
Hellstrom & Hellstrom 1974a). For instance, of patients clinically free
of tumour following surgery, 92.9% who showed post-operative 'blocking'
went on to develop recurrence within the first year whereas only 13%
of those with no significant post-operative 'blocking' did so. Currie and
Basham (1972) also showed that this inhibitory factor could be removed
from the lymphocyte surface by washing, greatly enhancing lymphocyte
cytotoxicity to autologous and allogeneic tumour cells of similar
histologic, but not other histologic, origin. They further showed that
this cytotoxicity was abolished following reincubation in cancer serum,
that the inhibitory factor acted only on the lymphocyte and did not
'block' the target cell, and that this factor was present in patients
with more advanced disease but absent in those with early disease,
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suggesting a correlation between tumour load and the presence of inhibitor.
Interestingly, this 'blocking' phenomenon appears to be even stronger
within the tumour and locoregional lymph nodes, Nind et al. (1973) having
demonstrated that lymphocytes derived from tumours displayed no cyto¬
toxicity against target cells whereas more than 50% of patients had
peripheral lymphocytes cytotoxic to the tumours. They further reported,
using a greater number of patients, that only 7% of these had lymphocytes
frcm regional nodes capable of tumour cell killing whereas 33% of
peripheral blood lymphocytes retained their cytotoxic ability. Currie
and Gage (1973) working with animals also found similar local and
regional node paralysis, later followed by peripheral blood anergy,
this invariably preceding the development of micrometastases. More
recently Hoon et al. (1987a) demonstrated depressed in vitro
responses to PHA, MLC and interleukin-2, by the lymphocytes from lymph
nodes nearest to primary malignant melanoma and breast tumours in
comparison with responses by lymphocytes from more distant nodes,
indicating decreasing immunosuppression of node lymphocytes with
increasing distance from the tumour.
In summary, the properties of this inhibitory or 'blocking' factor
appear to be that it acts on the lymphocyte to depress, the formation
of rosettes with SRBC, blastogenic transformation, cytotoxicity against
target cells and responses to skin test antigens. It can be removed
from the lymphocyte by washing, enzyme digestion and by incubation
in control sera and can be reapplied by incubation in cancer sera.
There is sane evidence that it is specific for tumour histologic types
implying the presence of TSAs, but others have noted no immunological
specificity. Further, the 'blocking' activity of cancer sera appears
to reflect the tumour burden of the host in a directly proportional
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fashion. It also appears that normal sera have an inhibitory capacity,
to a lesser degree than cancer sera, when incubated with non-autologous
lymphocytes and that sera from patients with benign active disease,
the elderly, multiparous and pregnant women (Carpentier & Miescher 1983),
also exert 'blocking' activity.
Whitehead et al (1977) have further shown that the inhibitory
factor in cancer sera does not affect B lymphocytes, appears like the
hepatitis associated lipoprotein demonstrated by Chisari and
Edgington (1975) to affect only a subpopulation of T lymphocytes, and
that its effectiveness is lost by dilution to one fourth of original
concentration. They further demonstrated that the cancer serum inhibition
was not due to C-reactive protein which can block E-rosetting formation
in its own right (Mortensen et al. 1975), anti-HLA activity also known
to inhibit E-rosetting (Pyke et al. 1975), anti-blood group activity,
nor to hepatitis associated lipoprotein (Chisari & Edgington 1975).
Others who have analysed the inhibitory factor have claimed it to be an
alpha macroglobulin, also seen in the serum of pregnant patients
(Stimson 1975), or an immunosuppressive peptide (Nimberg et al. 1975).
Perhaps the strongest claim, however, is that serum inhibition is due
to antigen or immune complexes.
3.3.2. Immune complexes
Initially, because Kaliss (1958) had shown that injection of specific
allo-antibody facilitated growth of allografted tumours in situations
where rejection would normally occur and Moller (1965) had demonstrated
that autologous antibody was capable of blocking ADCC, it was thought
that antibody might be the inhibitory substance. Added support was
supplied by the Hellstroms (1969) who observed that serum from tumour
bearing animals could abrogate in an immunologically specific manner the
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antitumour effects of specifically sensitised lymphocytes, this 'blocking'
activity being held in the 7S fraction of serum and being neutralised
by the addition of heterologous antimouse immunoglobulin. The logic of this
is lost however, when it is appreciated that antibody itself appears to
have an antitumour effect. For instance, it combines with lymphocytes
to effect cytotoxicity (Moller 1965; MacLennan & Loewi 1968), has
a protective anti-oncogenic virus role in chickens (Thompson & Linna 1973),
and antibody is detectable in the sera of patients with early cancers only
to disappear with advancing disease (Lewis et al. 1969) being replaced by
'blocking' activity (Basham & Currie 1974). Further, Baldwin et al. (1973a)
showed that antibody not detectable in tumour bearing animals could be
demonstrated in the sera of these animals following excision of the tumour.
It was postulated that the explanation for this phenomenon (Thomson et al.
1973) is that antibody to TSAs is produced early in disease but as tumour
bulk increases and the nodal architecture becomes disrupted, free soluble
TSA is released into the circulation with resultant formation of immune
complex (IC) and disappearance of antibody. Removal of the tumour, the
antigen source, would permit re-expression of antibody in the serum.
These authors further demonstrated that the disappearance of antibody
from the serum was not due to either induction of tolerance in the
animal or absorption of antibody by the tumour mass.
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Evidence that complexes are involved in the 'blocking' phenomenon, was
produced by elution and ultrafiltration experiments, dividing 'blocking'
sera (Sjogren et al. 1971) into heavy and light molecular weight (MW)
fractions. It was seen that the heavy MW fraction had no 'blocking'
capability and the light MW fraction could inhibit the effector cell
only but that a recombination of both fractions could inhibit at
both effector and target cell levels. Hattler and Soehnlen (1974)
removed the 'blocking' component from the lymphocyte membrane by washing
and, by crude fractionation of this, into heavy and light MW fractions
which they suggested might be antibody and antigen respectively,
showed that these independently could not produce the 'blocking' effect
but that recombination of the fractions resulted in inhibition of
lymphocyte reactivity, the implication being that ICs were the 'blocking'
factors. Unequivocal proof that antibody-antigen complexes participate
in 'blocking' reactions was obtained in the rat hepatoma system (Baldwin
et al. 1972, reviewed Baldwin et al. 1974) when it was demonstrated that
papain-solubilised tumour, antigen and its antibody, although individually
incapable of 'blocking' at the target cell level, could 'block' either at
the lymphocyte or target cell surface when recombined 'in the right mix'.
It was noted that post-excision serum, i.e. in antibody excess,
did not cause 'blocking' until sufficient antigen was added to form
complexes in the right proportions but continued addition of antigen
resulted in loss of 'blocking', presumably because the ICs would then bind
to free antigen instead of tumour cell or lymphocyte membranes. In the
rat hepatoma model the 'right mix' for optimal 'blocking' appears to be
free circulating TSA in excess together with specific ICs (Baldwin
et al. 1973c). These authors, however, also noted that antigen itself
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can be inhibitory at the lymphocyte (but not the tumour cell) surface,
although others (Tanaka et al. 1979) have found that antigen alone does
not inhibit lymphocyte function. Gorczynski et al. (1975) have suggested
that immunologically specific 'blocking' may be carried out by antigens
and ICs but that non-specific inhibition is a feature of ICs only.
Baldwin et al. (1974) have also suggested that of the two mechanisms
of 'blocking', IC inhibition is the more important. They have postulated
that antigen produces lymphocyte 'blocking' in the earlier stages of tumour
growth until the production of antibody occurs which, by forming complexes
with antigen, results in decrease of free antigen and 'blocking' by ICs
in the later stages of disease.
Further evidence that circulating immune complexes (CICs) are
responsible for 'blocking' has been produced by Tanaka et al. (1979)
who were able to show using assays of PHA blastogenesis and leukocyte
adherence inhibition (LAI) that the inhibitory effect of cancer sera,
already demonstrated by their laboratory to be tumour stage-related
(Yonemoto et al. 1978) correlated with ICs precipitated out of the
sera by polyethylene glycol.
There is evidence, both indirect and direct, that ICs are produced
by patients with malignancy. Indirect evidence comes from well recognised
but uncommon secondary immunopathological manifestations of immune complex
disease thought to be a consequence of malignancy. These tend to occur in
conjunction with lymphomas and leukaemias but occasionally present in solid
tumours, especially those of lung and ovary. Tumour associated cases
of autoimmune disease such as cerebellar degeneration, carcinomatous
neuromyopathy, dermatomyositis and nephritis have been reported
(reviewed by Burnet 1970a) and more recently autoimmune tumour associated
phenomena have been noted; haemolytic anaemia (Laszlo 1982), vasculitis
(Doyle & Perry 1982), nephrotic syndrome (Higgins et al. 1974), and
neuropathy and myelopathy (Richardson 1982). Further, Twomey et al (1976)
have reported an increased incidence of rheumgrf^iid factor (RhF) in the
sera of lung and breast cancer patients following chemotherapy or
irradiation therapy and Pascal et al. (1976) have shown an increased
incidence of subclinical glomerular IC deposits in patients with
malignancies. It has been suggested that these may be complexes between
antibody and either TSA (Pascal et al. 1976) or cellular breakdown
products (Higgins et al. 1974). Theofilopoulos and Dixon (1979),
reviewing this subject, have proposed that the infrequency of overt
immune complex disease in cancer patients is explained by the inter¬
mediate size of the ICs in the serum of such patients, these ICs not
being of appropriate size or composition for deposition in the tissues.
Direct evidence that CICs are produced by many patients with
spontaneous neoplasms has also been obtained by measuring these complexes
in patients' sera. Soluble CICs have frequently been reported to
be elevated in patients with leukaemias, lymphomas and a wide variety
of solid cancers (Heimer et al. 1976; Theofilopoulos et al. 1976;
Rossen et al. 1977; Teshima et al 1977; Poulton et al. 1978; Brandeis
et al. 1978; Mihas et al. 1981; Vellacott et al. 1981; Poskitt &
Poskitt 1985), and elevated levels shown to be related to pathological
stage of disease (Brandeis et al. 1978), tumour load (Heier et al. 1972;
Rossen et al. 1977; Amlot et al. 1978; Poulton et al. 1978; Brandeis
et al. 1978; Poskitt & Poskitt 1985), symptomatic lymphomatous disease
(Heier et al. 1977; Amlot et al. 1978), and lymphomas of poor histological
grade (Amlot et al. 1978). Levels of CIC have further been reported to
predict outcome (Hoffken et al. 1977; Rossen et al. 1977; Rossen et al. 1983
Poskitt & Poskitt 1979; Amlot et al. 1978; Gupta & Morton 1983) and
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to vary with change in disease status (Hoffken et al. 1977; Poulton et al.
1978; Brandeis et al. 1978: Amlot et al. 1978) and sometimes before
clinical evidence of this is evident (Gupta & Morton 1983). Others,
however, have reported little or no difference in CIC levels between
patients and controls (Herberman et al. 1981; Clarke et al. 1982;
Krieger et al. 1983) and that levels do not reflect tumour burden
(Heimer & Klein 1976; Vellacott et al. 1981). Indeed, although there
is a tendency for patients with more advanced or aggressive tumours
to havemeasurable or elevated levels of CIC, such patients may have
CICs within the normal control range.
There are many possible reasons for such discrepencies between
laboratories but one important possibility suggested (Lambert et al. 1978),
[because of poor correlation between measured CIC levels by different
techniques (Lambert et al. 1978; Herberman et al. 1981)], is that some
techniques are more suitable for detecting the IC of certain diseases, and
as there tends to be heterogeneity of IC in the circulation, not all of which
may be related to the disease under study (Jones & Orlans 1981), it is quite
possible to measure ICs unrelated to the disease process under
investigation.
3.3.3. Possible mechanism of blocking
The relationship between tumour burden and 'blocking' capacity
of the serum in animals could be explained on the following lines:
antibody against TSA would be formed in the regional nodes, such
antibody being measureable in the peripheral blood. However, with
increase in tumour bulk the nodal architecture would be disrupted
allowing free TSA access to the circulation where, by combining with
antibody it would form ICs, the antibody disappearing from the blood.
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Early in disease the resulting anergy would be localised but as more
TSA and IC was released into the circulation it would become generalised.
Baldwin et al. (1973) have suggested that the relative concentration
of substances with the potential to 'block' or inhibit the immune response,
i.e. antigen and ICs, are dependent on the strength of the host immune
response and the extent of tumour antigen release. Tumour antigen
release is essentially a characteristic of the particular tumour. It is
known that tumours have unstable membranes and shed surface antigen
more readily than normal cells (Davey et al. 1976) and that those which
shed their surface components more readily and extensively are those
which metastasise more easily (Currie & Alexander 1974), so it would
seem reasonable to conclude that very active cancers such as anaplastic
tumours, which we know to be highly metastatic, are those which produce
greatest amounts of antigen and IC.
The mechanism may be slightly different with regard to the spontaneous
tumours of man, which do not have apparent TSA. However, man does produce
autoantibodies to cellular components (Whitehouse & Holborrow 1971) probably
as a mechanism for clearing debris of dead or dying cells, and this may
explain the relationship between tissue necrosis and the serum
suppressive activity demonstrated in patients with tuberculosis, syphilis,
candidiasis, Crohn's disease, ulcerative colitis and acute viral
hepatitis (Gatti et al. 1971; Whitehead et al. 1978; Chisari & Edgington
1975). Further evidence on this point relating to tumour has been
presented by Shukla et al. (1980) who attributed the increase in serum
'blocking' activity in patients undergoing radiotherapy for advanced
locoregional inoperable breast cancer to tissue breakdown products from
the radiation induced necrosis. Currie (1980) however, has also
suggested that tumour cells may have 'natural' antibody directed against
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surface determinants not detectable on normal cells as a result of
defective glycolysation. Thus, in man rapidly growing anaplastic
cancers with their high degree of membrane shedding and production of
tissue necrosis breakdown products, would be those most prone to contain
high concentrations of non-specific antigen and IC in their host's serum.
The more aggressive the tumour, the more 'blocking' activity in the
patient's serum and the greater the depression of tests of immune
competence.
As a general rule, the heavier the tumour load, the more profound
the anergy but very bulky localised lesions without evidence of
dissemination might be expected to have relatively stable surface
membranes, shedding little antigen into the blood and, as a consequence,
exhibiting only moderate 'blocking' activity. This would explain the
apparent ananally in Stage III breast cancer where DHR, T lymphocyte
percentage counts and serum 'blocking' activity are virtually identical
to that of the control population. Small highly active cancers, while
still in the early phases of their development, on the other hand,
might, by their ability to rapidly shed large amounts of debris into
the circulation, exert a high degree of inhibitory activity. These
features may well explain why some authors have been unable to detect
differences in serum inhibitory capacity between the various stages
of disease (Matthews & Whitehead 1976; Whitehead et al. 1977). Therefore,
although serum 'blocking' activity appears to be related to tumour load
it is probably much more importantly a reflection of tumour cell turnover.
3.3.3.4. Possible use in assessment of cancer activity
Any mode of therapy causing a decrease in tumour load or activity
should effectively reduce serum 'blocking' capacity. For instance, it
84
might be expected that serum 'blocking' activity would disappear following
complete surgical ablation of all tumour, whereas surgery leaving
residual tumour would result in continuing serum 'blocking' activity.
Therefore, by measuring the post-operative 'blocking' capacity of sera
it should be possible to assess the efficacy of surgical treatment or
the presence of occult metastatic disease (see Haffejee et al. 1983).
This of course has important implications not only with regard to prognosis
but also to the application of adjuvant therapy. However, it must always be
borne in mind that a small focus of active tumour may be as effective
as a larger volume of equally active disease if sufficient 'blocking'
material is produced to saturate the proportion of T lymphocytes affected
by these factors, Whitehead et al. (1977) having shown that further
exposure of lymphocytes, already 'blocked' by one cancer serum to a second
cancer serum, resulted in no increase in lymphocyte inhibition. Once
maximal 'blocking' is attained it becomes impossible to assess the true
extent of disease.
On the other hand, systemic forms of therapy generally apply to all
foci of cancer throughout the host, so serum 'blocking', as measured by its
effect on T lymphocytes, may reflect whole tumour volume. Hormonal
manipulation of breast cancer, when effective, reduces disease load
but more significantly, by suppressing the production of constituents
necessary to maintain cancer cell survival and replication, it reduces
tumour cell turnover and consequently should diminish the shedding
of antigenic material. The efficacy of this mode of therapy should,
therefore, be particularly amenable to assessment by measuring the
effect of serum 'blocking' activity on lymphocytes.
85
3.4. Summary
It is generally accepted that the immune response is impaired
in many patients with solid cancers as well as in those with virally-
1inked tumours. When immunodeficient, they manifest depressed CMI
more so than impaired humoral inmunity. A vast quantity of literature
has been published on the relationship between various solid tumours
and tests of CMI in an attempt to predict prognosis, tumour load and
efficacy of treatment but these tests have been found wanting, perhaps
because of the many variables which can affect CMI and the differences in
results which even slight variation in technique in the performance of
these tests will give.
As a general rule the development of spontaneous cancers appear to
precede impairment of CMI but as the extent of disease increases
such impairment becomes more profound indicating that it is a secondary
phenomenon rather than a primary event. It would seem from the evidence
previously presented that assays of CMI are depressed as a consequence
of inhibitory or 'blocking' factor(s) present in the sera of tumour bearers,
and that these factors may be immune complexes of antibody and their
antigens in man, the latter probably being non-specific products of cell
turnover and necrosis.
Finally, it appears that the more actively a tumour produces antigen,
either because of rapid cell turnover or as a consequence of sheer
tumour bulk, the greater the amount of CIC formed and the more profound
the inhibitory effects of the sera on host CMI. Hopefully, we may be
able to utilise this relationship between IC production and its effect
on lymphocyte function to measure tumour load or disease activity more
efficiently than at the present time, perhaps even prior to clinical
evidence of change in disease status, permitting earlier modification
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4. Lymphocyte Counts and Carcinoma of The Breast
4.1. Introduction
As indicated in the preceding chapter absolute lymphocyte
and absolute percentage T lymphocyte counts have been reported by
many authors to be depressed in patients with breast cancer and various
other solid tumours and the degree of depression is roughly related
to the extent of disease. It has also been demonstrated (Shukla et al.
1980) that cancer and treatments which depress T lymphocyte counts
such as radiotherapy, may do so in two ways: a) by reduction of the
absolute number of circulating lymphocytes in the peripheral blood;
and b) by depressing the proportion of T lymphocyte counts in
the blood, probably by the action of serum inhibitory or 'blocking'
factor(s) which convert them into null cells.
It will be shown here that T lymphocyte counts are depressed
in patients with breast cancer and that this depression is related to
tumour load, while recognising that tumour activity is probably even
more important. Furthermore, it will be demonstrated that while local
treatment makes little, if any, difference to lymphocyte and T lymphocyte
counts that systemic hormonal treatments, when successful, increase the
proportion of lymphocytes often before there is objective evidence of disease
remission.
An attempt will be made to show that many authorities have failed to
demonstrate such a relationship because of variations in techniques used
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in counting T lymphocytes. In particular it is possible that much of the
discriminatory power of percentage T lymphocyte counts is lost because
certain methodologies in general use permit sheep red blood cells (SRBC)
to rosette with low avidity receptor cells from the null cell population
thereby increasing apparent T cell numbers significantly.
Finally, the relevance of circulating intmine complexes, assayed
by the Clq deviation tests, to breast cancer and their relationship
to depressed % T lymphocyte counts, will be explored.
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4.2. Part I
The Effect of Breast Disease and Treatment Response on Lymphocyte Counts
4.2.1. Materials and methods
Patients [Table 4.1]
Wcmen studied attended the Breast Clinic at the University Hospital
of Wales, Cardiff, and the Combined Breast Clinic, Velindre Hospital,
Cardiff. Fifty of these patients had benign breast disease; 10 underwent
mastectomy for Stage I breast cancer and 32 for Stage II breast cancer,
12 of the latter being given a two year post-operative course of adjuvant
tamoxifen lOmg b.d. Fifteen patients also underwent mastectomy for
Stage III breast cancer. Five patients with Stage I and II and 10 patients
with Stage III disease were treated solely with tamoxifen 20mg b.d.
Sixty patients with Stage IV breast cancer were treated by hormonal
manipulation; 47 with tamoxifen 20mg b.d. alone, 7 by oophorectomy, 1 by
adrenalectomy, and 5 with a combination of tamoxifen 20mg b.d. and
prednisolone lOmg t.d.s.
Evidence of extent of disease was obtained by clinical
examination, routine blood tests, mammography, chest x-ray and when
indicated, bone scans and ultrasonography of liver. Histological proof
of diagnosis was always obtained either by open biopsy or trucut needle
biopsy.
Pre- and post-treatment lymphocyte counts were performed as
often as feasible and the number of tests in each subgroup are indicated
in the results tables.
Treatment response









































































assessed applying U.I.C.C. criteria (Hayward et al. 1977), using data
from physical examination, photographs, radiographs, mammographs,
and measurement of lesions over a period of at least three months.
Lymphocyte separation
Approximately 15 to 20mls of venous blood was withdrawn from
each patient at the time of testing and placed in a sterile container
containing 50 U./ml preservative-free heparin. Eight ml aliquots
were layered over 3ml ficoll-hypaque (4.8ml, 10.8% ficoll and
2ml, 33.3% hypaque specific gravity 1.078, after Boyum 1968) and
the mononuclear cell layer, comprising mainly lymphocytes, isolated by
buoyant density centrifugation at 400g for 30 mins (Fig. 4.1). The mono¬
nuclear layer was immediately removed and washed twice in sterile isotonic
saline by centrifugation at 400g for 5 mins, following which the cells were
suspended in 1ml of sterile isotonic saline. A small proportion (0.05ml)
of this suspension was added to an equal volume of trypan blue stain and
counted on the improved Nebauer haemocytometer to assess lymphocyte
numbers, viability and contamination by granulocytes. The lymphocytes
were then adjusted to a concentration of 2x10^ cells/ml.
Preparation of sheep red blood cells (SRBC)
Normal sheep erythrocytes for the rosetting experiments were
obtained from Wellcome sheep. Blood between 10 and 14 days old and
containing no preservative was washed three times at 500g for 5 mins
and made up to a 2% suspension in sterile isotonic saline. A fresh
suspension was made up daily.
Preparation of ficoll-hypaque
Twenty-one gms ficoll (Pharmacia, Great Britain Ltd.) was added
to 216 mis of water, boiled at 151bs/sq inch for 15 mins in a pressure
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Fig. 4.1
Ficoll-Hypaque Separation of Mononuclear Cells
from Whole Blood
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cooker and then allowed to cool to room temperature. Sixty mis of 45%
hypaque (University Hospital of Wales Pharmacy) was added and this
solution stored at 4°C until use.
E-rosetting test [after Anthony et al. 1975a]
A volume of 0.25ml of 2% SRBC suspension was added to 0.25ml of
lymphocyte suspension in small bottomed glass tubes (Fig. 4.2). The tubes
were covered with Nescofilm (Bando Chemical Industries Ltd., Kobe,
Japan), gently shaken and incubated at 37°C for 10 mins following
which they were centrifuged at lOOg for 5 mins and then placed in a
refrigerator at 4°C for an hour and a half. After chilling,
the top layer of the pellet was resuspended with great care and a drop
of this suspension gently placed on a cooled haemocytometer. A cooled
coverslip was then gingerly lowered, using a fine needle, over the cells.
Lymphocytes were then counted to a total of 200 to ascertain the percentage
of rosetting cells, a rosette being defined as a lymphocyte with three
or more SRBC firmly attached to it (Fig. 4.3). Polymorphonuclear cells,
which were usually few in number, could be easily distinguished by their size
and multinucleated appearance. Because of the difficulty in differentiating
large lymphocytes from monocytes in unstained preparations, only small
and medium sized lymphocytes were counted. Duplicate tubes were invariably
used and the mean of the results taken but occasionally drops of suspension
from one tube were counted in duplicate on separate haemocytameters,
following which the mean of these results was calculated.
Absolute lymphocyte and absolute T lymphocyte counts
Full blood counts were performed in the Department of Haematology,
University Hospital of Wales, Cardiff, on the Coultor counter. Differential























Electron Microscopy Photomicrograph of T Cell
with Three SRBC Attached
[mag. x 18,000]
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lymphocyte count was taken as the multiple of the white cell count and
the percentage of white cells which were lymphocytes. The absolute T
lymphocyte count was taken as the multiple of the absolute lymphocyte
count and the percentage of lymphocytes which were T lymphocytes.
Oestrogen receptor assay
The oestrogen receptor content of tumours was determined using
the dextran coated charcoal assay described by Korenman and Dukes (1970) at
the Tenovus Institute for Cancer Research, Cardiff. Samples of tumour
were taken at operation, warm ischaemic time, if any, being kept to
an absolute minimum, placed in ice and delivered to the laboratory
immediately. The results for patients included in this study were
collected from a special register kept in the University Department
of Surgery, Cardiff. Tumours were considered positive for oestrogen
receptors only when they contained more than 5 f mol specific oestradiol
binding per mg cytosol protein.
Statistical methods
The significance of the difference in mean lymphocyte counts
and in mean age of patients between various disease stages and between
various response groups was determined using the two-tailed Mann-Whitney
U test.
The results quoted in the tables are the mean + standard
deviation of the lymphocyte counts.
4.2.2. Results
Little difficulty was usually encountered with the mononuclear
band separation over ficoll-hypaque. However, when patients were very
ill there was often severe contamination of the band by granulocytes
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and red blood cells and sometimes, though rarely, in such patients
no separation was possible at all. Granulocyte contamination in the
various groups prior to treatment was 3.1+1.5% for controls;
5.4+4% for benign breast disease; 5.3+3.2% for Stage I and II
breast cancer; 8.0+3.8% for Stage III breast cancer; 6.6+2.9%
for metastatic breast cancer. Viability was always greater than 95%
of the total lymphocytes.
Effect of age on lymphocyte counts [Appendix 4.1 - 4.4]
Percentage T lymphocyte counts (% T) did not vary with age in
patients with benign breast disease (Table 4.2) but the oldest woman assessed
was only 62 years. Absolute T lymphocyte (Abs T) and absolute lymphocyte
(Abs L) counts tended to decrease slightly with increasing age but there was
a significant difference only between women younger than 30 years and those
over 50 years (p<0.01).
There was no significant change in % T, Abs T or Abs L counts
with age in women with operable breast cancer until the age of 75 years
when there was a sharp and significant (p<0.05) drop in % T counts and
a non-significant decrease in Abs T and Abs L counts (Table 4.3). Patients
with Stage IV breast cancer similarly had no significant age related
change in % T, Abst T or Abs L count although, as in those with operable
disease, both Abs T and Abs L tended to be lower in women older than
75 years (Table 4.4).
Effect of disease status on lymphocyte counts [Appendix 4.1 - 4.4]
Patients with benign breast disease were significantly younger
(39.1+9 years) than those with breast cancer but between the stages
of cancer no significant age difference was noted (Table 4.5). Patients
with breast cancer had significantly depressed (p<0.001) % T counts
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Table 4.2
Variation in % T, Abs T, and Abs L, with Age in Patients with
Benign Breast Disease









Abs T 1.45410.196 1.264+0.430
(n=6) (n=11)
1 .278 + 0.581
(n = 1 0)
0 .855 + 0.206*
(n = 3)
Abs L 2.41410.207 2.150+0.743 2.125+0.948 1.512+0.387*
(n=6) (n=11) (n=10) (n=3)
*Compared with patients 15 to 30 years old (Z=0, p<0.01)
Mann-Whitney U test
Table4.3 Variationin%T,AbsndAbsLwithgePat entswithOp rableStagI,I,&I, BreastCancer
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p<0.05 p<0.05 NS p<0.05
Mann-WhitneyUtest















Variation in % T Lymphocyte Counts Between Different Stages
Mann-Whitney
Stage Age % T U test
Benign 39.119.0 60.115.2
Breast Disease (n=50)
Stage I & II 58.4115.0 52.7+10.0* Z-3.77
Breast Cancer (n=34) p<0.001
Stage III 64.2+12.8 50.9+9.7* Z=3.69
Breast Cancer (n=21) p<0.001
Stage IV 57.9+14.8 47.8111.3*+ Z=5.89*
Breast Cancer (n=45) p<0.001
Z = 1.78+
p<0 . 05
* Compared with benign breast disease
+ Compared with Stage I and II breast cancer
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compared to those with benign breast disease (Table 4.5, Fig. 4.4) and
patients with Stage IV disease had significantly lower (p<0.05) % T
counts than those with Stage I and II breast cancer. Abs T counts
were also significantly depressed (Table 4.6) in those with breast
cancer compared with benign breast disease (p<0.02), this depression
being most marked in patients with advanced disease (pCO.OOl). Abs T
counts were significantly lower in patients with metastatic disease
than in those with Stage I and II cancer (p<0.02). There was also a
trend for the Abs L counts to be depressed in cancer patients in
comparison to those with benign breast disease but this only attained
significance (p<0.01) in those with Stage IV breast cancer (Table 4.7).
Comparison between operable and metastatic breast cancer within each
group (Tables 4.8, 4.9 & 4.10) showed a trend to depressed % T, Abs T
and Abs L counts in those with Stage IV disease; apart from patients
over 75 years of age with operable disease, whose % T counts were
lower than those with metastatic cancer.
Effect of surgery on lymphocyte counts [Appendix 4.2 - 4.6]
All patients studied here had Patey mastectomy without any additional
adjuvant treatment and counts were performed at least 6 weeks after surgery.
There was no difference between pre- and post-operative % T, Abs T or Abs L
counts in patients undergoing mastectomy for either Stage I and II or
Stage III breast cancer (Table 4.11 & 4.12) (Fig. 4.5).
Relationship between prognostic factors and pre-operative
lymphocyte counts [Appendix 4.7 & 4.8)
Tumour histology was not sufficiently specific in the majority
of patients to allow useful comparison with pre-operative lymphocyte
counts. Histological status of axillary lymph nodes and oestrogen
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Table 4.6
Variation in Absolute T Lymphocyte Counts Between Different Stages
Mann-Whitney
Stage Age Abs T U test
Benign 39.3±9.9 1.266±0.451
Breast Disease (n=30)
Stage I & II 57.6±15.0 0.993±0.513* Z =2.3
Breast Cancer (n=32) p<0.02
Stage III 64.3±13.1 0.949±0.291* Z=2.59
Breast Cancer (n=20) p<0.01
Stage IV 56.3115.1 0.75110.492*+ Z=4.24*
Breast Cancer (n=37) p<0.001
Z=2.73+
p<0.01
* Compared with benign breast disease
+ Compared with Stage I and II breast cancer
1 04
Table 4.7
Variation in Absolute Lymphocyte Counts Between Different Stages
Mann-Whitney
Stage Age Abs L U test
Benign 39.3±9.9 2.149±0.753
Breast Disease (n=30)
Stage I & II 56.3114.7 1.84210.737
Breast Cancer (n=36)
Stage III 64.1+12.5 1.849+0.501
Breast Cancer (n=22)
Stage IV 56.3+15.1 1.55410.900* Z=3.03*
Breast Cancer (n=37) p<0.005
* Compared with benign breast disease
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Table 4.8
% T; Variation with Age, Stage I, II, III, and IV Breast Cancer
Pre-Treatment
Stage I, II, III Stage IV
Operable Mann-Whitney
Breast Cancer Breast Cancer U test
Age % T %_T
30-45 yrs 52.7±8.0 45.2±10.5
(n=9) (n=13)
46-55 yrs 54.5±6.8 46.6112.1
(n=13) (n=8)
56-65 yrs 50.118.4 50.8+9.1
(n=8) (n=8)
66-75 yrs 56.7110.3 49.5111.6
(n = 9) (n = 1 1)










Abs T: Variation with Age, Stage I, II, III, and IV Breast Cancer
Pre-Treatment
Stage I, II, III Stage IV
Operable Mann-Whitney
Breast Cancer Breast Cancer U test
Age Abs T Abs T
30-45 yrs 0.985±0.265 0.74810.480
(n=9) (n = 13)
46-55 yrs 0.97910.281 0.710+0.459
(n=12) (n=6)
56-65 yrs 1.241+0.949 0.814+0.694
(n = 6) (n = 7)
66-75 yrs 0.971+0.457 0.854+0.494
(n=9) (n-7)










Abs L: Variation with Age, Stage I, II, III, and IV Breast Cancer
Pre-Treatment
Stage I, II, III Stage IV
Operable Mann-Whitney
Breast Cancer Breast Cancer U test
Age Abs L Abs L
30-45 yrs 1.863±0.456 1.66010.994
(n=11) (n=13)
46-55 yrs 1.84510.451 1.443+0.829
(n=14) (n=6)
56-65 yrs 2.161+1.243 1.536+1.230
(n=8) (n = 7)
66-75 yrs 1.695+0.675 1.73010.682
(n=9) (n = 7)
75+ yrs 1.598+0.494 1.095+0.483









Stage I & II Breast Cancer
Comparison of Pre- and Post-Operative Lymphocyte Counts
Mann-Whitney
Pre-Operative Post-Operative U test
% T 52.918.2 52.017.5




1 . 199 + 0 .408










Stage III Breast Cancer
Comparison of Pre- and Post-Operative Lymphocyte Counts
Mann-Whitney




Abs T 0.953±0.308 0.904±0.352
(n=9) (n=7) NS
Age 57.8±12.4 59.6±7.3
Abs L 1.845±0.511 1.735±0.561
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Fig. 4.5



























Stage I& II Breast Cancer
Post- op
n = 8
Stage HI Breast Cancer
112
receptor (ER) status of primary tumours were reported in sufficient numbers
to permit such comparison.
Patients with node metastases tended to be younger than those
with tumour free nodes, this age difference being significant in the group
of women undergoing % T count assessment (p<0.05). No difference was noted
in pre-operative % T, Abs T or Abs L counts between patients found to
have tumour invasion of axillary nodes and those without node metastases
(Table 4.13)
Women with ER negative tumours were significantly younger
(p<0.05) than those with ER positive tumours. No difference in pre-operative
% T, Abs T or Abs L counts was seen between the two groups (Table 4.14).
Relationship of pre- and post-operative lymphocyte counts to later
tumour recurrence [Appendix 4.9 & 4.10]
Lymphocyte counts were examined pre-operatively and between
six and 12 weeks post-operatively in patients undergoing Patey mastectomy
without additional adjuvant therapy. These were related to recurrence
within a four year period from surgery, the minimum follow-up time,
to see if depressed pre-operative lymphocyte counts predicted earlier
recurrence, or if post-operative lymphocyte count depression indicated
residual disease in the form of micrometastases.
There was no significant age difference between patients developing
recurrence or those remaining disease free at 4 years. Those who developed
later recurrence tended to have slightly higher, but not statistically
significantly higher, lymphocyte counts pre-operatively (Table 4.15).
No difference was noted between lymphocyte counts post-operatively in
patients developing recurrence or remaining free of disease at four
years (Table 4.16).
Effect of adjuvant tamoxifen on lymphocyte counts [Appendix 4.11]
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Table 4.13
Stage I, II, & III Breast Cancer
Pre-Operative Lymphocyte Counts Related to Axillary
Node Histology
Mann-Whitney
Node Negative Node Positive U test
















Stage I, II & III Breast Cancer
Pre-Operative Lymphocyte Counts Related to Oestrogen Receptor
Status of Primary Tumour






















Stage I, II & III Breast Cancer
Pre-Operative Lymphocyte Counts Related to Tumour Recurrence




Patients 15 1 1
Age 54.3112.7 54.5112.5
% T 52.917.4 54.918 . 3 NS
Abs T 0.88210.266 1.02710.270 NS




Stage I, II & III Breast Cancer
Post-Operative Lymphocyte Counts Related to Tumour Recurrence
Within 4 Years from Mastectomy
Mann-Whitney
No Recurrence Recurrence U test
% T 52.017.2 52.218.7 NS
(n=17) (n=10)
Age 55.8+12.1 60.2+11.3
Abs T 1.107+0.455 1.093+0.411 NS
(n=13) (n=9)
Age 59.0+11.8 58.1+9.8





A group of post-menopausal patients with Stage II breast cancer
were given tamoxifen lOmg for 2 years following mastectomy as part
of a controlled randomised study. Data on lymphocyte counts was available
in 12 of these women but there was insufficient information on pre¬
operative lymphocyte counts to compare these with post-operative results.
A reasonably comparable group of post-menopausal patients undergoing
mastectomy for Stage II breast cancer, who were given no form of adjuvant
therapy, was selected and their post-operative lymphocyte counts compared with
those of the adjuvant tamoxifen group. The two groups were comparable
for age and axillary node histological status (Table 4.17) but there
was seme discrepancy in that a larger number of patients given adjuvant
tamoxifen post-operatively had ER positive tumours. Interestingly,
only one of 12 patients on tamoxifen developed tumour recurrence whereas
4 of 10 patients in the control group did so within 4 years.
There was a trend for patients on tamoxifen to have higher
Abs T and Abs L counts but % T counts were significantly elevated (Fig. 4.6)
in these patients compared with the non-adjuvant group (p<0.05), and
indeed were comparable to % T counts of patients with benign breast disease.
Bearing in mind that earlier results here have shown that surgery does
not result in an increase post-operatively from pre-operative % T counts,
tamoxifen by itself appears to have the effect of increasing % T counts.
Effect of tamoxifen on primary locoregional breast cancer and
on lymphocyte counts in such patients
Fifteen patients were treated with tamoxifen 20mg b.d. as they
were considered unfit for any other form of therapy. Seven achieved
partial remission (PR) of median length 28 (5-50) months; 3 died of
intercurrent illness soon after the start of treatment and disease
continued to progress in the remaining 5 patients. Pre-treatment lympho-
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Table 4.17
Stage II Breast Cancer - Post-Menopausal Women
Post-Operative Lymphocyte Counts Related to
Adjuvant Tamoxifen Therapy
No Adjuvant Adjuvant Mann-Whitney
Therapy Tamoxifen U test
Patients 10 12
Age 64.3±10.1 63.3±7.3
Recurrence <4yrs 4 1
ER Status 2+ve;4-ve;4N/A 7+ve;1-ve;4N/A
Nodal Status 7-ve;3+ve 9-ve;3+ve
% T 52.216.5 59.117.9 U=29.0,p=0.05
Abs T 1.20610.457 1.480+0.659 NS






% T Cell Counts in Post-Menopausal Patients with

















cyte counts were available in 12 patients and post-treatment data in
5 patients undergoing PR and in 5 with continuing disease progression
(Table 4.18).
There was no difference in lymphocyte counts between patients
pre-treatment and patients with progressive disease on treatment. There
was a non-significant rise from pre-treatment levels in % T, Abs T and
Abs L counts in patients developing PR of disease. When patients with
progressive disease were compared with those achieving PR at 3 months after
treatment, there was a significant difference in % T counts (p<0.05) and rises
approaching significance in Abs T and Abs L counts in patients benefiting
from treatment.
Effect of hormonotherapy on metastatic breast cancer
Two of 5 patients treated with a combination of tamoxifen
20mg b.d. and prednisolone lOmg t.d.s. responded, 1 PR of 13 months duration
and 1 achieving no change (NC) for 9 months. The remaining 3 patients were
all dead within 6 months. None of the 5 patients were assessed for
lymphocyte counts following treatment.
The remaining 55 patients were assessed in terms of age, menopausal
status, oestrogen receptor status and predominant site of disease, with
regard to outcome to treatments shown in Table 4.1. Twelve patients
achieved PR of median duration 15 to 16 (6-43) months; 4 developed NC
and 9 were not assessable (NA) in terms of UICC criteria, 3 having local
ulcers, 2 having lung effusions, 1 having multiple disease with bilateral
lung effusions, 1 having radiotherapy for femoral secondaries, 1 having
excision of a spinal dural lesion followed by radiotherapy and 1 having
excision of supraclavicular nodes. All of these 9 patients had resolution
of ulcers, effusions and symptoms and none developed any symptom or sign
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of progression for at least 6 months whilst on treatment. The median
duration of cessation of disease progression in those with NC or NA
was 14 (6-68) months, apparently doing as well as those achieving PR
on treatment. Overall the median delay to progression in disease for PR,
NC, NA, was 15 (6-68) months. Thirty patients did not benefit from
hormonal manipulation and their disease continued to steadily progress.
The mean age of those with progressive disease was
52.7+13.4 years, significantly younger (p<0.01) than those in
whcm the disease process was halted by treatment; 62.4+11.8 years.
This is in accord with the finding that 54% of patients with Stage IV
disease who benefited from hormone therapy were post-menopausal compared
with only 21% of pre-menopausal women (Table 4.19).
Oestrogen receptor data was available in only 28 of 55 patients
(Table 4.20) but it was notable that no patient whose tumour was ER
negative achieved benefit from treatment.
Patients with locoregional or bone disease tended to benefit
more than those with visceral or multiple disease (Table 4.21).
Effect of extent of Stage TV disease dissemination on pre-treatment
lymphocyte counts [Appendix 4.12]
Forty-one patients had clinically proven disseminated disease
and 14 had locoregional recurrence only, but of these only 26 with
dissemination and 12 with locoregional recurrence had pre-operative
lymphocyte count data. Those with locoregional disease were older
(64.3+15.3) and tended to have higher % T, Abs T and Abs L counts
although not significantly so (Table 4.22).
Effectiveness of hormone therapy on Stage IV breast cancer related
to lymphocyte counts [Appendix 4.13]




























Stage IV Breast Cancer. Oestrogen Receptor Status
PR NC/NA Prog.
Positive 3 5 14
Negative 00 6
*Jot 9 8 10Performed
Table 4.21
Stage IV Breast Cancer. Predominant Site of
Disease Related to Cessation of Progression
of Disease
PR NC/NA Prog. Cessation of
Disease Progression
(% of Patients)
Locoregional 4 5 7 56
Bone 6 4 11 48
Visceral 2 3 9 36
Multiple 0 1 3 25
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Table 4.22
Stage IV Breast Cancer
Pre-Treatment Variation in Lymphocyte Counts with

























6 weeks later, and a mean of counts performed later than 3 months from the
beginning of treatment was also calculated for each individual. With regard
to patients who appeared to benefit from treatment any lymphocyte count
within 2 months of objective recurrence was termed the pre-recurrence
count. Lymphocyte counts were also performed in these patients following
objective recurrence.
Where patients benefited the Abs L count tended to rise slightly
(Table 4.23) but this effect was not seen for at least 3 months. This
increase, although never significant, was most marked in patients who
achieved PR on treatment.
Abs T counts increased but not significantly in those showing PR
(Table 4.24). However, there was a significant difference (p<0.05) by 6 weeks
between this group of responders and patients in whcm disease progression
continued, this difference becoming more marked still (p<0.02) after 3
months' treatment.
Percentage T counts also increased significantly (p<0.002) by
6 weeks in patients in whom disease progression appeared to be halted by
treatment (Table 4.25) and this increase was maintained (p<0.05) during
the period of benefit. The difference between this group of patients
and those with progressing disease was highly significant (p<0.001)
by 6 weeks of therapy and continued to be marked during the period of
benefit (Fig. 4.7).
In those patients benefiting from hormone therapy Abs L counts
maintained their slightly increased value right up to and indeed following
objective evidence of recurrence (Table 4.26). Percentage T counts on the
other hand, in 8 patients in whcm lymphocyte counts were performed within
the two month period prior to objective disease progression, dropped
significantly (pCO.OOl) in comparison to their counts during response and
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Table 4.23
Stage IV Breast Disease -
Hormone Therapy Abs L Count Change with Treatment
Treatment Treatment Mean
Pre-Treatment 6/52 >3/12
PR 1.63010.733 1.86510.723 2.219+0.533
(n=6) (n=6) (n=8)
PR/NC/NA 1.59510.718 1.513+0.732 1.888+0.745
(n= 1 3) (n=13) (n=20)





Stage IV Breast Cancer -
Hormone Therapy Abs T Count Change with Treatment
Treatment Treatment Mean
Pre-Treatment 6/52 >3/12
PR 0.81910.431 1.12510.490 1.25910.306
(n=6) (n=6) (n=8)
PR/NC/NA 0.79810.466 0.885+0.454 1.040+0.415
(n=13) (n=13) (n=20)
Progression 0.828+0.565 0.717+0.336* 0.769+0.280+
(n=20) (n=16) (n=9)
* Compared with PR at 6/52 (U=21.0, p<0.05)
+ Compared with PR mean >3/12 (U=8.0, p<0.02)
Mann-Whitney U test
Table 4.25
Stage IV Breast Cancer -
Hormone Therapy . % T count Change with Treatment
Treatment Treatment
Pre-Treatment 6/52 >3/12
PR 49.4±5. 7 6 0.6 ±6.1** 56.9±5.8*
(n=10) (n=7)(U=3.5) (n=8)(U=13.5)
PR/NC/NA 4 8.9 ±10 . 9 59.5±5.0** 55.4±5.4*
(n=19) (n=15) (U=48.0) (n = 21) (Z =2.18)
Progression 46.2±10.9 46.619.4+ 40.6±9.4++
(n=21) (n=19)(U=13.0) (n=8)(U=5.5)
** Compared with pre-treatment count (p<0.002)
* Compared with pre-treatment count (p<0.05)
+ Compared with PR/NC/NA at 6/52 (p<0.001)
++ Compared with PR/NC/NA at >3/12 (p<0.001)
Mann-Whitney U test
Table4.26 PR/NC/NAStageIVBreastCanc r-HormoneTherapy.ChangiLymphocyteCou tswi hCes a ion ofPr gressionandF llowingRecurrencefProg ession TreatmentTreat ent Pre-Treatment6/52Mean>3/12Pre-RecurrenceR cur e
%T48.9110.959.5 5 05.4+5.446.4+3. *46.0 4 8+ (n=19)5( 21)(n=8( 9) AbsT0.798+0.466.885 . 541.040+0.4150.7 6+0.4010.951 . 62 (n=13)( 20)(n=5)8 AbsL1.595+0.718. 13 321.888+0.7451.778+0.9522 02 +0.978 (n=13)( 20)(n=5)8 *Comparedwithtreatmentresult6/52(U=1.0)n>3/12U2.0)(p<0.0 1) +Comparedwithtreatmentresult6/52(U=1.0)n>3/12Z 3.7)(p<0.0 1)
129
Fig. 4.7
% T Cell Counts in Stage IV Breast Cancer















this depression was maintained at time of clinical recurrence of disease
(Fig. 4.8). Objective evidence of clinical recurrence was therefore
pre-dated by a significant drop in % T counts.
The changes in % T lymphocytes in individual patients with
Stage IV breast cancer showing PR are demonstrated in Fig. 4.9. Changes
in % T counts of all patients with Stage IV breast cancer, related to
response to hormonal therapy are demonstrated in Fig. 4.10.
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To Show that Variation in E-Rosettinq Methodology Alters T
Lymphocyte Counts
4.3.1. Materials and methods
Peripheral blood was obtained from 5 groups:
(a) 9 healthy laboratory staff; b) 16 patients with benign breast
disease; c) 41 patients with Stage I or II breast cancer; d) 9 patients
with Stage III breast cancer; e) 31 patients with Stage IV breast cancer.
Assessment of patient responses, collection of blood, preparation
of SRBC, and lymphocyte separation were carried out as previously
described.
E-rosetting techniques:
1. Day 1 counts: This technique was the normal one used in the
previous section to assess % T counts in patients with varying stages
of breast disease, an aliquot of the lymphocyte suspension being rosetted
in the usual fashion and counted after being chilled at 4°C for one
and a half hours.
2. Day 2 delayed counts: This technique was as above but the
rosettes were not counted for at least 16 hours, being incubated at
4°C overnight.
3. Day 2 counts (fresh rosettes): The lymphocyte suspension
was left overnight at 4°C for at least 16 hours, centrifuged at
400g for 5 mins and the supernatant removed. Fresh sterile isotonic
saline was then added and the pellet resuspended vigorously and adjusted
to a concentration of 2 x 10^ cells/ml and assessed for viability.
A sample of this fresh suspension was then rosetted in the usual manner
with freshly made-up SRBC, and lymphocytes and rosettes counted after
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chilling at 4°C for one and a half hours.
4. Day 2 small pellet of lymphocytes: In some cases a third
aliquot of the lymphocyte suspension was removed on the first day,
pelleted without SRBC in a small round bottomed tube and incubated
overnight at 4°C. On the following day only the uppermost layers
of the pellet were gently resuspended, removed and resetted in the usual
manner with freshly made-up SRBC, and lymphocytes and rosettes counted
after chilling at 4°C for one and a half hours.
Statistical methods:
The significance of the difference in mean % T lymphocyte counts
within each group using different E-rosetting techniques was determined
using paired 't' tests.
The significance of the difference in mean % T lymphocyte
counts between groups for any particular E-rosetting technique was determined
using the two-tailed Mann-Whitney U test. This non-parametric test was used
to avoid the assumption that the data being analysed were parametric with
a normal distribution.
All analyses were carried out on a BBC Master microcomputer using
Microtab Statistical Software and probability values obtained from standard
tables (Documenta Geigy, 7th Edition, 1970).
4.3.2. Results of variation in E-rosetting techniques
[Appendix 4.14]
The mean + standard deviation of E-rosetting cells for each
of the control and patient groups using the four different techniques
of resetting is set out in Tables 4.27, 4.28 & 4.29.
Viability of lymphocytes stored overnight at 4°C in isotonic
saline was not impaired in comparison to that of freshly separated
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lymphocytes.
The effect of overnight incubation of lymphocytes with SRBC
Seme patients had % T counts performed on more than one occasion.
The number of experiments in each disease group and the results are
shown in Table 4.27.
There was a significant increase in % T counts in all groups
following overnight incubation of rosetted lymphocytes (p<0.001) with
resultant loss of any discriminatory differences in % T counts between
the groups. This was particularly notable in patients with Stage IV
breast cancer where the significant difference (p<0.002) in Day 1 counts
between depressed % T counts in those with progressive disease and those
with either early breast cancer or with disease responding to hormonal
manipulation was lost after prolonged incubation. Indeed all breast
disease patients had similar counts on the second day.
The effect of incubating lymphocytes alone overnight
The number of experiments in each disease group and the results
are shown in Table 4.28.
Percentage T counts in lymphocytes incubated at 4°C overnight
and then rosetted with SRBC on Day 2 did not rise to the levels seen
when rosettes were incubated overnight, the difference being significant
(pCO.OOl). Although these freshly rosetted Day 2 counts were very
similar to results seen on Day 1, they tended to be higher and there
was an increasing trend for this to happen with increasing stage of
disease, the difference in counts between the two methods being significant
in the group of patients with progressing Stage IV cancer (p<0.05).
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Table 4.27
Comparison of % T Counts Performed on First Day and Following

















38±5 63.914.4 74.716.9 t = 5.789
p<0.001
38+10 57.515.2 68.017.8 t=6.392

















60113 54.118.3 69.6+7.7 t=11.371
p<0.001
62+10 53.8+8.0 70.1111.5 t=6.641
p<0.001
59 + 16 44.2 + 1 0 .0* 66 . 517. 0 t = 11.945
p<0 . 001
Post Rx Stage




* Comparison of Day 1 counts: Progressive/New Stage IV
disease against Stage IV disease responding to hormone
therapy (Z=3.07 p<0.002).
Mann-Whitney U test









































































































The effect of incubating small pellets of lymphocytes alone overnight
A possible explanation for the increase in % T counts seen
following prolonged incubation of lymphocytes with SRBC is that cells
with adherent properties, such as small monocytes, may be counted as
non-rosetting lymphocytes on Day 1. Following overnight incubation
such cells might remain adherent to the glassware during the gentle
resuspension required to prevent rosette disruption, with consequent
imbalance occurring in the numbers of individual cells and rosettes
being counted compared with Day 1. To investigate this, small pellets
of lymphocytes were incubated in round bottomed tubes overnight as
described and then gently manipulated so that only the top layers of cells
were resuspended and removed such that any glass adherent cells should remain
behind. These resuspended cells were then rosetted with SRBC and counted
in the usual manner.
Nine experiments were performed comparing this method to all
three other methods in patients with benign breast disease and 19
experiments were similarly performed in patients with breast cancer.
The results shown in Table 4.29 demonstrated that E-rosette counts
were similar to those of Day 1 and freshly rosetted Day 2 counts, and
lower than Day 2 delayed counts, significantly so in cancer patients
(p<0.001), indicating that adherent cells do not interfere with the
results of rosetting.





To Assess the Relationship Between % T Lymphocyte Counts and
Circulating Immune Complexes
4.4.1. Materials and methods
Collection of sera
Sera was obtained from blood clotted at roan temperature usually
within 2 hours of venepuncture, placed in sterile containers in aliquots
and stored at -70°C until use. Sera were not heat inactivated.
Assay for circulating antigen-antibody complexes
The assay used was the Clq deviation test and this was performed
by Dr. Victor Danis PhD, University Department of Surgery, University
Hospital of Wales, Cardiff. Circulating antigen-antibody complexes
were assayed as previously described by him (Danis et al. 1980) with
the following modifications. Sera were diluted ten-fold in veronal
buffered saline (VBS) containing 1% BSA and normal human serum to a
final concentration of 1%. Aggregated human IgG diluted in VBS - 1% BSA,
1% normal human serum was used as a reference immune complex in the assay.
To 0.1ml of sample was added 0.1ml of radioactive iodine labelled
purified Clq (containing 20,000 cpm radioactivity) and incubated for
30 mins at roan temperature. Then 0.1ml of IgG coated latex (Behring -
RF latex) diluted in VBS - 1% BSA was added and incubated for 30 mins
at 4°C. Tubes were supported in microtitre trays while centrifuged
at 400g for 40 mins at 4°C. The supernatants were discarded and
the radioactivity in the latex pellets counted. Inhibition of the binding
of the Clq to the latex particles by putative immune complexes in the
serum was related to an equivalent inhibition produced by a known amount
of aggregated IgG from a reference curve shown in Appendix 4.15.
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All samples were assayed in duplicate and the results averaged. The
degree of sensitivity depended on the proportion of Clq that bound to the
latex and was dependent on the amount of latex used and also on the^
presence of normal serum factors, since the amount of Clq was kept constant.
The figure of 40% binding in the presence of normal human serum was chosen
because it gave maximum sensitivity with sufficient radioactivity to
require only a two minute counting time on the gamma counter.
4.4.2. Results [see Appendix 5.1 - 5.5.]
Assays were performed on sera from 3 healthy females and 10 healthy
males for comparison with % T counts and lymphocyte oxygen consumption
(see Chapter 5). Controls used here, however, were 31 women with benign
breast disease and their CIC levels compared with those from 20 patients
with Stage I and II breast cancer, 15 with Stage III breast cancer, and
18 with Stage IV breast cancer. All were assayed prior to treatment
for this comparison. Levels of CIC were also compared in pre- and post¬
operative patients with Stage I and II breast cancer and patients with
Stage IV disease had CICs assessed in relation to their response to
hormone therapy. The mean results and standard deviations are shown
in Table 4.30 which demonstrates significantly higher levels of CIC
in pre-treatment Stage I and II breast cancer (p<0.05) and Stage IV
breast cancer (p<0.001) than in benign breast disease. There was no
change in CIC levels following mastectomy for Stage I and II disease,
nor following successful hormonal manipulation for metastatic cancer.
Because sane patients have such high levels of CIC compared to others
even within the same disease group; a better way of assessing the
relevance of CIC is to look at the number of patients within each group
with CIC levels over a certain value. The number within each group with





Benign38±8 Pre-operative54±13 StagesI&I Post-operative58±1 StagesI&I PreRx58±14 StageIII PreRx58±14 StageIV Progressive57±15 StageIV PR/NC/NA70±10 StageIV
31 20 29 15 18 13 14
31 20 41 15 14 16
36.9±16 51.8±201 53.4±29.3 48.8124.5 75.8138. 88.0+42. 75.1+23.3
VS.BBD
1-2.11•,p<005




levels of CIC above one and two standard deviations of CIC levels in
benign breast disease are shown in Table 4.31. At two standard deviations
above the mean for CIC levels in benign breast disease, between a quarter
and a third of patients with locoregional breast cancer and half of
women with metastic breast disease, had positive levels of CIC. Again,
as with mean CIC levels, there was no apparent change with treatment.
To assess the relationship between % T counts and CICs, these were
correlated in 139 blood samples from healthy adults and patients with benign
and malignant breast disease who had both % T counts performed and serum
taken for CIC assay on the same day. The correlation coefficient
was -0.049 showing the negative coefficient value expected but the
degree of correlation was not significant.
Table4.31
BreastDisease-Numb rofP tientsPo itivef rCICWi hinEachDis aseG oup AgePositiveat1SDPositiveat2SD(=53p.g/200|ilAHGequivalents)(=69p.g/200p.1AHGequivalents)
Benign38±8 Pre-operative StagesI&I54±13 Post-operative58±11 StagesI&I PreRx StageIII PreRx StageIV Progressive StageIV PR/NC/NA StageIV
58±14 58±14 57±1 70±1
3/31(10%) 11/20(55%) 11/29(38%) 6/15(40%) 13/18(72%) 10/14(71%) 14/l6(88%)
1/31(3%) 3/20(25%) IO/29(34%) 3/15(33%) 8/18(44%) 7/14(50%) 8/16(50%)
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4.5. Discussion
There was a tendency for women in the older age groups to have
decreased absolute lymphocyte counts but this was significant only
in the eldest patients with benign breast disease. However, this group
was very small (3 patients) and cautious interpretation is therefore
required. Percentage T counts did not vary with age in those with benign
breast disease and appeared to reflect age changes noted by others
(Smith et al. 1974; Holland et al. 1975; Whitehead et al. 1978;
Nagel et al. 1981; Mascart-Lemone et al. 1982) only in patients with
operable breast cancer over the age of 75 years. There was no variation
of % T counts with age in patients with metastatic disease but such
variation if present may have been masked by the general suppressive
effect of such cancer on % T lymphocytes. Other investigators have
similarly found little variation in lymphocyte counts with age (Weksler &
Hutteroth 1974; Alexopoulos & Babitis 1976; Djeu et al. 1977) and it
would appear that up to the age of 75 years no correction of lymphocyte
counts need be made for age.
No variation was found in % T, Abs T or Abs L counts between
Stage I, II and III breast cancer but these patients tended to have
lower Abs L counts than patients with benign breast disease and higher
Abs L counts than those with metastatic breast cancer. There was
significant depression in Abs L counts in Stage IV patients compared
to those with benign breast disease and this finding is compatible
with that of other authors (Stein et al. 1976; Bolton et al. 1976;
Kopersztych et al. 1976; CWnby et al. 1983; Shukla et al. 1986a) who
found depressed Abs L counts only in patients with disseminated breast
cancer.
Patients with Stage I, II and III breast cancer had significantly
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depressed Abs T and % T counts compared to those with benign breast
disease, and patients with Stage IV disease, had significantly depressed
Abs T and % T counts compared to those with Stage I and II cancer. Indeed
even within the group of patients with Stage IV disease, there was a
trend for those with disseminated metastatic disease to have lower
lymphocyte counts than those who apparently had only locoregional
recurrence.
There is thus a relationship between cancer and depressed
lymphocyte counts and this depression appears to be proportional to disease
load, significantly so in terms of % T and Abs T counts. Whether the
decrease in Abs L counts in cancer is due to general debility or to seme
other mechanism is unknown but depressed T counts are probably a consequence
of increased blocking by serum in patients with larger tumour masses
as suggested in the previous chapter. Other authors have found depression
of T lymphocyte counts in early breast cancer (Stein et al. 1976; Keller
et al. 1976) and a correlation between depressed T counts and breast
cancer load (Whitehead et al. 1976), similar to findings reported here.
However, others have been unable to demonstrate any change in % T or Abs T
counts in untreated tumours (Stjernsward et al. 1972; Nemoto et al. 1974;
Wanebo et al. 1978; Mandeville et al. 1982; Braun et al. 1983;
McCluskey et al. 1983; Ludwig et al. 1985). The factors believed to
be the cause of such differences in results are discussed later in this
section.
Surgery in operable cancer did not result in any post-operative
change from pre-operative lymphocyte counts and perhaps this is not
surprising as many patients with apparently operable disease have occult
metastases which may not present for many years. Such metastatic disease
would still be able to exert a 'blocking' or other suppressive effect
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on lymphocytes following removal of the primary tumour. Taking this
a step further, examination of lymphocyte counts both pre- and post¬
operatively was undertaken to see if depression of pre-operative counts
predicted early recurrence or if depressed post-operative counts indicated
residual disease with serum blocking capability as demonstrated by
Haffejee et al. (1983). Although insignificant, there was a trend for
patients whose disease recurred within 4 years to have higher pre¬
operative absolute counts, a surprising finding and similar to the
observation of Shukla et al (1986a) who noted that elevated Abs L counts
in early breast cancer were more likely to indicate future recurrence.
The reason for this is unknown and at odds with the findings of others
(Papatestas et al. 1976; Ownby et al. 1983) who reported a positive
correlation between pre-operative Abs L counts and prognosis in operable
breast cancer. No difference occurred between pre-operative % T counts
in tumour recurrers and non-recurrers and is in agreement with the findings
of Stein et al. (1976) and Teasdale et al. (1979a) who suggested that this
test has no prognostic significance. There was no difference in post¬
operative Abs L, Abs T or % T counts between patients whose tumour recurred
within 4 years and those who remained disease free and hence these tests
do not appear to be of use as an indicator of residual occult disease.
However, the numbers studied here are admittedly small and follow-up is short
at 4 years.
The prognostic indicators measured, axillary node histology
and ER status of the primary tumour, also bore no relationship to
pre-operative lymphocyte counts. This is in agreement with findings
published by Wanebo et al. (1978) who found no significant change in
lymphocyte counts with increasing risk factors in early breast cancer.
An interesting finding in this study was the effect of adjuvant
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tamoxifen on post-operative lymphocyte counts. There was a trend to
increased Abs L and Abs T counts in patients given this adjuvant therapy,
although admittedly, despite being well balanced by the non-adjuvant group
in terms of axillary node status and age, these patients contained a
disproportionate number of ER positive tumours and a lesser number of
tumour recurrers. The latter fact, of course, may be explained by the
effects of adjuvant tamoxifen. The most notable finding, however, was
that % T lymphocyte counts were significantly elevated in patients on
tamoxifen and indeed were of comparable levels to patients with benign
breast disease. Sheard et al. (1986) have also reported increases in
Abs L, Abs T and % T, and additionally NK cell counts in patients given
tamoxifen, and that this drug even neutralises the depressive effect
exerted on lymphoycte counts by chemotherapy. The reason for this is
unknown but these authors implied that the favourable influence of this
adjuvant therapy on the course of early breast cancer; reported by
Baum (1985) to be unconnected with nodal, menopausal, or ER status, might
be related to these changes in lymphocyte numbers. Indeed, hormonally
induced increases in T lymphocyte counts have been claimed to be the
cause of treatment success in breast cancer through immune mechanisms
(Yonemoto et al. 1977). A more likely explanation is that any occult
metastatic disease present in those given adjuvant tamoxifen is
suppressed by this systemic treatment, thereby preventing tumour from
exerting its 'blocking' effect on T lymphocyte receptors, while concurrently
postponing early recurrence of disease. Such neutralisation of tumour
may also permit Abs L counts to increase towards normal levels, although
as yet, it is not known by what mechanism tumour causes Abs L depression.
It is of course possible that tamoxifen may directly effect an increase
in Abs L through perhaps a 'steroid effect' but this appears unlikely
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as patients with various stages of breast cancer who underwent hormone
treatment, the majority of whom were given tamoxifen, did not increase
their Abs L counts when disease progression continued. The trend to
increase in Abs L appeared therefore to be a secondary event following
cessation of cancer growth.
Patients who underwent successful hormonal manipulation, whether
for primary locoregional or metastatic disease tended to be older, to be
ER positive and to have soft tissue or bony disease rather than visceral
or multiple metastases, and these findings are in keeping with other
published data (Kardinal & Donegan 1979).
Pre-treatment lymphocyte counts were not predictive of outcome in
patients undergoing hormone therapy in this series, similar conclusions
having been drawn by Webster et al. (1979). On the other hand, others
(Franks & Williams 1978) demonstrated that the total lymphocyte count
was predictive of response of disseminated breast cancer to endocrine
manipulation.
Sequential studies demonstrated that there was a rise in Abs L
counts in patients in whom disease actually regressed, although this
did not quite reach statistical significance. The rise was slow, taking
at least three months. Over the same period of time Abs T counts rose
in these patients also and the difference from Abs T counts in patients
whose disease continued to progress was significant by 6 weeks (p<0.05)
and more so by 3 months or more of treatment (p<0.02). The most marked effect
seen in patients achieving PR, or indeed in those in whan the progression
of disease was halted, was a rapid, significant, rise in % T counts,
predating objective evidence of tumour remission or change in disease
status and being maintained during the period of benefit to the patient.
Patients in whom disease continued to progress despite endocrine
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manipulation had no increase in lymphocyte counts indicating that such
increases are secondary to the efficacy of treatment. All patients who
benefited from treatment and who had lymphocyte counts performed within
a two month period prior to objective evidence of recurrence showed a
return of % T counts to pre-treatment levels and this depression
was maintained following overt recurrence. Abs L counts did not drop
with such rapidity, a reflection of the apparently slower response by
absolute numbers to changes in disease status. It is possible that absolute
numbers reflect the slower changing, bulk of disease which may perhaps
exert a direct suppressive effect on the lymphoreticular system or act by
trapping lymphocytes in its own mass, whereas % T count fluctuations indicate
the more rapid changes in disease activity which should occur with successful
therapies, these changes being reflected by variations in release of
'blocking' factor(s). Sane support for this comes from the fact that rising
absolute counts were seen in patients who achieved PR, i.e. in whan
disease bulk decreased, whereas those in whan disease only ceased to
progress had no such rise in absolute counts. In all patients in whan
disease progression was halted, i.e. disease activity was slowed, there
was a rise in % T lymphocyte counts.
Others have also noted sequential changes in lymphocyte counts
in cancers responding to treatment. Increased Abs L counts have been
noted in advanced breast cancer responding to endocrine manipulation
(Franks & Williams 1978) and Abs L counts reported to drop prior to
disease recurrence in lung cancer patients (Anthony et al. 1975b).
Serial T counts have also demonstrated change in relation to clinical
status, increasing or remaining stable with successful treatment (Gross
et al. 1975a; Dellon et al. 1975), falling as disease progresses (Anthony
et al. 1975b; Dellon et al. 1975), rising in a small series of breast
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cancers responding to adrenalectomy (Yonemoto et al. 1977,) and falling
by as much as three months before objective evidence of recurrent lung
cancer (Anthony et al. 1975b; Dellon 1975). This however, is the first
large series of patients with breast cancer, mostly treated with tamoxifen,
which demonstrates the inverse relationship between disease load and
T lymphocyte counts and the predictive value of % T counts in the assessment
of treatment response or disease recurrence prior to objective evidence
of either.
Why then have some authorities (Stjernsward et al. 1972; Nemoto
et al. 1974; Wanebo et al. 1978; Mandeville et al. 1982; Braun et al. 1983;
Ludwig et al. 1985) been unable to show any relationship between T
lymphocytes and cancer? One reason for this may be the variation in
methodology used to separate and count T lymphocytes, these being very
sensitive and susceptible to many variables. For instance, the use of
vacutainers to remove blood, preservatives in heparin, active resuspension
of rosettes, increased centrifugal forces on rosettes and the holding of
blood for prolonged periods of time prior to separation, result in
decreased % T counts (Djeu et al. 1977). Variable results within a laboratory
using a single standardised technique will also occur if SRBC from
different sheep are used (Steel et al. 1974b; Djeu et al. 1977) or if
FCS sources vary (Djeu et al. 1977). Nylon wool columns which favour
T lymphocytes at the expense of B cells during separation (WHO/IARC
Workshop 1974) were used by Nemoto et al. (1974) and Stjernsward et
al (1972). Braun et al. (1983) and Mandeville et al. (1982) used FCS
in the E-rosette incubation phase but FCS has been demonstrated to cause
a loss in the marked difference in % T counts between cancer patients
and controls (Whitehead et al. 1976; Whitehead et al. 1978; Byrorn et al.
1978) by increasing cancer counts to control levels. Increased
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E-rosetting has similarly been associated with the use of bovine serum
albumin (Anthony et al. 1975a) and neuraminidase-treated SRBC (Sandilands
et al. 1975). Seme investigators (Stjernsward et al. 1972; Wanebo et al.
1978; Ludwig et al. 1985) incubated their lymphocytes with SRBC for
prolonged periods of time, this technique having been demonstrated
(Whitehead et al. 1976; Whitehead et al. 1978) to bring about an increase
in % T counts of cancer patients to control levels, neutralising the
previously noted differences in % T counts between the two groups.
The fact that FCS stabilises and enhances E-rosette formation
(Steel et al. 1974b; Anthony et al. 1975a) and increases E-rosetting
of cancer patients' lymphocytes to control levels implies that lymphocytes
with lower avidity receptors for SRBC could be forming E-rosettes under
more optimal conditions brought about by FCS. The similar effect on
cancer lymphocytes following overnight incubation with SRBC has been
verified here. Whitehead et al. (1976) suggested that this was the
outcome of dissociation of 'blocking' factor(s) from the lymphocyte
surface into the surrounding medium, thereby exposing surface membrane
receptors to SRBC. However, it has also been shown in this work that % T
counts rise significantly in healthy controls and in patients with benign
breast disease as well as in those with breast cancer. Such patients would
not be expected to carry 'blocking' factor(s) on their lymphocyte
surface membranes. Further, if Whitehead's hypothesis is correct,
lymphocytes incubated alone in isotonic saline for a prolonged period
of time should also lose 'blocking' factor by dissociation. Yet on removal
of isotonic saline on the following day and mixing and incubating the lympho¬
cytes with SRBC in the usual manner, the number of lymphocytes forming
E-rosettes is only slightly higher than the first day counts and
significantly lower than the number forming E-rosettes following prolonged
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incubation in the presence of SRBC. It seems probable therefore, that
the increase in % T counts following overnight incubation is mainly
an effect of the prolonged period of time lymphocytes spend in the
presence of SRBC. One possible explanation for this is that cells with
low avidity receptors for SRBC are permitted to form E-rosettes during
the time of prolonged incubation. What cells have this property?
It is known that B lymphocytes (Jondal et al. 1972), granulocytes
and monocytes (Bianco et al. 1970), do not form spontaneous rosettes
with SRBC, unless SRBC are first treated with neuraminidase (Sandilands
et al. 1975). The majority of null cells have been demonstrated to be
smaller than monocytes, non-phagocytic, non-adherent, OKM1+, la- cells.
However, they have counterparts with similar characteristics accounting
for approximately 14% of the E-rosetting population (Breard et al. 1980)
the vast majority of these belonging to, and accounting for most of,
a subgroup of T lymphocytes with Fc receptors for IgG (Kay & Horwitz 1980;
Reinherz et al. 1980), the T gamma (Tg) cells. When looked at more
closely with the T lymphocyte specific monoclonal antibody OKT3, this
T population has been found to contain few lymphocytes, and is not
enriched for T helper (0KT4+) or T cytotoxic/suppressor (0KT5+) sub-
populations, these virtually all being contained in the Tu population
which have Fc receptors for lgM (Reinherz et al. 1980). More wide ranging
tests of the Tg population with markers OKT3, OKT4, OKT5, OKT8, OKT9 and
OKT10 by Kay and Horwitz (1980) displayed similar findings; although Fox et
al. (1981), on the other hand, demonstrated that three other monoclonal anti¬
bodies specific for T cell associated antigens did react with Tg cells, and
suggested that because they were E+, non-adherent, non-phagocytic and esterase
negative, that they, despite being OKM1+, must be T lymphocytes.
Rosenberg et al. (1981) further demonstrated that the T cells did not
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react with the specific monoclonal marker for monocytes, 63D3 and as such
could not be monocytes. The Tg cells are therefore probably intermediate
cells ontogenically and phylogenically, as suggested by Kay and Horwitz (1980)
and together with their E-Ig- counterparts in the null cell population
probably comprise the group of cells known as K or NK cells, these similarly
having been shown to be OKMI+, la-, carry Fc-IgG receptors, 90% of NK
activity being exhibited by cells with Fc-IgG receptors (Masucci et al. 1983),
do not stain for T cell specific monoclonal antibody and do not became
phagocytic or esterase positive on culture (Kay & Horwitz 1980). Tg cells
are also radiosensitive (Moretta et al. 1977) like NK cells (Kiessling &
Wigzell 1979; Herberman et al. 1979) and at least 50% have similar
morphology to NK cells (Timonen et al. 1981). Finally approximately 50%
of NK or K cells carry low avidity E-receptors (Herberman & Ortaldo 1981;
Timonen et al. 1981) as do Tg cells (Herberman & Ortaldo 1981). Indeed
if cells with high avidity receptors for SRBC are removed from the lymphocyte
population, greater than 95% of NK or K cell activity remains in the
remaining lymphocytes (Herberman 1983a). It has further been demonstrated
that only the low avidity E-receptor cells within the apparent T lymphocyte
population are able to display K cell activity (West et al. 1978). These
low avidity E-receptor cells are therefore probably a subpopulation of
of the K or NK population, the Tg cells.
West et al. (1978) showed that these low avidity E-receptor
K cells could be encouraged to form rosettes by incubation overnight
at 4°C together with SRBC, a finding in keeping with the earlier
demonstration by Winchester et al. (1975) that lymphocytes which could
bind aggregated IgG only, i.e. carrying Fc - IgG receptors, were also
able to form E-rosettes if incubated at 4°C overnight. Similarly, it
has been shown here that the main requirement for rises in % T counts on
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overnight incubation is that lymphocytes are incubated together with SRBC
during that time, whereas lymphocytes incubated alone, prior to rosetting the
following day show much lesser rises in % T counts. Indeed, the difference in
% T counts obtained, comparing the two methods, results in a surprisingly
constant figure in all groups (controls = 11%; benign breast disease = 9.4%;
Stage I and II breast cancer = 12.6%; Stage III breast cancer = 11.1%;
Stage IV remission = 12.1%) indicating perhaps a relatively fixed
subpopulation of cells existing in both non-malignant and cancer
populations which will form E-rosettes only on prolonged incubation
at 4°C in the presence of untreated SRBC. This population bears a
strong numerical similarity to the number of Tg cells, which comprise
14% of the lymphocyte population.
However, there is also an increasing trend with increasing stage
of breast cancer, significant in those with untreated metastases or disease
progression despite treatment, for lymphocytes to form higher proportions
of E-rosettes when rosetted on the following day, than when counts are
performed immediately. This suggests a 'blocking' component present
on the cell which dissociates from the lymphocyte surface following
prolonged incubation in isotonic saline.
There thus appear to be two likely components to the increased
E-rosetting manifest by lymphocytes incubated with SRBC for prolonged
periods of time. One is the relatively constant formation of E-rosettes
in all patient groups by cells with low avidity receptors for SRBC,
these probably being Tg, KN/K cells. The second component, not seen
in controls, relates to T lymphocyte receptor 'blocking', cancer patients'
lymphocytes becoming 'unblocked' by dissociation of 'blocking' factor(s)
into the medium following prolonged incubation in isotonic saline. This
component was most obvious in patients with advancing metastatic disease,
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indeed the group with which the 'blocking' phenomenon is most closely
associated. Thus, when lymphocytes are incubated overnight with SRBC,
the differences between non-malignant, malignant disease and the various
stages of cancer, completely disappear as a result of these two components.
This may explain seme of the discrepancies in results between publications
from various institutions and why seme have found T lymphocyte counts
unhelpful in assessing tumour burden.
There is considerable evidence that circulating immunecomplexes
(CICs) are responsible for the 'blocking' phenomenon and, as such, a
correlation between positive levels of CIC and depressed % T counts, might
be expected. Assays of patients' sera, using the Clq deviation test,
indicated that both mean CIC levels and numbers of patients with positive
levels of CIC, increased with progressive disease stage as a general
rule; suggesting a positive correlation between CICs and tumour burden,
similar to the inverse correlation exhibited by % T lymphocyte counts.
Similarly, like % T counts, mean CIC levels and numbers of patients
positive for CIC did not change significantly following mastectomy for
for early disease. However, unlike % T counts, CICs were apparently
unaffected by beneficial hormone therapy in patients with Stage IV
breast cancer. Moreover, when CIC levels were correlated with % T counts
performed in the same patients and from the same blood samples, although
there was an inverse relationship between the two, there was no significant
correlation.
This may indicate that some other factor may inhibit E-rosetting.
For instance, acute phase proteins, although poor markers of tumour load,
occur in the serum of patients with breast cancer and in particular
C-reactive protein has been measured in two-fifths of those with metastatic
disease (Cooper & Stone 1979). C-reactive protein has been demonstrated to
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inhibit E-rosetting (Mortensen et al. 1975); but Whitehead et al. (1977)
have shown that this substance is not the cause of 'blocking' in carcinoma
of the breast. Although E-rosette inhibition, in this instance, by
substances other than CICs, cannot be excluded, it is still possible that
the failure to demonstrate correlation between this putative 'blocking'
factor and % T counts is due to inadequate measurement of CICs.
Some authors have found CICs when measured by assays which
utilise complement binding, to be of little value as tumour markers
(Krieger et al. 1983), lacking significant discrimination between cancer
patients and normal people (Herberman et al. 1981). Indeed, it has been
suggested that the use of a single assay technique is insufficient, and,
that several different types of assay should be used for each individual
sample if adequate analysis is to be obtained (Lambert et al. 1978;
Theofilopoulos & Dixon 1979). This is because of the heterogeneity of IC in
the circulation, not all of which may be related to the disease under study,
and because each individual assay is susceptible to complicating factors.
For instance, and in particular, the requirement by the Clq assay
for complement fixation by CICs may not be met if the tumour burden
is very great, in which case CICs formed in large antigen excess do not fix
complement (C) to the same degree as CICs formed at conditions near
equivalence (Poskitt & Poskitt 1979; Theofilopoulos & Dixon 1979) and,
as such, may remain undetected or under-estimated. Similarly, CICs
containing non-C activating antibodies like IgG^ or those made with
antibody which activates C preferentially via the alternative pathway
such as IgE and IgA will not be measurable (Theofilopoulos & Dixon 1979).
Falsely low values may also occur if CICs are already saturated with
endogenous Clq (Jones & Orlans 1981). On the other hand CIC levels
may appear disproportionately high because of Clq binding to contaminating
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molecules like DNA, bacterial products and aggregated IgG (AHG), AHG
formation being facilitated by heat inactivation and repeated freezing
and thawing (Lambert et al. 1978; Theofilopoulos & Dixon 1979;
Jones & Orlans 1981). However, in the assay employed in this particular
work, serum samples were not heat inactivated and were stored continuously
at -70°C until use. CIC levels may also be falsely elevated, to
a limited degree, by binding of C by monomeric IgG (Lambert et al. 1978).
Difficulties such as these, with assays which utilise Clq binding,
may possibly explain the poor correlation between CIC levels and % T
counts, and the apparent absence of change in serum CICs with therapeutic
responses in metastatic breast cancer.
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4.6. Summary
Abs T and % T counts are depressed even in early breast cancer
but Abs L counts only depressed in advanced breast cancer.
Abs T and % T counts decrease with increasing extent of breast
cancer and there is a similar trend with regard to Abs L counts.
Lymphocyte counts do not change following surgery in operable
breast cancer.
Pre-operative lymphocyte counts are not predictive of outcome
and show no correlation with other prognostic indicators.
Post-operative lymphocyte counts are not predictive of outcome
nor indicative of residual disease.
Adjuvant tamoxifen in early breast cancer results in a trend to
increased Abs L and Abs T counts but significantly raised % T counts,
suggesting systemic suppresion of tumour with a secondary decrease in
serum 'blocking' ability.
Hormone therapy in breast cancer results in a trend to Abs L count
increases in patients whose disease burden decreases, and significant
rises in Abs T and % T counts in patients benefiting from treatment.
Counts do not increase in patients whose disease continues to progress,
indicating that changes in lymphocyte counts are a secondary phenomenon
to tumour response.
Changes in % T counts are relatively rapid and occur in patients
in whan progression of disease ceases and predate objective evidence of
response or of disease recurrence. Changes in absolute counts are
slower and occur in patients only in whom there is actual disease
regression. Absolute counts may therefore relate more to tumour bulk
and % T counts more to tumour activity.
161
Overnight incubation of lymphocytes with SRBC results in
increased % T counts as a consequence of a combination of low avidity
E-receptor cell rosetting, possibly by K/NK cells, and dissociation of
'blocking' factor(s) from the T lymphocyte surface. This results in a loss of
the usual discriminatory value of % T counts between the various stages
of the cancer process.
CIC measured in patients' sera bears a positive correlation
to tumour burden but does not have the discriminatory capacity of % T
counts. Moreover, although patients with positive CIC values tend to
have depressed % T counts this correlation was not significant, indicating
perhaps that some other factor is responsible for E-rosette depression,
or that faults with either one or other assay are responsible.
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4.7. Conclusions
This work shows that absolute lymphocyte, absolute T lymphocyte
and especially % T lymphocyte counts are depressed in breast cancer, even
in its early stages. This depression becomes more pronounced with increasing
tumour burden. Lymphocyte counts have no prognostic significance and are
unrelated to other prognostic parameters prior to treatment and are unaffected
by surgery in early cancers, but tend to rise in such patients when given
systemic adjuvant hormone treatment.
Serum levels of IC increase with tumour load and bear an inverse
but non-significant correlation to % T counts. CICs do not, however,
have the same discriminatory powers in assessing treatment outcome in
patients with metastatic disease.
Earlier assessment of response of advanced breast cancer to
tamoxifen and other forms of endocrine manipulation can be achieved than
has been previously possible, a trial period of at least 12 weeks normally
being required, by studying changes in T cell and in particular % T cell
counts; thereby permitting earlier evaluation of the patient on treatment
and allowing a more rational selection of alternative treatment modalities
at an earlier phase in the patient's illness.
However, for this to be effective, strict laboratory methodology
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Stage I & II Breast Cancer Pre- & Post-operative Lymphocyte
Counts
Pre-operative Post-operative
Age % T Abs T Abs L % T Abs T Abs L
EC 48 60 1.540 2.567 60 1.286 2.144
PE 67 57 0.752 1.320
GF 60 64 3.003 4.692
GG 60 61 1.757 2.880
BN 56 54 0.720 1.334
VR 49 48 0.859 1.620 47 1.278 2.720
MR 60 64 0.977 1.527
JR 49 53
MB 72 48 0.586 1.221
PB 44 55 1.478 2.688
EB 49 58 0.845 1.456
JJ 43 48 0.814 1.696
PB 44 47 0.790 1.700
VC 39 51 1.053 2.064
PJ 78 38 41
MH 78 53 1.256 2.369 59 1.265 2.144
MM 74 66 0.835 1.265 57 1.160 2.034
VP 71 65 1.115 1.716 53 0.952 1.796
PP 59 47 1.960 4.171























% T Abs T Abs L % T Abs T Abs L
44 0.891 2.025
62 1.259 2.030 46 1.278 2.556
50 0.651 1.302 50 1.268 2.535





51 1.313 2.574 1.307 2.376
69 1.127 1.633
58 0.872 1.504
49 0.459 0.936 44 0.484 1.100
58 1.137 1.960 58 1.347 2.322
36 0.519 1.442






Stage III Breast Cancer Pre- and Post-operative Lymphocyte Counts
Pre-operative Post-operative
Age % T Abs T Abs L % T Abs T Abs L
AJ 42 45 0.990 2.200
AL 66 43 0.624 1.452 43 0.373 0.867
EL 50 56 0.926 1.653
PM 41 55 1.320 2.400
MWJ 68 63 1.270 2.016 66 1.030 1.560
EO 48 48 0.759 1.581
RF 79 42 0.670 1.596
LH 59 45 0.630 1.400
DM 65 41 0.780 2.052
IM 55 57 1.160 2.034
DG 55 63 0.756 1.200 52 0.755 1.425
KM 60 48 1.387 2.889 56 1.472 2.628





Pre-operative Lymphocyte Counts Stage I, II & III Breast Cancer
Axillary Node Negative Axillary Node Positive
Age % T Abs T Abs L Age % T Abs T Abs L
MR 47 44 0.891 2.025 EC 48 60 1.540 2.567
AB 38 48 1.056 2.200 PE 67 57 0.752 1.320
EH 60 51 1.313 2.574 GF 60 64 3.003 4.692
AJ 42 69 1.127 1.633 BN 56 54 0.720 1.334
GJ 66 58 0.872 1.504 VR 49 48 0.850 1.771
MS 40 49 0.459 0.936 PB 44 47 0.790 1.700
ET 49 58 1.137 1.960 VC 39 51 1.053 2.064
MJ 58 58 0.390 0.672 PJ 78 38
AJ 42 45 MH 78 53 1.256 2.369
KM 60 48 1.387 2.889 MM 74 66 0.835 1.265
PM 41 55 1.320 2.400 VP 71 65 1.115 1.716
MWJ 68 63 1.270 2.016 ES 41 62 1.259 2.030
IS 63 2.065 MT 48 50 0.651 1.302
KD 62 1.466 BT 53 56 0.902 1.610
NV 49 52 1.215 2.336
EJ 68 36 0.519 1.442
EE 73 62 0.729 1.176
JL 53 69 1.377 1.995
AM 72 60 2.020 3.366
RF 79 42 0.670 1.596
AL 66 43 0.624 1.452
WD 63 39
LH 59 45 0.630 1.596
DG 55 63 0.756 1.200
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Appendix 4.8
Pre-operative Lymphocyte Counts Stage I, II, III Breast Cancer
Oestrogen Receptor Positive Oestrogen Receptor Negative
Age % T Abs T Abs L Age % T Abs T Abs L
EC 48 60 1.540 2.567 VR 49 48 0.850 1.771
PE 67 57 0.752 1.320 VC 39 51 1.053 2.064
GF 60 64 3.003 4.692 MR 47 44 0.891 2.025
PB 44 47 0.790 1.700 MT 48 50 0.651 1.302
MM 74 66 0.835 1.265 BT 53 56 0.902 1.610
ES 41 62 1.259 2.030 AB 38 48 1.056 2.200
NV 49 52 1.215 2.336 AJ 42 69 1.127 1.633
MM 48 50 0.648 1.295 MS 40 49 0.459 0.936
EH 60 51 1.313 2.574 ET 49 58 1.137 1.960
GJ 66 58 0.872 1.504 AM 72 60 2.020 3.366
MJ 58 58 0.390 0.672
JL 53 69 1.377 1.995
AL 66 43 0.624 1.452
PM 41 55 1.320 2.400
FL 66 69 0.924 1.339
MWJ 68 63 1.270 2.016
LH 59 45 0.630 1.596
DG 55 63 0.756 1.200
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Appendix 4.9
No Recurrence Recurrence <Four Years
Age % T Abs T Abs L Age % T Abs T Abs L
BN 56 54 0.720 1.334 ER 48 60 1.540 2.567
MH 78 53 1.256 2.369 VR 49 48 0.850 1.771
MM 74 66 0.835 1.265 PB 44 47 0.799 1.700
VP 71 65 1.115 1.716 VC 39 51 1.053 2.064
MR 47 44 0.891 2.025 NV 49 52 1.144 2.200
ES 41 62 1.259 2.030 EH 60 51 1.313 2.574
MT 48 50 0.651 1.302 AJ 42 69 1.127 1.633
BT 53 56 0.902 1.610 GJ 66 58 0.872 1.504
MS 40 49 0.459 0.936 MWJ 68 63 1.270 2.016
AJ 42 45 0.990 2.200 RF 79 42 0.670 1.596
AL 66 43 0.624 1.452 DG 55 63 0.756 1.200
EL 50 56 0.926 1.653
PM 41 55 1.320 2.400
LH 59 45 0.630 1.400
MM 48 50 0.648 1.295
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Appendix 4.10
Post-operative Lymphocyte Counts Stage I, II, III Breast Cancer
No Recurrence Recurrence <4 Years





























































































































Stage II Breast Cancer - Postmenopausal Women
Age % T Abs T Abs L ER status Involved Recurrence Adjuvant
nodes <4 years Tamoxifen
MB 72 48 0.586 1.221 - 0 nil nil
MH 78 59 1.265 2.144 N/A 0 nil nil
MM 74 57 1.160 2.034 + 0 nil nil
VP 71 53 0.952 1.796 N/A 0 nil nil
PP 59 47 1.960 4.171 N/A 0 nil nil
ES 72 50 1.278 2.556 - 0 Brain 15/12 nil
BT 53 53 1.093 2.062 - 0 nil nil
PE 51 61 1.876 3.076 + 2 Bone 33/12 nil
EH 60 55 1.307 2.376 N/A 3 Bone 12/12 nil
MT 53 39 0.587 1.504 - 1 Brain 30/12 nil
EE 73 65 1.013 1.558 N/A 0 nil yes
CG 55 56 1.926 3.440 + 0 nil yes
MJ 58 52 1.287 2.475 + 1 nil yes
KK 67 49 0.558 1.139 + 3 nil yes
JL 53 75 2.738 3.650 + 0 Multiple 28/12 yes
PM 63 69 1.604 2.325 N/A 0 nil yes
AM 72 60 2.640 5.280 - 0 nil yes
MR 68 59 1.224 2.074 N/A 0 nil yes
MS 53 58 1.051 1.812 + 0 nil yes
CS 66 63 1.023 1.624 + 0 nil yes
RW 60 53 1.224 2.310 N/A 1 nil yes
MJ 71 50 1.475 2.950 + 0 nil yes
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Appendix 4.12
Stage IV Breast Cancer
Disseminated Disease vs Locoregional Disease
Age Pre Pre Rx Pre Rx Age Pre Pre Rx Pre Rx
RxT Abs T Abs L RxT Abs T Abs L
RB 42 35 1.021 2.916 EE 49 46 1.228 2.669
VB 48 52 0.366 0.704 MF 83 21 0.161 0.765
DB 37 51 0.685 1.344 EH 60 52 0.478 0.920
FD 72 27 0.351 1.140 WN 74 56
BD 50 59 0.504 0.855 AP 69 53 1.230 2.320
LE 78 45 0.796 1.769 AC 75 56 1.434 2.596
AL 76 48 ET 74 42 0.635 1.512
ML 31 51 0.968 1.898 OJ 60 55 2.035 3.700
BD 48 25 0.249 0.996 HD 61 54
WM 72 63 MJ 63 61 0.561 0.920
GW 81 62 0.730 1.118 BH 54 58 1.336 2.304
OJ 68 43 WG 49 50
CD 57 50 0.650 1.300
AB 38 42 1.053 2.508
VC 39 52 1.906 3.665
HT 65 30 0.139 0.462
EJ 63 50 0.320 0.639










MJ 75 39 0.325 0.833
EM 74 62 1.480 2.387
MH 38 31 0.095 0.308
EI 49 51 0.576 1.130
CL 40 47 1.167 2.484
RP 58 54 1.518 2.812
SJ 44 40 0.436 1.089
AM 45 42 0.318 0.756
LS 45 53 0.750 1.416
EE 49 32
vs Locoregional Disease
Age Pre Pre Rx Pre Rx
RxT Abs T Abs L
Appendix4.13StageIVBreastC nc r-HormoneTherapy-R spondersMedian
Delayto
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Appendix 4.14 Variation in Rosetting of Lymphocytes
Day 1 Day 2 Day 2 Day 2
Counts (New (Delayed (Small
Rosette Counts) Lymphocyte
Counts) Pellets)
Age % T % T % T % T
CONTROLS
GR 38 59 64 79
AP 36 64 64 64
NP 38 58 57 65
KR 38 61 56 71
DW 44 61 55 74
SH 44 67 67 82
RL 34 71 72 83
MO 42 66 68 78
SD 28 68 70 76
BENIGN BREAST DISEASE
LB 27 53 50 66
MB 62 58 59 66 72
DC 35 55 63 62 65
IE 54 56 63 67 58
JE 41 57 55 71 58
OG 29 64 60 74
CG 40 45 34 54 28
DJ 27 55 60 63 58
GJ 37 59 52 57
ML 41 63 64 72 69
DP 43 53 60 79 68
DP 42 54 68 58
CW 28 65 65 70
EW 33 61 65 81
LW 33 63 58 72 62
AE 37 59 61 75
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Appendix 4.14 (continued)
Day 1 Day 2 Day 2 Day 2
Counts (New (Delayed (Small
Rosette Counts) Lymphocyte
Counts) Pellets)
Age % T % T % T % T
STAGE I & II Pre Rx
EC 48 60 76
PE 67 57 50 75
PE 67 61 79
GF 60 64 40 80
BN 56 64 56 69 59
MR 47 52 63 77
MR 47 64 70
AB 38 48 53 79
PB 44 47 42 67
VC 39 51 66
EH 60 51 62
MH 78 53 53 55
MH 78 54 60
AJ 42 69 74 71
GJ 66 58 71
SJ 66 58 64
MM 72 66 76
MS 40 49 58
ES 41 62 60 76 60
MT 48 50 50 65
BT 53 56 68
ET 49 58 58 69 68
NV 49 52 41 64 25
MR 50 42 38 64 29
STAGE I & II Post Rx
VR 49 47 65 78
VR 49 57 68 78
GG 60 61 63 77 54
MR 60 62 61
MR 60 65 72
FP 87 43 58 60 57
FP 87 50 55 72
FP 87 50 76
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Appendix 4.14 (continued)
Day 1 Day 2 Day 2 Day 2
Counts (New (Delayed (Small
Rosette Counts) Lymphocyte
Counts) Pellets)
Age % T % T % T
MB 72 50 64 80
MB 72 45 45 64
PB 44 49 58 52
PB 44 60 60 67
EB 49 58 73 74
PG 51 64 63 82
PE 51 57 78
EH 60 43 59
MH 78 59 71
MH 78 55 73
VP 71 50 55 69
VP 71 50 63 67
PP 59 47 40 69
ES 72 50 39 54
MS 40 44 72
MS 40 41 70
GS 41 47 66
ES 41 44 71
MT 48 50 67
BJ 53 56 59 66
GT 49 55 78
GT 49 61 73
MT 53 33 42 61
MT 53 43 59 57
NV 49 62 65 69
EE 73 65 76
MJ 58 46 55 55
PM 63 69 69 71
PM 63 64 80
MR 68 59 67 62
CS 66 63 64 75
MS 53 68 67
MS 53 63 74


















Age % T % T % T
KK 67 51 72
KK 67 47 62
MJ 71 50 57 68
FP 87 68 64
BT 53 49 49 76
MT 53 37 61 56
STAGE III
AL 66 43 32 39
EL 50 56 65 69
PM 41 55 65 73
MWJ 68 61 57 76
GL 80 50 50 59
AM 53 49 60 72
ED 71 50 72
LH 59 45 65
DG 55 62 70
AL 66 43 62 74
AL 66 54 74
MWJ 68 68 65 83
MWJ 68 61 85
STAGE IV New/Progressive
VB 48 52 61 74
VB 48 51 54 76
FD 72 46 62
LE 78 43 57 69
LD 57 50 70
JJ 56 53 62
ML 31 37 54
ML 31 38 40 63
EM 74 45 62
MO 57 32 44 68
MP 63 35 54 70
RT 50 28 28 63
TC 39 52 61
AB 38 42 68





















Age % T % T % T
AC 75 56 72
ED 56 37 50 68
MF 83 21 56 52
EH 60 53 50 80
WN 74 47 59
MW 76 61 57 72
STAGE IV :Responders
AA 78 56 62
MB 51 39 51 69
EB 53 43 48 76
LE 78 62 69
LE 78 66 81
WG 49 55 50 62
NL 58 55 56 60
AL 76 61 73
WM 72 56 57 69
RP 59 52 65 85
RP 59 47 60 74
HT 74 51 54 61
PP 71 50 82
MF 83 58 50 66
MJ 63 56 75
MJ 63 46 52 57
WN 74 59 78
WN 74 56 62 59
WN 74 48 60















5. Lymphocyte Oxygen Consumption in Patients with Cancer
5.1. Introduction
Considerable evidence exists that immune complexes (ICs) are the
putative 'blocking' factors which exist in cancer and are responsible for
the immune depression seen in autoimmune and some other disease states.
It has been shown, in the preceding chapter, that CICs measured by
the Clq deviation test, appear to be, in general terms, directly related
to the extent of breast cancer tumour load. However, as previously
discussed, this particular method of measuring ICs is neither sufficiently
sensitive nor specific and most other IC assay techniques have been
similarly disappointing (reviews by Lambert et al. 1978; Theofilopoulos &
Dixon 1979; Jones & Orlans 1981).
ICs have been shown to increase the uptake of oxygen (C^) by human
blood (Strauss & Stetson 1960), to activate polymorphonuclear leucocytes
(PMN) measured by 0^ uptake (Rossi et al. 1970) and heat production
(Monti et al. 1980) and to sensitise (Uhr 1965) and stimulate lymphocytes,
measured by DNA activity (Moller 1969; Bloch-Shtacher et al. 1968; Lundgren
et al. 1968a; Soderberg & Coons 1978), and cell-mediated cytotoxicity
(Lundgren et al. 1968a). This stimulation is possibly exerted through binding
to cell receptors for Fc-Ig, complement (C) (reviewed by Theofilopoulos &
Dixon 1979) or possibly specific antigen binding sites (Theofilopoulos &
Dixon 1979; Kontiainen 1975; Kontiainen & Mitchison 1975). The effect of ICs
on immune cells to which they adhere is therefore to change their behaviour
and, it follows, their metabolic activity. Indeed, neutrophil aerobic
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metabolism has been used as a means of detecting such complexes (Clarke et
al. 1978).
Peripheral blood lymphocytes have a predominantly oxidative
metabolism with low or absent glycolysis (Barron & Harrop 1929; Kemper 1939;
Rauch et al. 1961; Elves 1972) but are capable of small amounts of aerobic
glycolysis and increased glycolysis under anaerobic conditions (Elves 1972).
Even the lymphocyte's requirement for carbohydrate during the 'lethal hit'
stage is independent of carbohydrate's capacity to act as an energy source
(MacLennan & Golstein 1978). Therefore, it would seem reasonable to
propose that metabolic changes occurring in the lymphocyte will be reflected
by changes in cell 0^ utilisation. For instance, PHA lymphocyte
stimulation, suggested to use aerobic oxidation as an energy source
(Becker & Henson 1973) for transformation, has been demonstrated in equine
lymphocytes to cause increased 0^ uptake by these cells, using
polarographic measurement (Pachman 1967).
It will be demonstrated in this chapter, that like CIC, lymphocyte
C>2 utilisation increases with tumour burden and that this is not
a feature of the lymphocyte per se, but rather a property of the serum
from which the lymphocyte has been separated. Evidence will be presented
which suggests that the serum factor(s) which stimulates increased
lymphocyte utilisation shows sane of the features necessary for
IC-mediated lymphocyte activation; that sera from patients with immune
complex associated disease, are also able to increase utilisation
of control lymphocytes, and further that a positive correlation exists
between CIC and lymphocyte uptake; all implying that the phenomenon
is an IC-mediated one.
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5.2. Methods
The Clark electrode [Clark et al. 1953] [Fig. 5.1]
This apparatus permits polarographic measurement of the C>2 tension
of solutions. Briefly, it comprises a silver anode and platinum cathode
connected by a potassium chloride bridge, enclosed in an epoxy block,
except for the exposed end of the cathode which is separated from the
external environment by a thin (25u) teflon membrane which allows 02
to diffuse into the probe but effectively isolates the sensor elements
from contamination by the external environment. When a polarising voltage
is applied across the probe all 02 within the probe is consumed
(reduced) at the platinum cathode
02 + 2e + 2H+ ^ H202
\
H202 + 2e + 2H+^=± 2H20
and the resultant reduction current measured at the non-polarizable
reference silver anode. Both voltage and C>2 tension affect the current
but within a certain voltage range, -0.65 to -0.8 volts, known as the
'current-voltage plateau' (Fig. 5.2), the current - C>2 tension relation¬
ship is essentially independent of the voltage. Thus, at any voltage within
this range, any change in current is a reflection of changing C>2 tension.
The reduction current will accordingly flow in direct stochicmetric relation
to the rate of C>2 consumption. 02 then diffuses through the teflon
membrane at a rate proportional to the 02 tension outside the probe,
since 02 tension within the probe is effectively zero.
This system satisfies the criteria essential for measurement of










at the platinum electrode surface (preferably zero) and a constant
diffusion zone between the sample to be measured and the platinum electrode
surface. It takes approximately 30 sees for steady state conditions
to develop, after which current flows through the probe proportional to the
external 0^ tension but the probe is capable of giving 90% of final
value readings by 10 sees.
The polarographic circuit is completed by a recorder to measure
reduction current in the Gilson 5/6 oxygraph apparatus (Gilson Medical
Electronics, Middleton, USA) (Figs. 5.3 & 5.4). The Clark electrode
in this system is pushed through an opening in a water jacketed reaction
chamber (capacity 1.5ml) (Fig. 5.5) such that the membrane only is in
contact with the contents of the chamber. Temperature changes which may
affect cell metabolic rate, saturation of the solution and teflon
membrane permeability are prevented by maintaining a flow of water at
37+^/2°C from a circulating water bath through the jacket
surrounding the reaction chamber. Stasis of the reaction chamber contents,
encouraging localised temperature variation and a static layer of cells
adjacent to the membrane, is avoided by the use of a magnetic stirring
flea, care being taken that its rotation is not sufficiently agitated to
damage the probe membrane or cells in the solution. The contents of the
chamber may be excluded from the outside environment by a capillary bore
stopper which permits venting of the chamber thereby equalising internal
and external pressures, and reduces diffusion of O^ into the chamber
by presenting a very small gas-liquid interface and any 0^ that does
pass across this must first diffuse through the long narrow liquid column
before entering the chamber.
Calculation of the amount of 0^ used by cells in a solution
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Fig. 5.3
Diagram of Gilson Oxygraph
/\- 1.5ml reaction vessel surrounded by a water-jacket
with capillary bore stopper
0= Clark electrode
£= Magnetic stirrer
Q= Circulating water bath







Clark Electrode in Water Jacketed Reaction Vessel
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requires prior knowledge of the normal saturation of in that
solution at 37°C and the atmospheric pressure. However, the latter
was found to influence results very little and its use in the calculations
was quickly discarded. Prior to the introduction of the capillary bore
stopper the recorder can be calibrated to read 100% saturation thus enabling
changes in recorder pen deflection to be read directly as a percentage.
The advantages of this polarographic circuit are that the system
is very sensitive permitting measurement of consumption by small
numbers of cells, the response is very rapid avoiding long periods of
equilibration time required in manometric techniques; there is no
contamination by the external environment; and the probe itself does not
consume large amounts of 02 (8x10 "'""'"gms/sec/uA). One disadvantage
of the apparatus is that O2 saturation is measured in a closed system
and it is necessary to perform readings over short periods of time to avoid
development of severe anaerobic conditions. Another problem is silver anode
contamination due to the formation of silver chloride on the anode after a
few weeks of use. This results in a non-linear response when calibrating
the probe against solutions of differing known 02 saturations (Fig. 5.6)
and can be removed by treating the probe with 15% ammonium hydroxide solution
for 10 mins. (Le Fevre 1969). This was done once a week.
5.2.2. Separation of lymphocytes
Polymorphonuclear leucocytes (PMNs) use similar (Barron & Harrop 1929;
Hedeskov & Esmann 1966) or slightly less (Rauch et al. 1961; Evans & Blore
1973) O2 than lymphocytes under resting conditions and monocytes rather
less 02 than neutrophils (see later). Platelets use approximately one




eleventh to one eighteenth as much as lymphocytes on a one to one
basis (Altman & Dittmer 1968; Muenzer et al. 1975). 02 utilisation
by erythrocytes is very low (Altman & Dittmer 1968) but these cells interfere
with C>2 tension measurements within the oxygraph chamber by dissociation
of oxyhaemoglobin and diffusion of 0^ into the medium as the
tension drops through use by other cells under assay. These contaminating
cells must therefore be excluded as best possible.
Twenty to 30ml of blood was taken by venepuncture, placed in a sterile
container and immediately defibrinated using a sterile glass rod, by
stirring gently for approximately 5 mins to get rid of platelets. The blood
was placed over sterile ficoll-'nypaque in aliquots of 7ml blood to 3ml
ficoll-hypaque and the mononuclear cells separated, washed and pelleted
as described in Chapter 4. The pellet was resuspended vigorously in 0.5ml
of distilled sterile water for 20 to 25 sees to lyse erythrocytes and
then flooded with 8mls of sterile isotonic saline and centrifuged for 5 mins
at 400g. This pellet was left in isotonic saline and stored at 4°C
until use. This did not affect viability within the 2 to 3 hours for which
the cells were, at most, stored prior to testing. The fact that centri-
fugation and hypotonic lysis did not affect either viability or ability
of lymphocytes to consume C>2 is in accord with the findings of
Pachman (1967) following centrifugation separation of lymphocytes and
hypotonic lysis of red cells. Granulocyte contamination of the lymphocyte
sample was assessed morphologically and ranged from 2.74+1.38% in
controls to 6.31+3.84% in patients with metastatic breast cancer,
similar to that of lymphocyte pellets from heparinised blood (Chapter 4).
5.2.3. Separation of polymorphonuclear leucocytes (PMN)
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Ten ml of venous blood was mixed with Dextran 110 in isotonic saline
(Fisons Pharmaceutical Division, UK) in a ratio of 2 parts blood to 1 part
Dextran and allowed to sediment for 1 hr. The leucocyte-rich plasma was
layered onto 3ml ficoll-hypaque and centrifuged at 400g for 30 mins. The
supernatant was removed and the residual pellet washed once at 400g for
5 mins in isotonic saline. Red cells were removed by hypotonic lysis as
previously described, leaving a resultant population of PMN of 98% purity.
Viability of cells was checked by Trypan blue exclusion and found always
to be greater than 95%.
5.2.4. Separation of monocytes
Twenty ml of venous blood was separated over ficoll-hypaque as
described in Chapter 4 and the mononuclear band removed and washed once
in isotonic saline. The monocytes were then purified using a discontinuous
hyperosmolar percoll gradient. (This discontinuous gradient is formed
by layering three differing specific gravity solutions of percoll on each
other. Stock solution of percoll comprises 9ml percoll to 1ml x 10 Eagle's
MEM. Percoll of SG 1.074 is made by adding 1.734ml of Eagle's MEM to
2.266ml stock percoll. Percoll of SG 1.066 is made by adding 2ml Eagle's
MEM to 2ml stock percoll. Percoll SG 1.057 is made by adding 2.304ml
of Eagle's MEM to 1.696 stock percoll.) The mononuclear cell pellet was
resuspended in 2ml. percoll of SG 1.074 onto which was carefully layered
2ml of percoll SG 1.066 followed by a layer of 2ml percoll SG 1.057.
This was centrifuged at 2,200g for 90 mins. The monocytes were recovered
from interface I between percoll of SG 1.057 and SG 1.066, and washed twice
at 400g in isotonic saline. Viability was checked by Trypan blue exclusion
and found to be greater than 95%.
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5.2.5. Separation of lymphoyctes into T-rich and B-rich fractions
Twenty to 30ml of venous blood to which had been added 150mg
carbonyl iron was mixed on a blood wheel at 37°C for 30 mins. The blood
was placed in 10ml sterile tubes over a magnet and allowed to sediment.
The monocyte depleted plasma was then layered over ficoll-hypaque and the
mononuclear band harvested in the usual manner and washed once in isotonic
saline. Enrichment of T and B cell rich subpopulations was achieved by
discontinuous percoll gradient (Gutierrez et al. 1979). Percoll 100% was
made by mixing 1 part x 10 phosphate buffered saline (PBS) with 9 parts
percoll which was progressively diluted in normal PBS to obtain solutions
containing 70, 60, 50 and 40% of percoll. The cell pellet was resuspended
in 100% percoll and 2ml of each percoll solution, in order of decreasing
concentration, layered over this with great care. This was centrifuged at
2,200g for 10 mins. Cells remaining in the interface between 40 and 50%
percoll concentration, 'fraction I', were B cells. Cells between 50 and 60%,
'fraction II' and between 60 and 70%, 'fraction III', were T lymphocytes
(Fig. 5.7).
Identification of purity of the T cell rich population was performed
by E-rosetting as described in Chapter 4. Identification of purity of the B
cell rich population was performed using immunofluorescence staining for
g
surface membrane immunoglobulin (SMIg). Essentially an aliquot of 10 B-
rich lymphocytes was resuspended in 1ml acetate buffered saline and incubated
at 37°C for 30 mins. The cells were washed twice in PBS and resuspended
in 5ml Eagle's MEM at 37°C for 1 hr to remove cytophilic antibodies.
The cells were then centrifuged at 400g for 5 mins and the pellet
resuspended in 1ml of 0.02% sodium azide in PBS and 50ul anti IgG fluorescent
conjugated rabbit antiserum (Becton Dickinson, Middlesex, UK) added to this,
mixed and allowed to stand on crushed ice for 30 mins. Five mis Eagle's MEM
Fig. 5.7
Percoll Separation of Lymphocyte Subsets
(
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was then added, mixed and centrifuged at 400g for 5 mins to remove unbound
conjugates. The supernatant was discarded and the cells washed twice in
Eagle's MEM. The cell pellet was mixed in 50ul Eagle's MEM, placed on a
slide and covered with a coverslip which was sealed with nail varnish and
examined under a fluorescent microscope and a % count performed.
5.2.6. Medium
The medium used in all experiments was Eagle's MEM.
Ten mis Eagle's MEM containing Earle's salts and L-glutamine without
sodium bicarbonate, 10 x concentration (Gibco Europe UK) was added to
90mls double distilled sterile water, lOOul streptomycin, 50ul crystapen
and buffered to pH 7.4 with 7% sodium bicarbonate. Protein supplements
were not used in the medium as they may cause an unpredictable loss of
sensitivity of the electrode and were felt unnecessary for the short period
of incubation.
5.2.7. Calculation of solubility coefficient of Ct, in Eagle's MEM
The C>2 concentration of fully air saturated Eagle's MEM
was calculated using an adaptation of Bruhn's modification of the Winkler
technique described by Golterman (1969). This is described in Appendix 5.6.
The value for Eagle's MEM was 4.24ul O^/ml of medium at atmospheric
pressure and 37°C.
5.2.8. Measurement of lymphocyte consumption
A flask of Eagle's MEM in a water bath at 37°C was air
saturated by slowly bubbling filtered preheated air through it at 37°C.
This medium was used to set the full scale deflection (FSD) on the pen
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recorder at the 100% value. The baseline was set by using the zero current
setting on the oxygraph and could be checked by depleting the content
of the medium with sodium sulphite.
The pellet of lymphoyctes, following removal of the isotonic saline
supernatant, was resuspended in 2ml of air saturated Eagle's MEM and allowed
to equilibrate for 10 mins in the water bath at 37°C. An aliquot
was taken for cell count and viability assay by Trypan blue exclusion test.
Viability was never less than 95% and all cells including PMNs and monocytes
were counted, no special calculations being made to exclude their potential
effect. It should be noted that later experiments showed PMNs and
monocytes were not affected by serum in the same way as lymphocytes, and
that there was little variation in the contaminating numbers of PMNs and
monocytes between different patient groups sufficient to have affected
results. 1.5ml of the cell suspension was then placed in the reaction
chamber, allowed a further 5 mins equilibration with respect to temperature,
following which, the capillary bore stopper was inserted, and the
percentage drop in 0^ tension of the medium measured over the ensuing
15 mins. This percentage drop reflected the percentage of 0^ in
the chamber consumed by the cells together with the small amounts of
normally used by the electrode itself. The electrode's consumption was
calculated at the beginning of each day, by measuring the percentage drop
in C>2 tension of Eagle's MEM without cells in the presence of the
Clark electrode over a 15 min period of time. By subtracting the percentage
drop caused by the electrode alone from that caused by the electrode plus
cell suspension, the percentage drop in 0^ tension caused by the cells
alone was calculated. With knowledge of the amount of 0^ dissolved
in 1ml of Eagle's MEM at 37°C at atmospheric pressure and the number
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of cells in the chamber, the absolute volume of C>2 consumed per
million cells per unit of time could be calculated. Lymphocyte 0^
consumption was then expressed in ul/million cells/sec.
Because of the 'crowding effect' on lymphocytes, described by
others using manometric methods, occurring after half an hour from the
beginning of measurements (Baron & Harrop 1929; Hedeskov & Esmann 1966),
a series of readings of 0^ consumption were plotted for different
concentrations of lymphocytes, monocytes and PMNs (Fig. 5.8; Appendix 5.7).
These indicated that the crowding effect, shown as a reduction in 0^
uptake per cell when cell concentrations are high, and thought to be a result
of reduced availability of (Hedeskov & Esmann 1966), was not a feature
of experiments utilising the oxygraph system. This may have been a
consequence of the short periods over which experiments were carried out,
or the efficient equilibration of O^ tension throughout the medium
by the magnetic stirrer. However, in order to prevent any doubt, aliquots
6of lymphocytes were kept as often as possible between 2 to 3 x 10
cells/ml of medium.
5.2.9. Measurement of PMN and monocyte consumption
These cells following separation were incubated and treated in
identical fashion to lymphocytes prior to assay of 0^ consumption.
5.2.10 Papain treatment
Lymphocytes or other cells separated and washed as previously
described, were incubated with 0.6mg/ml of papain (twice crystallised,




balanced salt solution containing 5% normal human serum for 1 hr at 37°C
(Chapel 1973; Whitehead et al. 1976) or at 4°C. The cells were then
washed once at 400g for 5 mins and resuspended in 2mls of air-saturated
Eagle's MEM and incubated at 37°C for 10 mins prior to numbers, cell
viability and O^ consumption being calculated; or in autologous or
allogeneic serum depending on the experiment being performed.
5.2.11. Serum incubation
All cells were first treated with papain as described and following
washing were resuspended in either autologous or allogeneic serum and
incubated at 37°C for a further 1 hr. The cells were then washed once
at 400g, resuspended in 2ml of air-saturated Eagle's MEM and incubated
at 37°C for 10 mins prior to numbers, cell viability and 0^
consumption being calculated.
5.2.12. Separation and storage of serum
Ten ml of venous blood was withdrawn by venepuncture from a
peripheral vein and placed in a sterile container containing no anti¬
coagulant. The blood was allowed to clot at room temperature and left
standing for 2 to 3 hrs following which it was centrifuged at 500g for
20 mins. The serum was removed aseptically and either used immediately
or stored at -70°C. Sera for experiments on patients with immune
complex related diseases however were stored at -20°C and used within
3 months.
5.2.13. Serum dilution
Sera stored at -70°C for less than 1 month from 3 patients
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with breast cancer and 2 with advanced colonic cancers were thawed and
diluted to varying concentrations with isotonic saline. Donor papain
treated control lymphocytes were incubated in these various sera at 37°C
for 1 hr, washed once and incubated in Eagle's MEM for a further 10 mins
prior to calculation of cell numbers, viability and lymphocyte C>2
consumption.
5.2.14. Heat inactivation of serum
Blood was withdrawn by venepuncture and lymphocytes and sera
separated in the usual manner from 5 controls, 3 patients with breast
cancer and 2 with advanced bowel malignancies. Lymphocytes from each subject
were divided into 4 aliquots, one of which was used to assess lymphocyte
C>2 consumption of the patients' cells and the remainder treated with
papain. Sera were split into 3 aliquots, 2 of which were heated to 56°C
for 30 mins. The remaining papain treated lymphocytes were incubated for
1 hr in a) autologous serum; b) autologous heat inactivated serum;
c) autologous heat inactivated serum to which mixed control donor serum
(200ul per 1800ul heat inactivated serum), as a complement source, was
added. The cells were then washed, incubated in Eagle's MEM and their
C>2 consumption assessed.
5.2.15. Sera and plasmapheresis
One patient with polymyositis, 2 with myaesthenia gravis,
1 with polyneuropathy, 1 with Guillain-Barre syndrome, 1 with autoimmune
pancytopaenia and myositis, and 2 with Waldenstrom's macroglobulinaemia
were examined (Appendix 5.17).
Plasmapheresis was performed by Mr. R. Nelson and Mr. R. Williams,
and members of the Department of Haematology, Singleton Hospital, Swansea,
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as part of the proscribed treatment by the patients' consultants. The
apparatus used was the 'Progress BT 790 A' blood cell separator manufactured
in Italy by 'Dideco' which can be used for plasma, platelet and leucopheresis
by means of centrifugation in a semi-continuous mode. The separator requires
the use of a sterile disposable circuit which includes a 'harness' attached
to the patient's circulation through a 'Venflon' intravenous cannula in a
peripheral vein, and a 'bowl', where the extracorporeal circulation of
the patient will develop. This circulation takes place in a semi-continuous
mode,becausethe machine operates at different phases; drawing a certain
volume of blood from the patient, based on the volume of the 'bowl' used
and the patient's haematocrit, and dividing it into its components.
In the case of plasmapheresis the plasma was collected into a waste bag
and the red cells together with a volume of 4.5% albumin and/or isotonic
saline, equivalent to the volume of plasma removed at each cycle, was
retransfused into the patients. By repetition of the operation it
was possible to collect significant volumes of plasma from each patient,
usually 2 to 3 litres at each procedure. At the beginning of the procedure
2
each patient was given a loading dose of heparin (2,000 units/m ).
Heparinised isotonic saline (25,000 units/500ml) was used to anticoagulate
the blood, prior to entry to the centrifuge 'bowl', through a pump which
delivered a constant volume of one part heparinised saline to eight
parts blood irrespective of the blood flow rate.
In each patient 10ml of blood for serum separation was removed
from the venepuncture cannula prior to heparinisation. The cell separator
was then connected to the patient's circulation through the intravenous
cannula and the procedure commenced by giving the appropriate loading dose
of heparin. After the required number of cycles had been performed
a 10ml sample of the plasma was collected aseptically from the waste bag
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and placed in a sterile container. The cell separator was disconnected
from the patient and between 1 and 2 hrs later, lOmls blood for serum
separation was ranoved from the cannula. The two samples of sera 'before'
and 'after' plasmapheresis were also placed in sterile containers and,
together with the plasma from the machine, stored at -20°C until the
day of testing. They were then transported packed in ice in polystyrene
boxes and were used within 4 hrs of removal from the freezer.
Papain treated control lymphocytes were incubated in all 3 samples
at 37°C for 1 hr, washed and assessed for their consumption
in the usual manner.
5.2.16. Statistical analysis
The significance of the difference in mean lymphocyte and other
cell C>2 uptake values between groups and within groups was determined
using the two-tailed Mann-Whitney U test.
Tables
Tables show the mean + standard deviation of lymphocyte
C>2 consumption.
Post-therapeutic values of C>2 consumption shown in the tables
and appendices are the mean of all post-treatment results derived later
than six weeks after the start of treatment in any single phase of the
disease, unless otherwise stated.
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5.3. Results
5.3.1. The effect of age, sex and disease status of patients and
controls on lymphocyte Ct, consumption:
Lymphocyte consumption was assessed in 13 males and 31 females
awaiting inguinal hernia repair or cholecystectomy; 75 women with benign
breast disease; 27 with Stage I and II breast cancer; 24 with Stage III
breast cancer and 25 with Stage IV breast cancer, prior to treatment
(Appendices 5.1, 5.2, 5.8, 5.9, 5.10, 5.11; Table 5.1)
Age: Lymphocyte consumption was not affected by age.
There was very little variation between different age groups in 31 female
controls (Table 5.2). Moreover, when age was correlated with lymphocyte
C>2 consumption within this group of women and 75 women with benign breast
disease the correlation coefficients (r) were r=0.046 and r=0.062
respectively, indicating that there is no relationship between age and
lymphocyte C>2 consumption.
Sex: Thirteen male controls had comparable lymphocyte C>2
consumption to the female controls indicating that sex of the patient
does not influence this (Table 5.3).
Disease status: Women with benign breast disease tended to
have greater lymphocyte 0^ consumption than female controls but this did
not quite reach significance (p=0.06). Patients with malignant breast
disease had significantly greater lymphocyte C>2 consumption than either
controls or patients with benign breast disease (p<0.001) (Table 5.3;
Fig. 5.9). This rise in lymphocyte 0^ consumption in those with breast
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Table 5.1
Patients and Controls who had Pre-Treatment Assessment of
Lymphocyte 02 Consumption
Treatment Male Female Benign Breast Breast Breast
Controls Controls Breast Cancer Cancer Cancer
Disease I & II III IV
Surgery- n/a n/a 75 21 15 0
Surgery &
Tamoxifen
0 0 0 1 0 0
Hormone
Therapy
0 0 0 5 5 25
Chemotherapy 0 0 0 0 4 0
Total 1 3 31 75 27 24 25
Table 5.2
Female Controls. Lymphocyte 02 Consumption for Varying Age Groups
(plxl0~5/i06 cells/sec)
Age Range Controls Lymphocyte 02 Consumption
<30 yrs 7 6.20 ± 0.86
31 - 40 yrs 6 6.01 ± 0.78
41 - 50 yrs 8 6.21 ± 0.80
51 - 60 yrs 5 6.38 ± 0.71
60+ yrs 5 6.13 ± 0.23
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cancer was also stage related but the difference was only significant
between Stage I and II cancer and Stage IV disease (p<0.05).
5.3.2. The effect of surgery in operable breast cancer on lymphocyte
0^ consumption (Appendix 5.8).
Lymphocyte 02 consumption values were available in 21 patients
pre-operatively and 22 patients at least 6 weeks post-operatively with
Stage I and II disease, and in 15 patients pre-operatively and 10 patients
at least 5 weeks post-operatively with Stage III breast cancer. There was
no significant difference between pre- and post-operative values (Table 5.4).
5.3.3. The relationship between prognostic factors in operable breast
cancer and lymphocyte 0^ consumption (Appendix 5.8).
Insufficient detailed data were available on primary tumour
grading but there was adequate data on oestrogen receptors and axillary
node histology to permit comparison with the lymphocyte C>2 consumption
of these patients (Table 5.5). Neither pre- nor post-operative lymphocyte
C>2 consumption bore any relationship to ER or axillary node status.
Furthermore, there was no significant difference in lymphocyte
consumption, either pre-operatively or post-operatively, between patients
who developed disease recurrence in less than 4 yrs from surgery and those
who remained disease free (Table 5.5).
5.3.4. The effect of hormone therapy in primary locoregional disease
on lymphocyte consumption (Appendix 5.7).
Six patients with Stage I and II disease had their lymphocyte
02 consumption assessed; 5 prior to tamoxifen, 2 during PR on tamoxifen
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Table 5.3
Lymphocyte 02 Consumption in Controls, Benign Breast Disease and
Varying Stages of Malignant Breast Disease Prior to Treatment
( m x1 0-5/1 C)6 cells/sec)






female 44116 6.18+0.70 vs male controls Z=0.78; NS
(31)
Benign
breast 42+15 6.69+1.23 vs control Z=1.84; p=0.06
disease
(75)
Stage I & II vs control Z=5.92; p<0.001
breast cancer 57+17 8.89+1.30 vs benign Z=5.78; p<0.001
(27) breast disease
Stage III
breast cancer 64115 9.54+1.89 vs I & II Z=0.93; NS
(24)
Stage IV
breast cancer 55+13 9.74+1.76 vs I & II Z=2.0; p<0.05
(25)
Table 5.4
Pre- and Post-Operative Lymphocyte 02 Consumption
in Stage I, II, and III Breast Cancer
Pre-Operative Post-Operative Mann-Whitney
Lymphocyte 02 Consumption U Test
Stage I & II 8.97+1.35 8.39+1.67 Z=1.34; NS
(n=21) (n=22)





Pre- and Post-Operative 02 Utilisation in Stage I, II and III
Breast Cancer Compared with Prognostic Factors and Recurrence
Within 4 Years from Treatment


















No recurrence <4 yrs 9.17+1.21
(n = 7)
8.77 + 1 .62
(n=13)
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Male Female Benign breast Stagel&H StageHI Stage HZ
Controls Controls Disease Breast cancer Breast cancer Breast cancer
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and 1 during progression of disease. Eight patients with Stage III breast
cancer were similarly assessed; 5 prior to tamoxifen, 1 during PR on
tamoxifen, 2 during NC on tamoxifen and 4 during progression of disease.
There was no difference between the lymphocyte consumption
of patients prior to treatment and those with progressive disease (Table 5.6;
Fig. 5.10) but patients benefiting from tamoxifen had significantly
reduced lymphocyte 0^ consumption compared with pre-treatment and
progressive disease values (p<0.02).
5.3.5. The effect of hormone therapy in Stage IV breast cancer on
lymphocyte 0^ consumption (Appendix 5.10).
Data on lymphocyte C>2 consumption were available in 42 patients
with Stage IV disease, 36 of whom were treated with tamoxifen, 5 with
oophorectomy and 1 with androgens. Twenty-two patients were tested prior
to treatment; 18 during progression of disease, 7 during PR, 2 during
NC and 2 who were not assessable using UICC criteria but had no symptomatic
or clinical evidence of disease progression for at least 6 months.
There was no difference between lymphocyte 0^ consumption
in patients prior to treatment and in those in whom disease continued
to progress or following failure of remission (Table 5.7; Fig. 5.11).
Patients in whom disease was affected in a beneficial manner by treatment
showed significantly decreased lymphocyte 0^ consumption compared with
pre-treatment and progressive disease patients (p<0.001) and even patients
with Stage III disease (p<0.005) and Stage I and II breast cancer (p<0.01).
Five patients with primary locoregional breast cancer and 12 with
Stage IV disease treated by endocrine manipulation had their lymphocyte
C>2 consumption tested in more than one phase of their illness. The
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Table 5.6
Primary Locoregional Breast Cancer Treated with Tamoxifen
Change in Lymphocyte 02 Consumption with Response
(h1x10-5/106 cells/sec)
Patients Lymphocyte 02 Consumption Mann-Whitney U Test
Pre Rx (10) 9.80±2.10
Progression (5) 10.01±1.75 vs Pre Rx U-24.0; NS
PR/NC/NA (5) 5.2211.10 vs Pre Rx U = 2 . 0;
p<0 . 02
vs Prog. U=0 ;
p<0 .01
Table 5.7
Stage IV Breast Cancer Treated with Hormone Therapy.
Change in Lymphocyte 02 Utilisation with Response.
(|ilx1 0-5/i 06 cells/sec)
Patients Lymphocyte O2 Utilisation Mann-Whitney U Test
Pre Rx (25) 9.7411.76
Progression (18) 9.67+2.02 vs Pre Rx Z = 0 . 0 7 ; NS























yte 09 Consumption Related to Response of Patients with
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changes in lymphocyte 0^ consumption with respect to treatment outcome
are shown in Fig. 5.12. Moreover, it was noted in 11 patients with various
stages of breast cancer treated by hormone manipulation who were tested
between 6 and 8 weeks from the start of therapy that patients who derived
benefit had decreased lymphocyte 0^ consumption compared with their
pre-treatment values and with that of patients in whan disease continued
to progress (Table 5.8).
5.3.6. The effect of other cancers on lymphocyte 0^ consumption
(Appendix 5.12).
Several patients with other types of cancer were also investigated
with regard to their lymphocyte consumption. Six had carcinoma
of the stomach, 2 carcinoma of the pancreas, 3 malignant melanoma,
1 carcinoid tumour, 1 carcinoma of the lung, 1 ovarian cancer and 13 had
colorectal carcinoma. One patient with colorectal cancer was staged
Dukes' A, 3 Dukes' B, 4 Dukes' C and 5 Dukes' D.
The majority of these cancer patients had lymphocyte
consumption values at least as great as that of patients with disseminated
breast cancer with the exception of those with Dukes' A and B colorectal
carcinoma in whom lymphocyte C>2 consumption was lower (Table 5.9).
Indeed, there was a stage related trend for lymphocyte C>2 consumption
to increase with progression of colorectal cancer, the difference between
localised node negative disease and disseminated cancer being significant
(p<0.02).




Lymphocyte 02 Consumption in Patients Tested Between 6 and 8 Weeks
from the Start of Hormone Therapy
Patient Stage Response Pre Rx Post Rx
6 to 8 weeks
EW II PR 9.32 6.99
FL III NC 13.12 6.14
VB IV NC 9.20 7.20
CD IV PR 11.99 7.75
LS IV N/A 12.70 8.29
EP II Prog. 9.91 9.22
ED III Prog. - 8.60
GL III Prog. 1 1 . 75 13.68
GJ IV Prog. - 9.90
AM IV Prog. 8.90 8.99
CS IV Prog. - 9.60
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Table 5.9









Colorectal Dukes' C 9.2312.35
(n = 4)
Colorectal Dukes' D 1 1 .57 +2.03*
(n =5)
Stomach Locally Advanced 10.53
(n=1)





1 1 . 1711.53
(n = 3)
Ovary Disseminated 14.21
* Comparison of Dukes' D with Dukes' A & B
colorectal cancer (U=0, p<0.02) Mann-Whitney U Test
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Fig. 5.12
Stages II, III & IV Breast Cancer. Lymphocyte O2 Consumption
with Response to Hormone Therapy
Pre-Treatment PR/NC/NA Progression
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Separation of lymphocytes into T-rich and B-rich subpopulations
showed no difference in separation properties of control and cancer
lymphocytes (Table 5.10). The T cell rich fraction from control patients
however, consumed significantly more than did B cells (pCO.OOl).
The T cell rich fraction from cancer patients consumed more 0^ than
the B-rich cells (p<0.001) and also more than the T-rich population
from controls (p<0.001). There was no difference between the C>2
consumption of B-rich lymphocyte populations from cancer patients and
controls.
5.3.8. To show that increased lymphocyte 0^ consumption in cancer
patients is an effect of a serum factor(s) (Appendix 5.14).
It has previously been shown that incubation of lymphocytes
from patients with cancer, with papain, results in a loss of 'blocking'
factor(s) from the cell surface and that this factor(s) can be replaced
by subsequent incubation in cancer serum (Whitehead et al. 1976;
Whitehead et al. 1977), or indeed that lymphocytes from healthy individuals
may become 'blocked' by incubation in cancer serum (Whitehead et al. 1977;
Shukla et al. 1979). Experiments were performed to see if a similar
factor(s) was responsible for stimulated lymphocyte 0^ consumption.
Lymphocytes from 15 healthy controls and 19 cancer patients were
separated and incubated with papain at 37°C and lymphocytes from 4
controls and 10 cancer patients incubated with papain at 4°C for 1 hr,
washed and incubated in Eagle's MEM prior to assessment of lymphocyte
C>2 consumption. Papain treated lymphocytes from 11 controls and 15
cancer patients were also incubated in their autologous sera at 37°C
for 1 hr. Eight cancer patients also had their papain treated lymphocytes
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Table 5.10
C>2 Consumption of Unseparated Lymphocytes and B Rich and T Rich
Subpopulations from Patients with Cancer and Controls




























U = 0 ; p<0.001
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incubated in allogeneic individual control freshly prepared sera for 1 hr
and 10 of the controls had their papain treated lymphocytes similarly
incubated in individual sera from cancer patients which was either freshly
prepared or had been stored at -70°C for less than 3 months. Lymphocytes
incubated in allogeneic or autologous sera were then washed and incubated
in Eagle's MEM prior to assessment of lymphocyte consumption.
Papain treatment of lymphocytes at 37°C had no effect on control
lymphocyte 0^ consumption but following incubation of these lymphocytes
in cancer sera their 02 consumption rose significantly (p<0.001)
(Table 5.11). Papain treatment at 37°C of lymphocytes from cancer
patients had a significant effect (p<0.001) on their 02 consumption,
decreasing this to control values (Table 5.12). This fall in 02
consumption was maintained following incubation in allogeneic control sera
but reversed by reincubation in autologous cancer sera.
Papain treatment at 4°C had no significant effect on either
control or cancer patients' lymphocytes, indicating that its effect on
lymphocyte 02 consumption was most likely to be mediated through its
enzyme activity (Table 5.11; Table 5.12).
5.3.9. The effect of cancer sera on other white blood cells
(Appendix 5.15).
Lymphocytes, PMNs and monocytes were isolated from peripheral
venous heparinised blood of 5 healthy controls as earlier described,
treated with papain at 37°C and each cell type divided into aliquots,
one of which was incubated in autologous serum and the other, in allogeneic
cancer serum previously prepared from a patient with breast cancer and
stored at -70°C for less than 3 months. Following incubation and
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Table 5.11
Papain Treated Control Lymphocytes Incubated with Autologous













(Papain 37°C) (10) 10.0110.97*
+ cancer sera
* Compared with all other values U=0; p<0.002
Mann-Whitney U Test
Table 5.12
Papain Treated Cancer Lymphocytes Incubated with Autologous
Serum and Allogeneic Control Serum
( p, 1x1 0-5/1 06 cells/sec)
Lymphocyte 02 Mann-Whitney U Test
Utilisation
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Lymphocytes (19) 9 . 82±2.1
Lymphocytes (19)
(Papain 37°C)





















6.9310.71 vs L (U=8.5; p<0.002)
vs Papain 37°C (U=51; NS)
vs Papain 4°C (U = 3; p<0.002)
vs Papain +autol serum
(U=8; p<0.002)
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washing the C>2 consumption of each cell type in its own and allogeneic
cancer serum was assessed.
Lymphocytes tended to use slightly more 0^ than PMNs and
significantly more than monocytes when incubated in autologous serum
(p<0.01). Lymphocytes from all 5 controls were stimulated to consume more
C>2 by incubation in cancer serum (p<0.01) but this stimulatory effect
was completely absent in PMNs and monocytes (Table 5.13).
5.3.10 The effect of storage of cancer sera on lymphocyte
consumption
Six patients with advanced cancers had aliquots of serum stored
at -70°C for at least 3 months. Papain treated lymphocytes from
1 control were incubated in these aliquots at various time intervals
in the usual fashion. There was no significant decrease in the ability
of cancer sera to stimulate control lymphocytes at 3 months. Three of
these patients were similarly examined following storage of serum for
7 months. These sera retained their stimulatory capacity (Table 5.14).
5.3.11. The effect of cancer serum dilution on lymphocyte
consumption
The effect of cancer on consumption of papain treated control
lymphocytes was completely abrogated by dilution of the sera to 50%
concentration (Table 5.15).
5.3.12 The effect of heat inactivation of cancer serum on lymphocyte
C>2 consumption (Appendix 5.16).
Neither heat inactivation of control serum nor the addition
of complement to heat inactivated control serum changed the CL
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Table 5.13
Oxygen Consumption of Control Lymphocytes, PMN and Monocytes in
Autologous and Cancer Sera
Lymphocyte O2 Consumption
Lymphocytes + autologous serum (5) 5.6410.36
Lymphocytes + cancer serum (5) 8.2310.48*
PMN + autologous serum (5) 4.98+1.10
PMN + cancer serum (5) 4.6511.06
Monocytes + autologous serum (5) 3.75+0.69*
Monocytes + cancer serum (5) 3.30+0.88
* Comparison with lymphocytes + autologous serum
(U-0; p<0.01) Mann-Whitney U Test
Table 5.14














ER 9 . 70 9 .55 8.99
9.40
9.33 -
ME 10.88 - - 9.81 9.79
BW 10.10 9 . 79
9.87
- - 9.81
IM 8.92 - - - 8.47
JE 12.37 1 1 .33 - - -
AA 9 .53 10.28 _ _ —
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Table 5.15
Papain Treated Control Lymphocytes in Cancer Sera at Varying
Concentrations by Dilution with Isotonic Saline
Lymphocyte 02 consumption donor cells
with each patient' s serum
Serum
Concentrations AA BW ME IM AH MeanlSD
100% 1 1 .24 10.10 10.88 9.09 9.93 10.2510.84
90% 10.28 8.81 9.79 8 .92 8.65 9.2910.71
80% 1 1 .88 8.66 10 .85 7.84 9.93 9.8311.63
70% 8 .28 8.95 7. 34 8.30 6 .64 7.9010.91
60% 7.13 6 .85 7. 72 6.71 6.18 6 .9210 .57
50% 5.93 6.24 7.60 6.53 6 .53 6 . 5710 .63
Lymphocyte 02 consumption donor cells in autologous serum
6.12 6.39 6.84 6.09 6.44 6.38±0.30
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consumption of autologous papain treated control lymphocytes incubated
in such sera. On the other hand, heat inactivation of serum from cancer
patients resulted in a drop in the lymphocyte 0^ consumption of
their autologous papain treated lymphocytes to control levels (p<0.01).
The addition of complement brought about a return to previous values of
lymphocyte 0^ consumption associated with cancer sera (Table 5.16).
5.3.13. The effect of serum from patients with immune complex associated
disease on lymphocyte CL consumption and the effects of
plasmapheresis on this (Appendix 5.17).
Fifteen experiments were performed in 8 patients. Pre-plasmapheresis
sera stimulated papain treated control lymphocytes to consume more C^,
in amounts equivalent to that seen in patients with disseminated malignant
disease. Post-plasmapheresis sera although still capable of stimulating
an increase in control lymphocyte consumption, did so to a
significantly lesser degree (p<0.002) (Table 5.17). Plasma from the cell
separator had a stimulatory capacity greater even than that of pre-
plasmapheresis serum (p<0.02).
It was noticeable that in all 4 patients who underwent plasma¬
pheresis on more than one occasion that the pre-plasmapheresis serum's
ability to stimulate lymphocyte C>2 consumption had fully returned
by the time of the next treatment, i.e. between 3 and 4 weeks later
(Appendix 5.17).
5.3.14. Correlation between lymphocyte CL consumption and % T
lymphocyte depression and CICs







Papaintreated lymphocytesin autologous serum
Papaintreated lymphocytesin heatinactiv ted autologousserum
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counts from the same blood specimens of 125 controls and patients with
benign and malignant breast disease (Appendix 5.18). The correlation
coefficient was r-0.409, showing a significant (p<0.001) correlation
between increased lymphocyte consumption and depressed % T
lymphocyte counts (Fig. 5.13).
Lymphocyte consumption was correlated with CIC values
of sera from the same blood specimens of 75 controls and patients with
benign and malignant breast disease (Appendix 5.19). The correlation
coefficient was r=0.399, showing significant correlation (p<0.005) between
increased lymphocyte consumption and raised levels of CICs (Fig. 5.14).
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Fig. 5.13
Correlation Between O? Consumption and Percentage T
Lymphocytes in Breast Cancer,
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Neither age nor sex of the individual affected lymphocyte 02
consumption but disease state did. Women with benign breast disease tended
to have higher lymphocyte consumption than healthy female controls
and it is of interest to note that mean CIC levels in women with benign
breast disease have been reported to be twice that of controls (Day et al.
1982); that PHA responses and skin sensitivity to recall antigens tend
to be more depressed in women with benign breast disease than controls
(Mandeville et al. 1982), and % T counts in those with benign breast disease
when compared with controls tend to be lower (Keller et al. 1976; see
also Chapter 4, Table 4.27). Women with breast cancer had significantly
increased lymphocyte 0^ consumption compared both with controls
and patients with benign breast disease, this increase tending to be
more pronounced with greater disease load and indeed the difference was
significant between early localised disease and metastatic disease.
Other types of advanced tumour displayed increased lymphocyte 0^
consumption but early colorectal cancers, although showing this tendency,
had significantly lesser values. Colorectal tumours which had disseminated
to liver, rather than only to nodes, or which were restricted to local
invasion of surrounding organs, showed the highest lymphocyte
consumption indicating perhaps that such tumours, thought to facilitate
their metastatic potential by an increased ability to shed membrane
molecules, produce greater amounts of substances which stimulate lymphocyte
C>2 consumption. Unlike early breast cancer, colorectal tumours when
treated in the early stages of disease, have a reasonably high incidence
of cure implying that these particular cancers are commonly unaccompanied
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by occult metastases. As such they would be expected to be comparatively
stable in terms of surface membrane 'shedding' and this may be reflected
by the lower lymphocyte consumption seen in these patients.
Lymphocyte consumption was unaffected by surgery and bore
no relationship to any of the prognostic factors studied and was not
predictive of later tumour recurrence occurring within a 4 year period
from treatment. These findings are remarkably similar to those reported
and discussed earlier on % T lymphocytes in breast cancer and it therefore
appears that lymphocyte C>2 consumption has no place as a prognostic
indicator, although admittedly the numbers of patients tested in each
group were small and the follow-up period of 4 years, taken as a cut-off
point, is rather short for the study of patients with early breast cancer.
It may be that prolonged follow-up (and the increased numbers presently
under study) will show significant differences.
Systemic hormonal treatment was shown to affect lymphocyte
C>2 consumption both in early and advanced breast cancer, when beneficial
to the patient, reducing this significantly compared with pre-treatement
or progressing disease values. This effect, like that seen with the change
in % T lymphocyte counts, was noticeable by 6 to 8 weeks after the initiation
of endocrine manipulation. Similarly, 2 women who, following initial benefit,
developed further progression of disease, displayed increased lymphocyte
C>2 consumption compared with their response values, at the time of this
event.
Chapel (1973) demonstrated that treatment of control human
lymphocytes with papain at 37°C removed a serum factor, present on
a proportion of SRBC receptors, from these without damaging the receptor
itself and that this factor could be reattached following incubation of
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lymphocytes in normal serum. Serum factor(s) present in cancer patients,
as previously noted, is also removable from a proportion of SRBC receptors
and this is reversible by incubation in cancer sera. Similar experiments
were performed to investigate if such a factor(s) was responsible for the
increased 0^ consumption of lymphocytes from cancer patients. These
showed that papain, working enzymatically, was able to remove the factor(s)
responsible for the increase in consumption from the surface of
lymphocytes from cancer individuals. Subsequent incubation of such
lymphocytes in control serum had no effect, but incubation in cancer
serum resulted in return of the increase in lymphocyte consumption.
Papain treatment of control lymphocytes did not affect their 0^
consumption, nor did subsequent incubation in autologous serum, but
incubation of these cells in cancer serum resulted in an increase in
their 0^ consumption to levels comparable with that of lymphocytes
from cancer patients. It therefore appears that this increased C>2
consumption, exhibited by lymphocytes from cancer patients, is not a property
of the lymphocyte itself but rather a feature of a factor(s) present in
the cancer serum, which bears remarkable similarity in terms of behaviour
following enzyme treatment and serum incubation, to the 'blocking factor'
of cancer sera. However, the 'blocking' effect can be induced by simple
incubation of control lymphocytes in cancer sera (Whittaker et al. 1971a;
Gatti 1971; Suciu-Foca et al. 1973; Whitehead et al. 1977; Shukla
et al. 1979), whereas it was impossible to demonstrate stimulated 0^
consumption in control lymphocytes unless these were pre-treated with papain.
This phenomenon also appears, like that of E-rosette inhibition
(Whitehead et al. 1977), to be independent of blood groups and HLA
243
activity, in that papain treated lymphocytes incubated in allogeneic
control serum were not stimulated to consume more 0^. One reason for
this may be that papain also removes the HLA antigen from the lymphocyte
surface and this takes at least 6 hrs to be replaced by the cell (Chapel
1973). However, it has also been reported that even heterologous rabbit
serum will not stimulate human lymphocyte proliferation in the absence
of ICs (Soderberg & Coons 1978). Allogeneic serum stimulation therefore
does not appear to complicate this system and stimulated 0^ consumption
is dependent on the presence of tumour or other disease states (see later)
in the serum donor.
Storage of sera at -20°C or -70°C did not affect the
capacity of immune complex related disease or cancer sera to stimulate
papain treated control lymphocytes over a period of several months. The
factor(s) responsible therefore appears to be as stable as those contained
in 'inhibitory' sera of tumour bearers, which retain their 'blocking'
capacity for as long as one year following storage at -20°C (Gatti 1971),
or CIC which maintain their integrity for up to 2 years when stored at
-20°C (Jones & Orlans 1981).
When cancer serum was diluted by 50% its capacity to stimulate
papain treated control lymphocytes to consume more C>2 was abrogated.
This is reminiscent of the loss of the inhibitory effect of cancer serum
to inhibit E-rosetting when diluted to one fourth (Whitehead et al. .1977)
and of the loss of the stimulatory capacity exerted by ICs on lymphocyte
transformation when serum is diluted to 30% (Bloch-Shtacher et al. 1968;
Soderberg & Coons 1978).
Heat inactivation of cancer serum abrogated its stimulatory
effect on lymphocyte 0^ consumption but this was reversed by the
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addition of complement to the system indicating firstly, that the stimulating
factor(s) is resistant to heating to 56°C for 30 mins, a property
which it holds in common with the inhibitory factor(s) in cancer sera (Gatti
1971; Whittaker et al. 1971b), and secondly, that the serum factor(s) is
dependent on complement to induce stimulation. IC stimulation of lymphocyte
DMA synthesis was demonstrated to be complement independent by Moller (1969)
but he was unable to exclude the presence of residual complement on the cell
membrane following lymphocyte washing. Others (Bloch-Shtacher et al. 1968;
Soderberg & Coons 1978) have shown that IC induced lymphocyte transformation
is virtually completely complement dependent. Indeed, this is hardly
surprising as it has been clearly demonstrated that ICs cannot sensitize
lymphocytes unless first complexed with complement (Uhr 1965; Uhr &
Phillips 1966). Once such complexes become attached to monocytes,
macrophages, PMNs and B lymphocytes, these cells are activated
(Theofilopoulous & Dixon 1979; Cooper 1987) triggering release of biologically
active substances and inducing phagocytosis and cell regulation. Some T
lymphocytes and NK or K cells also have C receptors (Ross & Hedof 1985)
although binding of ICs may not necessarily be to these, as lymphocytes
have antigen receptors on their surfaces (Kontiainen 1975; Kontiainen &
Mitchison 1975) and some, Fc-Ig receptors which are mainly for IgG (reviewed
Theofilopoulos & Dixon 1979). Complement nay be necessary in instances
of IC binding to such receptors by permitting increased aggregation of
solubilised ICs (Maurer & Talmage 1953) through classical pathway activation
and by such aggregation, facilitate adherence to the receptors; or it may
act in some, as yet, undefined way.
The sera from patients with IC related diseases exerted a stimulatory
effect on control papain treated lymphocyte 0^ consumption similar to
that of sera from individuals with advanced cancer. Following removal of
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plasma by plasmapheresis, this stimulatory capacity was still present in
the sera but significantly reduced. The plasma had the greatest capacity
to increase control lymphocyte 0^ consumption suggesting that a factor(s)
responsible for this had been removed from the host by plasmapheresis and
remained concentrated in the removed plasma. Factor(s) responsible for
increased lymphocyte C>2 consumption therefore also appears to be present
in patients with IC related diseases. Such patients also carry inhibitory
or 'blocking' factors (Gatti 1971) in their sera. Furthermore, it has been
demonstrated that plasmapheresis will remove 'blocking' factors from
patients with advanced malignancies affecting E-rosetting (Browne et al.
1976), macrophage migratory capacity (Samak et al. 1981) and MLC reactions
(Retsas et al. 1981). Taken together with the fact that there was significant
correlation between depressed % T counts and increased lymphocyte
consumption in controls and patients with benign and malignant breast disease
in this study; these facts imply that the factor(s) causing increased
lymphocyte consumption and 'blocking' is one and the same, and
further because it occurs in IC related disease groups that it may be CIC.
However, other factors which can suppress lymphocyte activity such as acute
phase proteins (Mortensen 1975; Cooper & Stone 1979) are also present in the
serum of both patients with autoimmune disease and malignancy. Indeed,
plasmapheresis has been demonstrated to remove both acute phase proteins and
CIC from the serum of cancer patients for short periods of time (Samak et al.
1981; MacDonald et al. 1981; Salinas et al. 1981; Cupissol et al. 1981),
resembling the short lived effect of removal of the stimulator of lymphocyte
(?2 consumption by plasmapheresis. The CICs removed were of medium size
(MacDonald et al. 1981; Salinas et al. 1981) and the antibody moiety, mainly
IgG (Cupissol et al. 1981; Samak et al. 1981), that is, having the properties
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usually associated with the CICs implicated in 'blocking' (Theofilopoulos &
Dixon 1979). Some evidence, perhaps indicating the more important place of
CIC over acute phase proteins, as an inhibitory factor in cancer, was
produced by Samak et al. (1981) who demonstrated a significant drop in IgG,
suggested to be incorporated in CIC, only in patients with advanced cancer
who responded clinically to plasmapheresis. Furthermore, Whitehead et al.
(1977) were unable to demonstrate any correlation between C-reactive protein
and E-rosette inhibition in breast cancer. Also, this acute phase protein
occurs in only 42% of patients with metastatic breast disease (reviewed by
Cooper & Stone 1979) whereas the majority of patients with such dissemination
have significantly increased lymphocyte C>2 consumption. Acute phase
proteins, such as C-reactive protein, by themselves are therefore unlikely to
be the sole, if at all, stimulator of increased lymphocyte
consumption. Furthermore, there was a highly significant correlation between
CIC levels and lymphocyte consumption in blood specimens from controls
and patients with benign and malignant disease, implying that CIC may be
responsible for the phenomenon.
Monocytes and PMNs were demonstrated to consume rather less C>2
than lymphocytes under basal conditions and their 0^ consumption remained
unaffected by cancer sera. However, both these cells derive much of their
energy from anaerobic metabolism and demonstrate a high degree of glycolysis
even under aerobic conditions and only during the process of phagocytosis
will these cells utilise in larger quantities (Cline 1975). It
would therefore be expected that cancer serum, although possibly exerting
seme irrmunological effect on these cells, would not increase their C>2
consumption. The population of B-rich lymphocytes from both controls and
cancer patients consumed equal quantities of 0^ and significantly less
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C>2 than the T-rich population from controls; but the T-rich population
from patients with cancer had significantly higher 0^ consumption than
that from controls. These facts indicate that the factor(s) in cancer serum,
responsible for stimulating 02 consumption does not affect the B
lymphocyte rich population and exerts its effect on the T lymphocyte
population only. This is reminiscent of the 'blocking1 effect exerted by
cancer sera on T lymphocytes; but not on B lymphocytes, as demonstrated by
their normal EAC-rosetting (Whitehead et al. 1977; Shafir et al. 1980) and
PWM stimulation (Shafir et al. 1980).
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5.5. Summary
Lymphocyte C>2 consumption is increased in patients with breast
cancer and other cancers and this is a stage related phenomenon. It is
unaffected by surgery, bears no relationship to the prognostic factors
studied, and is not predictive of later tumour recurrence. Systemic
hormonal treatment in both early and metastatic breast cancer, significantly
reduces elevated lymphocyte 0^ consumption in patients benefiting
from treatment, and this effect can be seen between 6 and 8 weeks prior
to clinical evidence of benefit.
The factor(s) responsible for the stimulation of lymphocyte
C>2 consumption can be removed from the cell and is present in the
serum of cancer patients and those with IC related diseases. This factor(s)
is heat stable at 56°C and can be stored at -20°C for several
months without diminishing its potency but loses its stimulatory capacity
on dilution. The factor can be removed from the serum by plasmapheresis
but only for 3 weeks at most and appears to be independent of HLA and
blood group activity.
Only the T-rich subpopulation of lymphocytes can be stimulated to
increased consumption of O2 and this reaction is complement dependent.
Lymphocytes must first be treated with papain digestion for stimulation
of O2 consumption to occur in vitro.
There is a high degree of correlation between lymphocyte O2
consumption and both CIC levels and depressed % T lymphocyte counts




Lymphocyte consumption is increased in breast cancer,
even in its early stages, and this stimulated consumption becomes more
pronounced with increasing tumour burden. Lymphocyte consumption
is unaffected by local treatment of breast cancer, indicating perhaps
the high proportion of women with metastatic disease at the outset, but
stimulated levels are diminished significantly in patients responding
to systemic therapy and this effect predates objective clinical evidence
of benefit.
This phenomenon may therefore be used to evaluate patients'
responses to hormonotherapy at an earlier phase of their illness.
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Appendix 5.1






EC 73 F - 5.86 - osteoarthritis
SD 26 F 68 - 57 nil
- 7.21 90
CD 43 F — 5.65 _ gallstone obstructive
jaudice
EG 25 F - 7.05 - appendicitis
MG 59 F - 6.02 - nil
AG 45 F - 5.60 - nil
SH 43 F 61 nil
67 66 nil
DH 54 F - 6.53 - nil
AJ 50 F - 4.96 - nil
PC 38 F - 5.69 - duodenal ulcer
NR 31 F - 5.17 - duodenal ulcer
LT 35 F - 5.52 - duodenal ulcer
KO 42 F - 7.03 - nil
MO 42 F - 7.34 18 nil
66 - 46 nil
JE 36 F - 7.35 - nil
KM 63 F - 6.45 - nil
IW 37 F - 5.90 - nil
RP 55 F - 5.60 - nil
ET 58 F - 7.50 - nil
GR 38 F 50 - 108 nil




































































































Age Sex % T 02
Consumption
CICs Disease
AP 34 M 63 - - nil
61 6.17 64 nil
FP 40 M — 7.94 — non-specific
abdominal pain
KR 36 M 61 — 30 nil
JT 37 M 60 - - nil
- 5.64 50 nil
ES 34 M - - 25 nil
DW 38 M 61 - 37 nil
HY 31 M 74 - 30 nil
RL 30 M 71 - 30 nil
- 6.00 28 nil
GB 72 M 51 6.42 - hernia
GF 58 M 60 6.39 - hernia
RH 60 M 58 5.81 - hernia
















































































































































































































































Meno % T 02 Consumption CICs Post-treatment
Pre 50 5.73 22
Pre - 5.60
Pre - 7.03
Pre - - 44
Pre 57 -
Pre 63 - 29
Pre 53 - 36





Pre - 4.47 23
Pre 50 - 49
Pre 65 9.18 45
Pre 68 - 96
Post - 7.83
Pre 70 - 62
Pre 61 7.4 52
Pre - 8.13
Pre 63 - 30
Pre - 5.92
Pre - 5.85 52



































































































Stage I & II Breast Cancer CICs (combined with % T)
Pre-operative Post-operative
Age % T CIC % T CIC
EE 73 65 83
CG 55 55 30
MJ 58 46 30
MJ 71 50 80
JL 53 69 79 75 86
PM 63 69 140
- 120
CS 66 63 33
RW 60 53 94
MB 72 50 70
45 57
WB 42 66
PB 44 49 30
60 44
AB 38 48 30
EB 49 58 30
PB 44 47 42
VC 39 51 33
PE 51 57 34
PG 67 57 30
GF 60 64 70
NG 55 - 84




Age % T CIC % T CIC
EH 60 51 78 55 88
MH 78 53 30 59 30
AJ 42 69 60
GJ 66 58 54
MM 74 66 44 57 60
BN 56 54 30
NP 71 65 84 55 51
50 88
VR 49 47 38
MR 60 62 48
65 30
ES 72 50 30
- 19
MS 40 49 30 44 30
ES 41 62 37 47 30
39
45 29
MT 48 50 50 50 78
49 90
56 88
GT 49 58 30 58 18







Stage III Breast Cancer CICs (combined with % T)
Age Pre Rx Post-Op
Surgery % T CIC % T CIC
DG 55 63 55 - -
LH 59 45 18 -
AJ 42 45 28 33
AL 66 43 30 54 30
EL 50 56 22 -
PM 41 55 31 -
EO 48 - 46 -
AR 86 - 102 -
MWJ 68 63 49 -
IM 55 - - 57 38
Pre Rx PR/NC/NA
Tamoxifen Age % T CIC % T CIC %
ED 71 50 41 — — —
GL 80 50 76 -





Inoperable Age % T CIC
BD 48 - 69~
IH 50 43 24
IM 53 49 71
DM 45 - 70
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Appendix 5.5
Stage IV Breast Cancer CICs (combined with % T)
Age Pre Rx PR/NC/NA Progression
% T CIC % T CIC %T CIC
GB 33 - 30 - - - -
RT 60 28 51 - - - -
MW 77 61 71 - - - -
AA 78 - - 56 80 - -
MB 51 - - 39 76 - -
EB 53 - - 33 68 - -
VB 48 52 47 - - - -
AB 38 42 58 - - 50 117
AC 75 56 78 69 86 - -
VC 38 42 58 - - - -
ED 55 - - - - 37 118
FD 72 - - - - 46 150
BD 48 25 86 - - - -
LE 78 - - 64 61 43 63
MF 83 21 108 58 121 - -
EH 60 52 66 - - 53 86
MJ 63 - - 46 93 - -
GJ 39 - 51 - - - -
EJ 63 50 183 - - - -
























Pre Rx PR/NC/NA Progression
% T CIC % T CIC % T CIC
57 148- - - -
55 78 - -
- 102 - -
— — 61 57
__ __ 56 80
- - 59 66
- - 56 43
53 30 68 100
- 61 52 55
- - 50 112











Calculation of Solubility Coefficient of 0^ in Eagle's MEM
The C>2 concentration of fully air saturated Eagle's MEM was
calculated using a modification of Bruhn's modification of the Winkler
technique (described by Golterman 1969). The principle behind this
titrimetric calculation of the 0^ content of a solution is that C>2
combines with manganese hydroxide (Mn [OH^) forming higher hydroxides
which on subsequent acid fixation in the presence of iodide (I ), liberate
iodine (1^) in an amount equivalent to the original dissolved C>2
content of the sample. The is then determined by titration with
sodium thiosulphate (Na2S2C>2). Nitrite (NC^) interference
is eliminated by the use of sodium azide (NaN^).
Ten ml of solution to be tested was drawn into a syringe, ensuring
that no air bubbles were trapped in the syringe and placed in a water
bath at 37°C after the sample had been air saturated using a
Charles Austin pump, the air being preheated in a coil at 37°C and allowed
to equilibrate for 10 mins. 0.1ml of manganese sulphate (MnSO^St^O)
and 0.1ml of alkaline iodide-azide solution was added to the test sample
using a fine gauge needle and thoroughly mixed and the resultant precipitate
allowed to settle. Mixing was repeated and the precipitate again allowed
to settle leaving a completely clear supernatant. 0.2ml of phosphoric acid
[H^PO^ (s.g. 1.75)] was then added and mixed thoroughly, the
precipitate dissolving almost instantaneously. The solution was thoroughly
mixed again before measurement and placed in a 50ml conical flask and the
iodine C^) titrated against sodium thiosulphate (^2826)2).
Starch solution, 0.2ml, used as an indicator was added towards the end of
the titration.
The amount of dissolved 02 was calculated from the formula.
C^ug/ml = ml of titrant B x N x 8 x 1000
ml of flask - 0.2ml
Where B = Na^^^
N = Normality of Na^^^
Allowance is made in the formula for the slight displacement of
sample by 0.1ml MnSO^SH^O and 0.1ml of alkaline-azide solution.
To convert ug/ml to ul/ml at 37°C, because:
lug/ml = 0.7ul/ml at 0°C, equate:






















Cells CP, Consumption Plotted Against Cell Concentration
"
Z" * " ~ ■ ~ ■





xl06/ml % % %
0.25 1 1 -
0.5 2 1.5 0.5
1.0 5 3 -
1.5 8 5.5 -
2.0 9.5 10 4
3.0 15 11 -
4.0 20.5 18 9
5.0 24 21 -
6.0 31.5 25 11.5
8.0 41 37 18.5
10.0 48 39 20
Correlation
coefficient
r = 0.998 r = 0.975 r = 0.990
Lymphocytes, PMN and monocytes from one control.
The experiment was run over several days.
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Appendix 5.8
Stage I, II and III Breast Cancer Surgery
Lymphocyte 0^ Consumption




SURGERY I & II
MB 72 - 10.11 NP 0 NSR
WB 42 5.48 9. 72 - 0 Local 21/
OB 58 9.59 - + 0 NSR
EB 49 - 8.84 + 0 NSR
BR 40 9.22 9.33 - 1 Bone 15/1
NG 55 - 7. 79 + 0 NSR
MH 54 9.49 - NP NP NP
EH 60 8.98 8.84 + 3 Bone 12/1
MH 78 - 9.42 NP 0 NSR
AH 54 - 10.07 + 0 NP
AJ 42 9.42 8 . 73 - 1 Multiple 43
JJ 43 11.48 - - 4 + Multiple 12.
GJ 66 9.71 - + 3 Local 29/12
MM 48 11.68 6 . 99 + 0 NSR
AM 47 8 . 54 - - 0 NSR
BM 40 8.91 - NP 0 NSR
PP 59 - 11.75 NP 0 NSR
MR 47 - 8.31 - 3 NSR
JR 49 10.18 6.59 NP NP NP
ES 72 - 5.80 - 0 Brain 15/12
MS 40 - 7.12 - 1 NSR
ES 41 - 6.78 + 0 NSR
GS 53 8.11 - + 0 NSR
MT 48 - 11.62 - 0 NSR
MT 72 8 . 08 - + 0 NP
MT 53 - 7.88 - 1 Brain 30/12
HL 42 7.96 - NP 1 too early
EL 62 9.38 8 .44 NP 0 too early
OD 51 - 6 . 24 NP 0 too early
PJ 78 9 . 35 8 .20 NP 0 too early
DR 42 7.88 - NP 0 too early
SR 38 9.45 - NP 0 too early
EJ 68 8 . 06 - NP 0 too early
JR 41 7.48 - NP 0 too early
PT 52 - 6 . 08 NP 0 too early
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Appendix 5.8 (continued)




SURGERY AND ADJUVANT TAMOXIFEN
JL 53 9.20 - + 0 Multiple 28
SURGERY III
RF 79 13.06 - NP 0 Local 12/12
DG 55 1 0 . 06 9.46 + 0 Lungs 43/12
JF 37 7.96 8.72 + 0 Local 7/12
DM 65 - 8.95 + 1 NSR
PM 41 8.34 8 . 55 + 2 NSR
EO 48 9.01 7. 73 + 0 NSR
AR 86 5.51 - NP NP NP
KW 61 - 9.23 NP 1 Lungs 45/12
IM 55 - 8.66 + 2 Lungs 37/12
DE 78 12.04 - NP NP too early
PS 63 7.88 - NP 2 too early
KM 60 9.44 8.10 NP 1 too early
WD 63 8.25 8.04 NP 0 too early
FS 74 7.88
- NP 0 too early
BW 40 9.46
- NP 12 too early
IA 74 8. 24
- NP 1 too early
KD 62 8 .56
- NP 1 too early
GW 82 10.96 8.75 NP 4 + too early
NP = not performed
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Appendix 5.9
Stage I, II & III Breast Cancer
Hormonotherapy: Lymphocyte Ct Consumption
Stage I & II




EP 80 9.91 9.22
EW 84 9.32 5.96 (PR)
FM 85 7.98
Stage III
FL 66 13.12 6.14(NC)
ED 71 8.60
GL 80 11.75 12.32
JP 73 5.91(PR)






Stage IV Breast Cancer - Hormone Therapy
Lymphocyte 0? Consumption
Age Pre Rx PR/NC/NA Prog





VB 48 9.20 7.20(NC)
AB 38 8.73 8 .29
AC 75 7.09
VC 38 7.43
EC 48 1 1 .02
MD 74 10.68
BD 48 9. 04
CD 57 1 1 .99 8.09(PR)
MF 83 8.40 6.84(PR)
MJ 63 9.00
GJ 39 6 . 06 5.84
SJ 44 9.51
EJ 63 10.31 9.90
NL 58 9.64 11.31
AM 45 9.80 9.18
ER 65 10.28
LS 45 12.70 11.72(N/A)
MW 46 9. 79
WW 64 9.61
EH 60 9.84 10.91
FD 72 - 11.45
LE 78 - 8.57
PE 73 - 10.50
WG 49 - 7.63(PR) 9 .84
ML 77 - - 7. 30
IM 58 - - 8.47
WN 74 - - 10.26
MP 63 - 6.25
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Appendix 5.10 (continued)
Age Pre Rx PR/NC/NA Prog.
ER 85 - 11.42
CS 36 - 9.61
HT 74 - - 10.76
EN 45 - - 14.16
MJ 63 - 8.03(PR)
GM 53 - 6.88(PR)
PP 61 - 7.34(PR)
MB 51 - 7.97(NC)
EM 74 - 8.47(N/A)
Appendix 5.11
Stage III & IV Breast Cancer













Lymphocyte 0n Consumption in Tumours Other Than Breast Cancer
Age Grade Lymphocyte 0^ Utilisation
AL 52 Dukes' A 7.84
MR 58 B 9.53
HW 71 B 6.42
WA 78 B 7.96
MR 58 C 6.18
WE 69 C 8.60
IS 57 C 10.93
BD 47 C 11.22
ME 55 D 13.99 (liver)
BW 79 D 11.48 (liver)
WE 63 D 11.85 (liver)
AG 55 D 15.29 (liver)
TC 53 D 9.97 (local invasion)
Stomach/Lower Oesophagus
RW 54 Local 10.53
EB 58 Disseminated 11.48 (local invasion)
MM 60 Disseminated 8.81 (local invasion)
AW 74 Disseminated 10.36 (liver)
PC 69 Disseminated 9.58 (liver)
RN 62 Disseminated 12.85 (liver)
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Appendix 5.12 (continued)
Age Grade Lymphocyte 0^ Utilisation
Pancreas
CM 74 Disseminated 11.04 (local invasion)
CC 70 Disseminated 10.04 (liver)
Ovary
ES 74 Disseminated 14.21
Lunq
MR 55 Disseminated 10.58
Carcinoid
JH 65 Disseminated 11.06
Malignant Melanoma
FA 63 Disseminated 9.45
PL 28 Disseminated 11.69
JE 49 Disseminated 12.37
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Appendix 5.13
Separation of T-rich and B-rich Lymphocyte Populations
Purification Oxygen Consumption
% T % B T-rich B-rich Unseparated
CONTROLS
DG 83 79 6.14 4.89 6.08
DB 80 81 6.34 4.26 5.98
MW 81 77 5.98 4.01 5.36
PJ 85 83 6.28 4.66 6.14
SB 78 74 6.00 4.04 5.78
FH 84 72 5.90 4.00 5.44
JJ 76 78 6.31 5.00 6.30
JS 80 69 6.00 5.08 6.09
FB 73 80 5.96 4.34 5.66
SB 79 79 6.34 5.00 6.22
MT 80 76 6.28 4.86 6.00
2AST CANCER
HW 81 80 9.95 5.08 9.14
FP 79 81 11.12 4.96 10.98
MT 78 76 8.76 5.20 8.89
HT 77 77 7.98 4.84 7.64
RH 82 80 9.14 4.79 8.90
CK 79 79 10.00 5.00 9.00
LH 78 76 9.26 5.02 9.14
KB 80 74 11.08 4.88 10.83
CL 80 80 9.22 4.69 9.00
Appendix 5.13 (continued)
Purification Oxygen Consumption
% T % B T-rich B-rich Unseparated
COLORECTAL CANCER
MA 81 79 11.72 5.00 11.00
AS 84 81 12.14 4.97 11.98
FB 78 79 10.07 4.88 9.24
HC 76 74 9.28 5.24 10.02
JB 83 75 8.88 4.11 7.94
CW 82 76 12.28 5.24 11.99




































































































































































































































LymphocytesLymphocytesL mphocytesRxPapain37°CRxP pain37°CRxP pain4°Cplusautologousplual ogeneic serumcontrolserum 12.13 11.75 12.05 10.40 10.52 5.88 8.87 9.20 9.40 13.05 13.51 11.00 9.10 9.09 10.967.83 7.58 6 .78 5.98 7.80 6 .50 6.42 6 .58





Control Lymphocytes, PMN and Monocytes
Ct, Consumption in Autologous and Allogeneic Cancer Serum
Lymphocytes Lymphocytes + PMN PMN + M M +
DG 5.64 8.84 6.51 6.27 4.62 4.14
PC 5.69 8.28 5.71 4.91 2.86 2.90
RL 6.17 8.43 4.41 4.36 3.31 3.11
NR 5.17 8.03 4.46 4.31 4.13 4.20
LT 5.52 7.56 3.82 3.38 3.81 2.13
Appendix5.16






















































































































































Lymphocyte 02 Consumption and % T Counts
Age O2 Uptake % T Count
GB 72 6.42 51
GF 58 6.39 60
RH 60 5.81 58
CV 40 7.33 58
EH 50 6.47 60
SJ 49 6.04 68
WG 71 6.09 53
OT 70 6.25 54
ET 68 5.99 50
JG 56 6 . 25 61
CB 41 6.10 64
EB 38 5.63 68
MB 80 6.12 51
DC 42 6.16 62
JC 60 6.53 64
MH 44 5.88 59
JH 23 6.02 63
GH 48 5.51 56
SH 42 5.92 63
AM 30 5.97 66
KM 26 5.94 68
SP 33 6.46 68
JR 40 6.18 58
NR 38 6.06 59
JR 51 8.38 51
GT 59 7.45 58
SW 43 6.38 59
AM 29 6.77 61
SH 43 5.92 63
LY 41 6.20 64
DN 46 6.12 60
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Appendix 5.18 (continued)
Age Uptake % T
AH 40 5.44 54
MD 48 6 .31 58
JH 19 6.16 64
LB 27 7.13 53
RB 38 6.11 60
ID 62 7.54 56
AM 33 5.73 50
ER 68 6.68 50
CW 28 9.18 65
EL 62 9. 38 42
EL 62 8.44 40
PJ 78 9. 35 38
SR 38 9.45 43
EL 68 8.06 36
MB 72 10.68 45
AB 38 8.73 42
AB 38 8.29 36
VC 39 7.43 52
VC 39 11.02 50
EH 60 8.98 51
EH 60 9.84 44
AJ 42 9.42 69
JJ 43 11 .48 48
MM 48 1 1 .68 50
JR 49 10.18 53
MS 40 7.34 36
JL 53 9.20 69
JL 53 8.93 50
MF 80 8.05 64
EP 80 9.91 51
EP 80 9.22 46
EW 84 9.67 49
KM 60 9 .44 48
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Appendix 5.18 (continued)
Age 02 Uptake % T C
WD 63 8.25 39
RF 79 13.06 42
DG 55 10.06 63
DG 55 10.88 51
PM 41 8.34 55
IM 55 8.66 57
IM 55 8.47 40
GL 82 10.96 44
IH 50 9.23 43
BD 48 9 . 04 25
FL 66 6.14 57
ED 71 8.60 44
GL 80 11 .75 50
GL 80 13.68 53
JP 73 7.09 68
JP 73 4.72 71
GS 71 8.81 38
BW 75 12.61 44
OA 76 9.18 41
MA 44 8.94 27
EB 53 5.46 33
EB 53 7.34 54
VB 48 9.20 52
VB 48 7.20 68
AC 75 7.09 56
EC 48 1 1 .02 50
FD 72 11.45 46
CD 57 11.99 50
CD 57 7.75 57
CD 57 7.12 54
MF 83 8.40 21
MF 83 6.84 58
WG 49 7.63 55
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Appendix 5.18 (continued)
Age 02 Uptake % T Count
WG 49 5.46 50
WG 49 9.84 52
MJ 63 7.96 49
GJ 39 5.84 50
SJ 44 9.51 40
EJ 63 10.31 41
EJ 63 9.90 50
MJ 49 9.56 57
NL 58 11.31 46
AM 45 8.99 57
IM 58 8.47 40
WN 74 10.26 47
WN 74 10.11 61
PP 61 7.34 50
LS 45 12.70 53
LS 45 12.49 45
LS 45 8.29 56
LS 45 13.72 56
EH 60 9.84 44
EM 74 9.92 51
MP 63 6.25 35
HT 74 10.13 47
HT 74 10.76 50
MH 38 13.30 31
JJ 61 11.37 42
MS 24 14.80 50
RW 54 10.53 41
JH 65 11.06 44
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Appendix 5.19
02 Consumption and Immune Complexes
Age 02 Uptake Immune C<
DG 32 5.88 19
DM 25 6.39 30
SD 26 7.21 90
MO 42 7. 34 18
RB 38 6.11 43
WH 39 5.49 94
BM 36 5.91 41
AM 33 5.73 22
EW 37 7.40 52
MW 47 5.85 52
MW 47 6.91 32
MB 72 10.68 57
WB 42 5.48 66
AB 39 8.73 58
VC 39 7.43 68
EH 60 8.98 78
EH 60 8.84 88
AJ 42 9.42 60
MT 53 7.88 34
JL 53 9.20 79
EP 80 9.91 14
EW 84 9.32 39
EW 84 6.99 49
DG 55 10.06 55
PM 41 8.34 31
EO 48 9.01 46
AR 86 5.51 102
IM 55 8 . 66 38
BD 48 9.70 69
IH 50 9.23 24
BD 48 9 . 04 86
GL 80 1 1 . 75 76
EB 53 5.46 69
VB 48 9 .20 47
VB 48 8.81 66
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Appendix 5.19 (continued)
Age 02 Uptake Immune Complexes
AB 38 8.73 58
AC 75 7.09 78
VC 38 7.43 68
FD 72 11.45 150
MF 83 8.40 108
MF 83 6.84 121
WG 49 7.63 44
GJ 39 6.79 54
GJ 39 5.32 51
MJ 49 9.56 148
GH 39 5.84 60
NL 58 9.64 102
ER 65 10.28 141
MP 63 6.25 47
WW 64 9 .61 66





Evidence indicates that spontaenous cancers, such as carcinoma
of the breast, do not develop as a consequence of impaired immune
surveillance, but rather as a result of exposure to carcinogens. Such
tumours tend to be poorly immunogenic. Tests of immune function are
however, affected adversely in these tumour bearing hosts and the extent
to which immunity is impaired is generally a reflection of tumour load,
indicating that depressed immune competence is secondary to the presence
of cancer. There is strong evidence that the 'blocking' factors responsible
for this phenomenon are CICs, formed by the combination of cell breakdown
or membrane products of rapidly dividing cells, and antibody to these
(non-tumour specific) antigens.
This immune depression may be harmful to the patient in terms
of reduced resistance to bacterial, viral and fungal diseases or, possibly,
as a result of immune complex deposition although the latter is rare.
Are there other ways in which ICs may be harmful to the cancer patient?
Moller (1969) suggested that IC formation was perhaps beneficial
in that the antibody manufactured by a few sensitised lymphocytes at
the tumour site would combine with locally produced antigenic tumour
material to form ICs. They in turn perhaps stimulate uncommitted cells
into a cytotoxically active state only in the region of the tumour,
that is, restricting the cytotoxic reaction to the site of antigen
production. Indeed T lymphocyte activity is stimulated and ADCC activity
inhibited under conditions of antigen excess (reviewed by Theofilopoulos
& Dixon 1979). However, in vivo, such enhancement of T lymphocytes
disappears to be replaced by inhibition when antigen excess changes to
288
antibody excess (Weigle 1975). Furthermore, ADCC activity is stimulated in
antibody excess (Theofilopoulos & Dixon 1979). Thus, it is possible that
different lymphocyte subsets are stimulated depending on the molar ratio
of ICs.
Inhibition of T cell induced activity is probably effected through
increased suppressor cell activity. Suppressor cells comprise mainly
cells of the monocyte/macrophage system and of the T lymphocyte population
(Herzenberg et al. 1973; Gershon et al. 1974; Moretta et al. 1977;
Reinherz et al. 1980; Yamagashi et al. 1980; Herberman & Ortaldo 1981;
Herberman 1983b) and are thought to exert their effect on interleukin -
2 - dependent cells (T, NK, LAK) through release of a factor which
specifically blocks the action of interleukin - 2 (Daya et al. 1987).
Such suppressor cell activity appears to be part of the normal apparatus
for the induction of peripheral tolerance (Theofilopoulos 1987) and there
is evidence that suppressor cell activity is continuously occurring
in normal people (Vento et al. 1987). The reason for this is that there
is continual recognition by immune cells of self antigens, the success
of this being dependent on the immunogenicity of the antigen (Cunningham
1975). Self antigens most immunogenic are those normally sequestered,
such as intracellular materials and cell membrane surface molecules
expressed during cell death. Cancer patients with their persistent
antigenaemia would be expected to display continuous immune reactivity
to these antigens. However, constant stimulation, even with a foreign
antigen, ultimately results in its being treated like 'self' (Gras & Dalmau
1966) probably through suppressor cell activity (Cunningham 1975).
That ICs are able to stimulate suppressor cell activity has been
amply demonstrated (Gershon et al. 1974; Stout et al. 1976; Moretta et al.
1977). The Fc receptor portion of the complex is mandatory for stimulation
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of suppressor or activity, but not for the 'blocking' effect exerted on
other cells (Chan & Sinclair 1973), and it may be that only cells with
Fc-Ig receptors are able to exert this activity. It would be expected
that cancer patients with their persistent antigenaemia would have high
levels of ICs in their blood and indeed, as has been previously discussed,
this tends to be the case. It follows that suppressor cell activity
in such patients would also be increased and this has been demonstrated
(Toge et al. 1983; Braun et al. 1983; Kanayama et al. 1985). This
activity tends to be greatest in areas of higher blood concentrations
of ICs (Kanayama et al. 1985), that is closest to the tumour. For instance,
cell cytotoxicity in animals and man is most markedly depressed within
tumours and becomes less so within regional lymph nodes the further away
from the tumour they are (Currie & Gage 1973; Nind et al. 1973; Hoon
et al. 1987a). This effect is secondary to increasing suppressor cell
activity with increasing proximity to the tumour (Kanayama et al. 1985;
Hoon et al. 1987b) and such suppressor cell activity becomes more apparent
the greater the aggression displayed by the tumour (Kanayama et al. 1985).
Furthermore, as disease load increases tumour cytotoxicity diminishes
(Currie & Gage 1973; Kanayama et al. 1985) and suppressor cell activity
increases (Kanayama et al. 1985) in the peripheral blood. This spreading
anergy may be explained by suppressor cell activation first in the
vicinity of the tumour and its regional lymphoid system and then generally
as the initial local production of ICs by the tumour becomes widespread,
through release into the host circulation, as tumour load increases.
Does this suppressor cell activity have any consequences in human tumour
bearers?
Whilst accepting that the impaired immunity plays no part in
the development of spontaneous cancers there is evidence that such tumours
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may, to some extent, be under the control of the immune system. Indeed,
it has been shown that a weak immune response may increase the ability
of tumours to grow locally and metastasize (Prehn 1976) and further,
that this may be an effect of suppressor cell activity (reviewed by
Murasko & Prehn 1983). Furthermore, it has been demonstrated that cancer
patients given additive immunosuppressive therapies have a worse prognosis
than patients treated with less immunosuppressive regimes. For instance,
patients with inoperable Stage III breast cancer treated with a combination
of radiotherapy and chemotherapy, as part of a controlled study, had
significantly poorer survival than those given radiotherapy alone (Paterson
& Webster 1986). Patients with various spontaneous tumours if transfused
with whole blood, which has apparent immunosuppressive properties in that
it may help to suppress allograft rejection (Woodruff & van Rood 1983),
have earlier recurrence of their tumours and poorer survival than patients
given no blood or packed cells only (Blumberg et al. 1986; Hamblin 1986).
It has been suggested that a factor present in the plasma is capable
of 'turning on' suppressor cells (Woodruff 5c van Rood 1983). Tumour
autotransplant and even allotransplant (dependent on HLA activity) rejection,
has been demonstrated to be slower and sometimes incomplete in patients
with advanced cancers and this is most significant in those with poorest
CMI (Southam et al. 1965; Southam et al. 1966). These phenomena and others,
discussed in Chapter 2, such as dormancy, the incidence of subclinical
tumours, spontaneous tumour regression, variation in tumour growth rate
between individuals with similar histological tumours, the beneficial
effects of immune reactions histologically and the high incidence of failure
of circulating tumour cells to seed, imply that the immune system may
play a role in the control of spontaneous cancers once they have developed.
Immune suppresssion by IC stimulated suppressor cells may perhaps aid
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the growth and increase the metastatic potential of these tumours.
Thus, it may be proposed that CICs may act detrimentally on the cancer
patient firstly through 'blocking' thereby preventing antigen recognition
and activation of cells cytotoxic to tumour cells and secondly, by suppressor
cell stimulation and suppression of any induced immune response. It has
been demonstrated in this work that patients with breast cancer exhibit
'blocking' as manifested by depressed % T counts, and lymphocyte stimulation,
displayed by increased respiration. There is no proof at the present that
the lymphocytes so stimulated are suppressor cells and this must wait until
the T lymphocyte subsets are examined in this context. There is evidence
however, that the same factor(s) is responsible for both 'blocking' and
stimulation of T lymphocytes.
There are many similarities between the serum factor(s) responsible
for inducing increased 0^ consumption in lymphocytes and 'blocking'
factor(s) of cancer. Both appear to exert their effect on T cells, are
removed from the lymphocyte surface by papain digestion and reattached
by incubation in cancer sera after as little as an hour. They appear
to be independent of HLA and blood group activity; unaffected by storage
at low temperature or incubation at 56°C but lose their effect on
dilution and are removed by plasmapheresis. Furthermore, neither affects
B lymphocytes in an obvious manner, but both have been shown to be
dependent on disease status and tumour load or activity, reflecting
responses to systemic therapy within 6 to 8 weeks from the start of treatment.
Finally, there is a strong correlation between depressed % T counts and
increased lymphocyte consumption, indicating that the factor(s)
responsible for both phenomena may be one and the same. There is one
point of obvious difference however, in that it is impossible to demonstrate
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stimulation of consumption in control lymphocytes incubated in cancer
sera, unless they are first treated with papain.
CICs also have much in common with the serum factor(s) which
stimulates lymphocyte C>2 consumption. Whilst recognising that heat
inactivation causes difficulties in measuring CICs, due to aggregation
of IgG, it does not affect the CICs themselves. Similarly, heat inactivation
has no effect on the factor(s) responsible for lymphocyte consumption
stimulation. The factor(s) is however, complement dependent and like CIC
cannot exert its stimulatory effect on lymphocytes in the absence of
complement. Both are also present in patients with immune complex related
diseases and removed by plasmapheresis but reattain previous levels within
3 weeks and both reflect tumour burden. Finally, there is significant
correlation between CIC levels and lymphocyte C>2 consumption.
It seems reasonable to suggest therefore, that CICs are responsible
both for 'blocking' of T lymphocytes and their increased C>2 consumption.
This may appear rather anomalous at first sight, but there are similarities
between substances which 'block' immunological responses and those which
stimulate these responses. Specific antigen on its own (but not non-specific
antigen) can 'block' at the lymphocyte surface (Baldwin et al. 1973c;
Baldwin et al. 1974; Gorczynski et al. 1975) and has been demonstrated
to stimulate sensitised lymphocytes to synthesise DNA (Lundgren et al. 1968a;
Moller 1969) or exhibit cytotoxicity (Lundgren et al. 1968a) whereas
non-specific antigen does not have this capability (Lundgren et al. 1968a;
Bloch-Shtacher et al. 1968; Moller 1969). Antibody, by itself, is similarly
incapable of 'blocking' at the lymphocyte surface (Baldwin et al. 1973c;
Baldwin et al. 1974; Gorczynski et al. 1975) and cannot stimulate
lymphocytes unless specifically sensitised against them (Lundgren et al.
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1968a; Bloch-Shtacher et al. 1968; Moller 1969). ICs however, are capable
of 'blocking' at the lymphocyte (as well as at the tumour) surface
(Sjogren et al. 1971; Hattler & Soehnlen 1974; Baldwin et al. 1972;
Baldwin et al. 1973c; Baldwin et al. 1974; Gorczynski et al. 1975; Tanaka
et al. 1979) in a non-immunologically specific fashion provided antibody
and antigen are in the correct ratio. Both sensitised and non-specific
ICs can also stimulate lymphocytes into their active state (Lundgren et al.
1968a; Bloch-Shtacher et al. 1968; Moller 1969; Soderberg & Coons 1978) when
near equivalence in slight antigen excess, i.e. the 'right mix' required for
exhibition of the 'blocking' phenomenon (Baldwin 1974).
Thus, it appears that substances which display 'blocking' ability
are also those which are stimulatory to the lymphocyte. This is not
surprising when it is considered that lymphocytes stimulated to transformation
or cytotoxicity by ICs have been shown to be refractory to other stimuli,
for instance, the non-specific stimulation of PHA on the cell (Lundgren
et al. 1968a; Lundgren et al. 1968b). This suggests that lymphocytes
triggered by one process beccme 'blocked' to certain other triggering
reactions, perhaps by exerting suppression of the different membrane
receptors responsible for stimulation by other agents.
This work suggests that the effects exerted on T lymphocytes,
probably by CICs, appear to reflect tumour activity and may be utilised
to permit earlier evaluation of hormone treatment responses in breast
cancer. Neither % T counts nor measurement of lymphocyte consumption
seen prone to the difficulties associated with assays of CICs, and both
are simple to perform and can be assessed on the day of the patient's
visit to the clinic. Furthermore, lymphocyte 0^ consumption may be
an index of suppressor cell activity, although this has yet to be proved,
and used in this way might allow us further insight into the complex
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